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ABSTRACT 
 
This thesis investigates the biological activity of selected non-steroidal analogues of sex 
steroid hormones by examining two different effects of analogues on endogenous sex 
hormone activity. Non-steroidal analogues of sex hormones were synthesised to study their 
biological interactions with a sex steroid receptor and a sex steroid metabolising enzyme. 
 
Chapter One introduces the steroid hormones and their physiology, which leads to a review 
of the mechanisms by which steroids exert their effects. Their implication in disease is 
discussed, with particular emphasis on the sex steroids. As the biological activity of 
steroids is related to their chemical structure, the important features of steroid structure are 
identified, including the cyclopentanoperhydrophenanthrene nucleus, arrangement of ring 
substituents and ring junction conformation. The concept of non-steroidal analogues of 
steroids is introduced, and the harmful or beneficial effects analogues have on endogenous 
steroid activity are considered. Alteration of steroid activity and its consequences are 
focussed on two main areas; the potential adverse effects of environmental chemicals 
which mimic sex steroid activity, and the use of non-steroidal analogues in medicinal 
chemistry for treating sex steroid related disease. 
 
Chapter Two describes an investigation into the 17β-estradiol mimicking activity of non-
steroidal analogues. Exogenous chemicals that mimic estradiol are of concern as they may 
alter endogenous estradiol activity and disrupt endocrine systems. Firstly, an introduction 
to the field of research concerned with environmental chemicals that mimic steroid 
hormones is given. The interaction of xenoestrogens with the estrogen receptor is 
described, as are the methods available for assessing the estrogen mimicking activity of 
xenoestrogens. The concern for insecticides mimicking estrogen activity is described by 
reviewing reported activities of insecticides, which leads into a discussion of work carried 
out as part of this thesis. Metabolites of the pyrethroid insecticides permethrin and 
cypermethrin, 2.14, 2.15, and 2.16 were synthesised while others were commercially 
obtained. The interaction of pyrethroid insecticide metabolites with the human estrogen 
receptor expressed in recombinant yeast (Saccharomyces cerevisiae) was studied, 
following the establishment and validation of the assay. Metabolites 2.11, 2.12, and 2.14 
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were found to weakly stimulate estrogen receptor-mediated estradiol responsive gene 
expression in the yeast assay (105 less active than 17β-estradiol). Since the activity of the 
metabolites using the yeast assay was greater than for the parent compounds, metabolic 
pathways need to be considered when assessing the impact of exposure to environmental 
estrogens. The low estrogenic activity suggests these compounds are not individually 
contributing significantly to the xenoestrogenic impact on humans, but will add to total 
xenoestrogen exposure.  
 
Chapter Three describes the inhibition of a sex steroid metabolising enzyme, steroid 5α-
reductase, by novel non-steroidal compounds. Inhibitors of this enzyme are potentially 
useful therapeutic agents for regulating the activity of an androgen in prostate disorders. A 
review of the literature on non-steroidal inhibition of 5α-reductase identified three key 
structural features known to enhance inhibitor potency; ring substitution, position and 
nature of ring unsaturation and angular methyl group presence. These features were taken 
into account in the design of inhibitors synthesised in this thesis (3.55-3.57, 3.59, 3.61, 
3.62, 3.110 and 3.111). Inhibitors consisting of non-steroidal 5- or 1-aryl pyridone 
scaffolds were synthesised to investigate SAR for 4’-substituents. The 5-aryl 1-methyl-2-
pyridone/piperidone scaffold of compounds 3.55-3.57 and 3.59 was constructed by Suzuki 
cross coupling methodology, while the 1-aryl 2-methyl 2,3-dihydro-4-pyridone scaffold of 
3.61 and 3.62 was constructed by aza Diels-Alder methodology. Long carbon chain olefin 
containing tethers 3.107 and 3.108 were synthesised for conjugation to inhibitor 3.57 by 
cross metathesis to give conjugates 3.110 and 3.111. Compounds 3.55-3.57, 3.59, 3.61, 
3.62, 3.110 and 3.111 inhibited the type 1 5α-reductase isozyme expressed by HEK-I cells, 
with activities comparable to those of related literature compounds. The 1-aryl 2,3-
dihydro-4-pyridone 3.62 inhibited both the type 1 and 2 isozymes (expressed by HEK-II 
cells) of 5α-reductase. The presence of bulky hydrophobic groups (benzoyl, long chain 
tethers) at the 4’position enhanced the potency of type 1 inhibition by 5-aryl pyridone type 
compounds in comparison to N,N-diisopropyl- and N-allylacetamide groups. This 
information provides further understanding of SAR within and across different classes of 
non-steroidal inhibitors of steroid 5α-reductase towards improved drug design. 
Abbreviations 
 
 
 
III
ABBREVIATIONS 
 
AF  activation function 
AMC  ceric ammonium molybdate solution (TLC) 
AR  androgen receptor 
BPH  benign prostatic hyperplasia 
br  broad (in NMR) 
CAT  chloramphenicol acetyl transferase 
cDNA  complementary deoxyribonucleic acid 
CFU  colony forming units 
COSY  correlation spectroscopy 
CPRG chlorophenol red β-galactopyranoside  
CYP  cytochrome P450 
d  doublet (in NMR) 
DBD  DNA binding domain 
DCM  dichloromethane 
dd  doublet of doublets (in NMR) 
DDE  1,1-dichloro-2,2-bis(p-dichlorodiphenyl)ethylene (DDT metabolite) 
DDT  1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane  
DES  diethylstilbestrol 
DHT  dihydrotestosterone 
DIPEA N,N-diisopropylethylamine  
DMAP  4-(dimethylamino)pyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dt doublet of triplets (in NMR) 
EC50 median effective concentration (calculated concentration of agonist which 
generates 50% maximum response from binding to receptor) 
EDC  endocrine disrupting chemical 
EDCI  1-[3-(dimethylamino)propyl]-3-carbodiimide hydrochloride 
EDTA  ethylenediaminetetraacetic acid 
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EI  electron impact (in mass spectrometry) 
ELISA  enzyme-linked immunosorbent assay 
EPA  Environmental Protection Agency 
ER  estrogen receptor 
ERE  estrogen response element (DNA sequence) 
ESI  electrospray ionisation (in mass spectrometry) 
ESR  Institute for Environmental Science and Research 
FDA  Food and Drug Administration (USA) 
h  hour(s) 
HEK  human embryonic kidney cell 
hER  human estrogen receptor 
HOBt  1-hydroxybenzotriazole 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
hsp  heat shock protein 
HSQC  heteronuclear single quantum correlation (in NMR) 
Hz  hertz (in NMR) 
IC50  inhibitor concentration that decreases enzyme activity by 50% 
J  coupling constant (in NMR) 
Kd  receptor-ligand dissociation constant 
Ki  enzyme-inhibitor dissociation constant 
Km  Michaelis-Menten constant (enzyme-substrate dissociation constant) 
LBD  ligand binding domain 
LRMS  low resolution mass spectrometry 
m  multiplet (in NMR) 
min  minute(s) 
mp  melting point 
mRNA  messenger ribonucleic acid 
NA  no activity  
NADPH nicotinamide adenine dinucleotide phosphate (reduced form) 
NADP+ oxidised form of above 
NMR  nuclear magnetic resonance 
OD  optical density 
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PBS  phosphate buffered saline 
PCB  polychlorinated biphenyl  
PCDD  polychlorinated dibenzodioxin 
PCDF  polychlorinated dibenzofuran 
ppm  parts per million 
QSAR  quantitative structure-activity relationships 
rt  room temperature 
RVP  rat ventral prostate 
s  singlet (in NMR) 
SAM  self assembled monolayer 
SAR  structure-activity relationships 
SD  standard deviation 
SHBG  steroid hormone-binding globulin  
SRE  steroid response element  
t  triplet (in NMR) 
TBT  tributyltin 
THF  tetrahydrofuran 
TLC  thin-layer chromatography 
Tris-HCl tris(hydroxymethyl)aminomethane hydrochloride 
TS  transition state 
YES  yeast estrogen screen 
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1.1 OVERVIEW 
 
The steroids are a group of naturally occurring compounds that possess a lipophilic 
cyclopentanoperhydrophenanthrene skeleton (Fig 1.1), or a derivative thereof. Steroids are 
hormones (chemical messengers) that play a critical role in endocrine systems which 
control the regulation of metabolic processes. These hormones stimulate biological 
responses in a wide range of tissues to influence endocrine processes such as sexual 
differentiation, reproductive physiology, and maintenance of salt balance and sugar 
metabolism. They have also been implicated in responses to stress and behaviour. The 
most important classes of steroids are the sex hormones (estrogens and androgens), 
progestins, mineralcorticoids and glucocorticoids, vitamin D and its derivatives, bile acids, 
and sterols found in cell membranes (Fig. 1.1). Synthetic derivatives of steroids have also 
attracted a good deal of attention for the purpose of developing drugs to treat hormone 
related disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. (i) Steroid skeleton numbering and ring notation. 
(ii) Examples of naturally occurring steroids. 
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Compounds that do not possess a steroidal structure (non-steroidal analogues) can mimic 
the biological activity of steroids, and this is the theme of this thesis. The purpose of this 
chapter is to provide an overview of the biological activity of steroids (the sex steroids in 
particular); their role in normal physiology and their molecular and biochemical 
mechanisms of action. Key molecular events that steroids are involved in will be 
described, followed by their roles in certain disease states which can arise because of 
problems associated with hormone action. As the biological activity of steroids is related to 
their chemical structure, the chemistry of steroid structure will also be discussed. This 
provides the context for the study of biological effects of non-steroidal analogues, in 
particular, the potential adverse hormonal action that analogues may induce, and the use of 
non-steroidal analogues in drug design and development. 
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1.2 STEROID HORMONE PHYSIOLOGY 
 
Most steroids are biosynthesised in the cell from cholesterol, the principal mammalian 
sterol (Scheme 1.1). Steroids are produced mainly in the adrenal gland, testis, ovary and 
liver, and secreted into the bloodstream where they are transported to target tissues by 
plasma transport proteins. Based on the distance of a target site from the site of synthesis 
and secretion, steroid hormones are classified as endocrine (distant target tissue), paracrine 
(neighbouring cells), or autocrine (same cell) factors. Because of their hydrophobic nature 
steroid hormones diffuse across the lipid bilayer into target cells where they play a vital 
role in differentiation and regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.1. Synthesis of steroid hormones from cholesterol. 
 
 
The hormonally active form of a steroid is the ‘free’ steroid which has dissociated from its 
plasma transport protein. Each transport protein binds its ligand with high affinity, with Kd 
values in the range of 5-500 nM.1 The concentration of free steroid in the blood is a key 
determinant of steroid activity, and depends on three factors (Scheme 1.2);  
i) The rate of biosynthesis of steroid and transport to body pools. 
ii) The rate of catabolism which inactivates steroids and removes them from body 
pools. Steroids are inactivated by metabolism, and because of their hydrophobic 
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nature, they are metabolised to more hydrophilic compounds suitable for excretion. 
Conjugation with sulfate or glucuronide groups increases their water solubility.  
iii) The affinity (Kd) the steroid has for its plasma transport protein. For example, 
estrogens bind quite tightly to transport proteins, so only a small proportion (1-2%), 
is available to cells to exert their physiological effects.2  
 
 
Scheme 1.2. Regulation of active steroid concentration. 
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1.3 STEROID MODE OF ACTION 
 
The present understanding of the major pathways by which steroid hormones generate 
biological responses is shown in Scheme 1.3.1 The biological effects of steroid hormones 
in cells are mediated by non-genomic and genomic mechanisms. In the non-genomic 
action, the rate of appearance of biological responses to the hormone is generally rapid, 
varying from seconds to an hour.1 Here, plasma membrane associated receptors have been 
implicated in hormone action.1 These receptors are believed to stimulate secondary 
messenger cascades, such as protein kinases, changes in intracellular pH and Ca2+ 
concentration.3 However, the nature and characteristics of such membrane sites remain 
unclear. The genomic action of steroids is well understood, in which a steroid ligand-
receptor complex acts as a transcriptional factor for gene expression. This mechanism is 
non-rapid in contrast to the non-genomic, with biological responses taking a few hours to 
days to manifest.1 Crosstalk may occur between genomic and non-genomic mechanisms. 
For the remainder of this section, discussion will focus on the well characterised genomic 
mechanisms of action.  
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Scheme 1.3. Genomic and non-genomic modes of steroid hormone action (adapted from 
Norman et al.1). 
 
 
1.3.1 Genomic action of steroids  
 
The genomic action of steroid hormones is mediated by the formation of a complex 
between a steroid and a specific nuclear protein called a receptor. This steroid-receptor 
complex functions in the cell nucleus as a transcription factor which selectively modulates 
gene expression (generating ‘genomic’ responses). Steroid receptor mediated gene 
expression is well understood and is regarded as the ‘classic’ steroid mechanism of action.1 
Steroid receptors recognise minimal structural differences among steroid molecules to bind 
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their cognate steroids tightly with dissociation constant (Kd) values in the range of 0.05-50 
nM.1 Steroids have higher affinity for their receptors than plasma transport proteins (see 
section 1.2) which facilitates dissociation of the steroid-transport protein complex. 
 
 
Steroid receptors 
 
Steroid receptors are a subfamily of the nuclear receptor group, which also includes the 
thyroid hormone and retinoic acid receptors, and orphan (unknown ligand) receptors. The 
elucidation of steroid receptor structure and function has been made possible by the 
cloning of corresponding gene sequences.4 Steroid hormone receptors are a highly 
conserved group of ‘ligand-dependent’ nuclear transcription factors, consisting of 
particular amino acid sequences (domains) that give rise to various receptor functions. 
These include ligand binding, DNA binding, and transactivation domains. Other functions 
such as dimerisation and translocation to the nucleus have been assigned to more complex 
regions of the protein. The DNA binding domain (DBD) is the most highly conserved 
region of the nuclear receptors, followed by the ligand binding domain (LBD) located 
towards the carboxy terminus of the protein.4  
 
 
Steroid receptor mediated gene expression 
 
In the absence of steroid hormones, steroid receptors are localised in the cell nucleus, 
where they are kept in an inactive state as part of complexes with heat shock proteins 
hsp90 and hsp70. They are also present in the cytoplasm or can be partitioned between the 
cytoplasm and nucleus, depending on the particular steroid hormone.1 The mechanism of 
action of steroid hormones begins when they move passively from the bloodstream across 
cell membranes to the nucleus where they bind and activate nuclear steroid receptors.5 
Once a steroid binds to its cognate receptor, a different conformation of the receptor 
becomes energetically favourable, and helix-12 of the receptor closes over the ligand 
binding pocket.6 This ‘active’ conformation promotes dissociation of the heat shock 
proteins. The receptor is also phosphorylated, converting it to the transcriptionally active 
form that binds to specific DNA sequences termed steroid response elements (SREs). 
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SREs are different for different steroid-receptor complexes, and are associated with 
promoter regions that regulate gene transcription. The activated steroid-receptor complex 
binds to DNA as a homodimer where it recognises individual base pairs in the major 
groove of DNA. Following DNA binding, transcriptional factors are recruited and 
stabilised at the target gene promoter, and RNA polymerase is activated to begin mRNA 
synthesis. As well as being stimulated, transcription rates can also be inhibited. The final 
product of the steroid-receptor-gene interaction is the expression of specific proteins that 
modulate cell and tissue function. 
 
 
Regulation of steroid action 
 
Since the cell response to steroid hormones is dependent on receptor levels, mechanisms 
that modify receptor concentration also control steroid action. Nuclear steroid receptors are 
regulated by their ligands in a feedback mechanism termed autoregulation,7 e.g. sex steroid 
receptors are down-regulated by their cognate ligand (negative autoregulation). However 
vitamin D receptors are up-regulated (positive autoregulation).8 The overall effect steroids 
have on cells is the induction and inhibition of cell growth.5 Their effects are profound at 
the cellular level; it is for this reason that multifaceted active steroid level control 
mechanisms are important. 
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1.4 STEROIDS AND DISEASE 
 
Steroids play essential and pervasive roles in the short-term and long-term regulation of 
endocrine processes. For this reason there are strict control mechanisms that regulate 
steroid activity (some of which were discussed in section 1.2). However disorders relating 
to steroid activity may arise when control mechanisms fail. Both overactive and 
underactive steroid secretion, resulting in changes to normal steroid activity, inevitably 
leads to diseases which are often debilitating or life threatening. 
 
The sex steroids (estrogens and androgens) are extremely important hormones that are 
responsible for fundamental endocrine processes such as sexual differentiation 
(feminisation and masculinisation), the development of secondary sex characteristics and 
the control of cell growth in various tissues. Changes to normal sex steroid activity within 
these processes may contribute to the pathogenesis of diseases such as cancer of sex steroid 
target tissues and developmental and reproductive abnormalities. Estrogens and androgens 
are linked to breast and prostate cancer, two of the most common types of cancer in the 
Western world.9,10 These prominent diseases have attracted a great deal of research into the 
role of sex steroids in cancer, and the development of therapeutic drugs. The following 
section describes the role of estrogens and androgens within the endocrine system, which 
lead to a discussion on their implication in breast and prostate cancer and other 
pathological states. 
 
 
1.4.1 Sex steroids 
 
The sex steroids consist of two major groups, the estrogens and androgens. Estrogens are 
responsible for the development of the female sex organs, and secondary sex 
characteristics. Estrogens are biosynthesised mainly in the ovaries but also in the adrenal 
cortex, testes and other tissues. The androgens stimulate development of the male sex 
organs and secondary male sex characteristics. Androgens are largely biosynthesised in 
Leydig cells in the testes, the adrenal cortex, and a small amount in the ovaries and 
placenta (Scheme 1.4). Circulating sex steroids are transported by the plasma transport 
protein, steroid hormone-binding globulin (SHBG). The estradiol to testosterone ratio is 
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important when these steroids exert their effects. For example, in females the ratio is very 
much in favour of estradiol, but very much in favour of testosterone for males. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.4. Biosynthesis of estrogens and androgens. 
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Estrogens 
 
Ovarian steroid hormone pharmacology began over 40 years ago when in 1962 Jensen et 
al. showed that radiolabelled estradiol was held in cells that demonstrated a response to 
this hormone.11 This finding led to the discovery of a protein that mediates the biological 
activity of estrogens, which was named the estrogen receptor (ER). A second type of ER 
was discovered in 1996, when the two receptors were named ERα and ERβ (these will be 
discussed further in Chapter Two). The presence of ER in a tissue usually indicates 
estrogen mediated biological responses at that location (Table 1.1). Such responses include 
the stimulation of growth and development of the vagina, uterus and Fallopian tubes. 
Estrogens initiate breast enlargement through the promotion of duct growth, stromal 
development and fat accumulation. Estrogens also control the menstrual cycle, along with 
progesterone, with main roles in preparing the reproductive tract for reception of a 
fertilised ovum, and maintaining a pregnancy. There are also effects on the hypothalamus 
and brain, and cardiovascular system.12,13  
 
Distribution of Estrogen Receptors in Tissue 
 
Reproductive Tract 
Uterus 
Placenta 
Ovary 
Corpus luteum 
Mammary tissue 
 
 
Neuroendocrine 
system 
Pituitary 
Hypothalamus 
Brain 
 
Male tissue 
Testis 
Epididymis 
Prostate gland 
Seminal vesicles 
 
 
Visceral organs 
Liver  
Kidney 
Lung 
 
 
Table 1.1. The presence of estrogen receptors in tissue types. 
(Taken from Norman and Litwack14). 
 
 
The main estrogen found in a non-pregnant female is 17β-estradiol. Estradiol is 
biosynthesised from testosterone, via aromatisation of the A ring, or from estrone, by 
reduction of the ketone (Scheme 1.4). Aromatase, a cytochrome P450 enzyme, catalyses 
the conversion of testosterone to estradiol, and requires NADPH and O2. These reactions 
occur mostly in ovarian granulosa cells, but also in the adrenal cortex, the foetal-placental 
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unit and adipose tissue. Small amounts are synthesised in the testes, prostate, muscle 
tissue, and liver. The presence of the ER in tissue cells indicates the biological actions of 
17β-estradiol at that location. In these target cells, estradiol diffuses across the nuclear cell 
membrane where it binds to the ER. The ER is predominantly found in the cell nucleus, but 
constantly shuttles between the nucleus and cytoplasm. Once bound with estradiol, the ER 
acts as a transcriptional regulatory protein which modulates gene expression (see section 
1.3.1) and ultimately cell proliferation or death. Chapter Two of this thesis investigates ER 
mediated gene expression stimulated by chemicals other than estradiol, to identify agents 
that have the potential to disrupt endocrine processes. Recent research reports that estradiol 
is also capable of acting through non-genomic mechanisms (described in section 1.3), 
including increasing intracellular Ca2+ levels, activating a kinase enzyme associated with 
cardiovascular system protection, and binding to plasma-membrane receptors to block 
apoptosis (for a review and references therein see Norman et al.1). 
 
 
Estrogens and cancer 
 
Estrogens are important factors in cancers of their main target organs, the breast, 
endometrium and ovary. Breast cancer is the most common cancer in women worldwide, 
with more incidence in Western countries than compared with Asian countries.9 Estrogens 
are involved in the pathogenesis of breast cancer, of which the mechanisms are yet to be 
fully understood. The genotoxicity of estrogen and several metabolites have been 
suggested as factors in the development and growth of tumours.15 Estrogens are implicated 
in the development of mammary cancer in rodents and aid in the proliferation of cultured 
human breast-cancer cells.16 Therefore, exposure to estrogen affects the risk of breast 
cancer. Genetic and environmental factors are able to influence estrogen homeostasis and 
exposure to estrogen and its metabolites. The life-stage of a woman, exercise and diet, 
serum concentrations of SHBG and exposure to exogenous sex steroids contribute to 
individual variation in estrogen exposure. Estrogen levels may be enhanced by exposure to 
endocrine disrupting chemicals (EDCs), some of which mimic the chemical structure of 
17β-estradiol and can activate ER mediated gene expression. Many different classes of 
compounds have been identified as estrogen mimics, including environmental chemicals 
such as pesticides. Chapter Two describes an investigation into ER mediated gene 
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expression stimulated by pesticide metabolites. Because of their steroid-like effects, EDCs 
have been linked to cancer but their relationship remains to be determined. The activity of 
enzymes in the metabolism of estrogen is another factor implicated in cancer, due to the 
generation of potentially carcinogenic estrogen metabolites.15 
 
 
Androgens 
 
Androgens are responsible for sex determination, foetal development, growth and sexual 
maturation. The two most important androgens are testosterone (the main androgen 
secreted in the testes) and 5α-dihydrotestosterone (DHT). Testosterone and DHT have 
different physiological roles in the male (see Table 1.2). At the embryonic stage, the 
production of testosterone regulates gonadotropin production, spermatogenesis, and 
formation of internal male genitalia (epididymis, seminal vesicles and vas deferens). In the 
embryo DHT stimulates formation of male external genitalia (penis, scrotum, urethra, and 
prostate). At puberty testosterone is associated with modifying external genitalia, 
increasing muscle mass, voice deepening, and male sexual behaviour, while DHT is 
responsible for increasing body and facial hair and prostate enlargement. 
 
Biological Response Androgen responsible 
 
Reproductive tract- differentiation and growth of tract: 
epidiymus, prostate, seminal vesicles, vas deferens, bulbourethral glands 
Stimulation of male secondary sex characteristics: 
growth of external genitalia, voice deepening, hair growth and body 
distribution 
Anabolic actions: skeletal and muscle growth, subcutaneous fat distribution,  
growth of prostate 
growth of seminal vesicle 
CNS action and brain: 
differentiation of regions 
libido development 
 
DHT 
 
T 
 
 
T 
DHT 
T, DHT 
 
T metabolised to E 
T 
 
 
Table 1.2. Biological responses of testosterone (T) and DHT (E - estradiol). 
(Taken from Norman and Litwack14). 
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The biosynthesis of testosterone and DHT is shown in Scheme 1.5. The ∆5-pathway 
predominates in humans. Other androgens synthesised are released in low concentrations. 
Any steroid on the ∆5-pathway can be converted to the corresponding steroid on the ∆4-
pathway by the enzyme 3β-steroid dehydrogenase/∆5,∆4 isomerase.  
 
 
 
Scheme 1.5. Biosynthesis of testosterone by ∆5- and ∆4-pathways and conversion to DHT. 
 
 
Both testosterone and DHT are produced by the testes and circulate in the plasma, but there 
is significant metabolism of testosterone to DHT in target cells, e.g. prostate cells. This 
reaction is carried out by the enzyme steroid 5α-reductase. The tissue distribution of 
steroid 5α-reductase determines whether testosterone or DHT is the initiating androgen in 
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target cells. Both bind very efficiently to the androgen receptor (AR), whilst stimulating 
different biological responses (Table 1.2). The AR functions, like all steroid receptors, as a 
transcriptional regulatory protein in gene expression when activated by androgen binding 
(the genomic action of steroids was discussed in detail in section 1.3.1). Of all the 
androgens, testosterone and DHT have the highest affinity for the AR, hence their 
designation as the active androgens. DHT has approximately twice the affinity for the AR 
compared to that of testosterone.14  
 
Testosterone and DHT effect different biological responses despite the fact they bind to the 
same receptor. DHT amplifies the androgen signal (compared with that of testosterone) 
because of its higher affinity for the AR. It has been suggested that DNA binding and 
expression by the testosterone-AR complex is different to that of the DHT-AR complex 
(which is proposed to have higher affinity for DNA).17 Another explanation is that tissue 
response differences are related to the activity of steroid 5α-reductase and also AR 
concentrations in target tissues.18 In muscle tissue for example the activity of steroid 5α-
reductase is so low that testosterone produces the hormonal effect. 
 
 
Androgens and prostatic disease 
 
Androgens are required for normal prostate growth, in particular DHT which promotes cell 
growth. However, androgens are also implicated in prostatic disease. Prostate cancer is one 
of the most common cancers in men over the age of 50 in the Western world, and 149,000 
deaths occur annually worldwide.10,19 The tumour is endocrine-responsive as DHT 
stimulates tumour growth. Benign prostatic hyperplasia (BPH) is a non-cancerous 
enlargement of the prostate which is also common in men over the age of 50, and causes 
bladder outlet obstruction and urination problems. Prostatectomy (removal of all or part of 
the prostate) is the second most common operation in men over the age of 65.20 The 
presence of androgens, the AR and steroid 5α-reductase are requirements for the 
development of BPH (5α-reductase activity is 2-3 times higher in the prostates of BPH 
sufferers21). Although it is known that prostate cancer and BPH occur when the balance 
between cell growth and apoptosis (programmed cell death) is not maintained,19 the exact 
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cellular mechanisms involved in upsetting this balance are not fully understood. Factors 
that have been implicated in initiating prostate cancer and BPH are: 
 
i) Increased androgen levels: Changes in cell growth/death balance could be due to 
increased androgen synthesis and decreased inactivation, which is regulated by the 
pathway of steroidogenic and steroid-metabolising enzymes (see Scheme 1.4). As a 
consequence, higher than normal levels of androgens may be produced, promoting 
increased cell growth.  
 
ii) Estrogen: Evidence suggests that exposure to estrogen can also lead to the 
development of changes in cell growth within the prostate, and is therefore implicated in 
the development of BPH and prostate cancer.10,19 Testosterone levels decline in men with 
age, while estrogen levels are maintained by enhanced levels of aromatase activity, 
resulting in estrogen accumulation in the prostate. 
 
Controlling androgen levels in prostate disease is the aim for therapeutic intervention. A 
strategy for treatment of DHT-dependent tumours and BPH is to reduce the level of DHT 
in the prostate. Halting the production of DHT by inhibiting steroid 5α-reductase activity 
is one such strategy that has been investigated. Steroidal inhibitors of 5α-reductase have 
been developed, two of which are in clinical use (see section 3.1.4.1, Chapter Three). 
However their steroidal nature is associated with side effects. For this reason, the recent 
focus of 5α-reductase inhibitor development has been on non-steroidal compounds. 
Chapter Three of this thesis describes the synthesis and assay of novel non-steroidal 
inhibitors of steroid 5α-reductase. 
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1.5 STEROID CHEMICAL STRUCTURE  
 
Because of the key role that steroids play in health and disease, it is essential to understand 
the molecular details of steroid action. The biological activity of steroids is due to their 
chemical structure which is recognised by steroid receptors and metabolising enzymes. 
Examination of the molecular structures and three-dimensional shapes of endogenous 
steroids that stimulate biological responses provides useful information for several reasons; 
predicting exogenous compounds which can mimic steroids and be recognised by receptors 
(a subject of concern which is the focus of Chapter Two) or enzymes, and for designing 
analogues of steroids for the synthesis of drugs to target disease (the subject of Chapter 
Three). 
 
The chemical structure of steroids is derived from the cyclopentanoperhydrophenanthrene 
nucleus (see Fig. 1.1), which consists of a phenanthrene molecule (rings A to C) with a 
five membered carbocyclic ring attached (ring D). The basic ring structure is biologically 
modified to produce a particular steroid hormone. Hydroxyl or carbonyl substituents and 
varying degrees of unsaturation are added in various positions. Another important 
structural feature of steroids is the presence of asymmetric carbon atoms. The three-
dimensional arrangement of atoms plays important roles in the structure and therefore 
activity of steroids, especially in selective binding to steroid receptors and metabolising 
enzymes. Fusion of the rings leads to a surface (which is almost flat for many steroids) 
having readily discerned upper and lower faces. Functional groups can be above/in, or 
below the plane of rings as drawn in Figure 1.2.  
 
 
 
 
           (i)          (ii) 
 
Figure 1.2. (i) Steroidal α and β nomenclature and (ii) ring junction orientations. 
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The three-dimensional structure of steroids varies greatly depending on the types of ring 
junction present. The rings in steroids can be trans or cis fused (see Fig. 1.2). The three 
most commonly encountered structures result from differences in the AB ring junction 
which may be trans or cis (Fig 1.3). The BC and CD ring junctions normally exist as the 
trans form. Cis-trans isomerism is not possible at the AB ring junction when the A ring 
possesses unsaturation as shown in Figure 1.3 (e.g. in testosterone).  
 
 
 
 
 
 
Figure 1.3. Common three-dimensional conformations of steroids. 
 
 
In the estrogens the A ring is aromatic (see Scheme 1.3) so there is no cis-trans isomerism 
possible. The aromatic ring is completely planar which has significant effects on their 
biological activity (which will be discussed in more detail in Chapter Two). 
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1.6 NON-STEROIDAL ANALOGUES OF SEX STEROIDS 
 
The structure and conformation of steroids play a vital role in recognition and binding to 
their cognate receptor or metabolising enzyme, and it is now widely recognised that 
compounds which mimic steroidal conformation can also bind to these cellular targets.6 
Steroid mimics without the steroidal cyclopentanoperhydrophenanthrene nucleus are 
termed non-steroidal analogues. These mimics are of interest because they may enhance or 
decrease steroid activity which potentially has beneficial or harmful consequences. The 
effects of non-steroidal analogues on steroid activity are implicated in several areas of 
research. Non-steroidal analogues of steroids have been developed to treat disease, for 
example cancer, for the purpose of reducing steroid activity within the tumour. From 
another perspective, unintentional exposure to non-steroidal analogues of steroids may 
enhance steroid activity. An area of concern is the exposure to environmental chemicals 
which may mimic steroid activity. The following section describes the potential adverse 
effects of non-steroidal analogues, and the use of non-steroidal analogues in medicinal 
chemistry for health benefits. This thesis focuses on these two different effects of non-
steroidal analogues on steroid activity. 
 
 
1.6.1 Adverse effects of non-steroidal analogues on steroid activity 
 
While pharmaceuticals are used intentionally to alter steroid activity in disease treatment, 
there is increasing knowledge of natural and synthetic compounds which are suspected to 
have unintentional adverse effects on steroid activity. A wide range of non-steroidal 
compounds from environmental sources have been found to mimic endogenous steroids, in 
particular the sex steroids, either by binding to hormone receptors, or to enzymes involved 
in steroid biosynthesis and metabolism, or through other mechanisms.6,22 The activity of 
these compounds is encompassed in a research field termed ‘endocrine disruption’. There 
is concern that steroid mimics may alter endogenous steroid activity and disrupt endocrine 
processes, the result of which may be disease. A widely investigated area within endocrine 
disruption research is that of exogenous chemicals which bind to the ER, and thus mimic 
17β-estradiol activity. Genistein and bisphenol A (Fig. 1.4) are examples of natural and 
synthetic exogenous compounds which have been found to bind and activate the ER. An 
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understanding of how exogenous compounds mimic 17β-estradiol is important for 
predicting compounds capable of altering endogenous steroid activity. Such information 
could lead to further elucidation of causative agents in disorders like cancer and 
reproductive abnormalities. Chapter Two of this thesis will discuss endocrine disruption 
and estrogen mimics in further detail to introduce an investigation into non-steroidal 
compounds which activate ER mediated gene expression in recombinant yeast. 
 
 
 
 
 
 
 
Figure 1.4. 17β-Estradiol and examples of environmental mimics. 
 
 
1.6.2 Non-steroidal analogues in medicinal chemistry 
 
Non-steroidal analogues of steroids provide the basis of various pharmaceuticals used to 
treat hormone related problems. The biological targets for such drugs may be steroid 
receptors or enzymes involved in steroid biosynthesis and metabolism. Pharmaceuticals 
with a steroidal based structure designed for a particular receptor (or enzyme) have the 
potential to bind to other steroid receptors, as there is a high degree of homology in steroid 
receptor LBDs. The non-selective binding of steroid drugs may lead to adverse side 
effects. Non-steroidal drugs offer advantages over steroidal drugs by enhancing receptor 
selectivity. Non-steroidal compounds also offer better pharmacokinetic properties, such as 
oral bioavailability and hepatic metabolism.23 These properties make them attractive 
targets for novel pharmaceuticals. Non-steroidal compounds have been developed to 
mimic androgens and bind to the AR for the purpose of reducing the level of androgens in 
cancer cells. AR antagonists are used clinically in treating prostate cancer; one example is 
flutamide (Fig. 1.5). Flutamide competes with DHT for binding to the AR in prostate 
tissue. Non-steroidal mimics of estrogen are also in clinical use for the treatment of ER 
positive breast cancer, for example tamoxifen (Fig. 1.5). This drug is metabolised to the 
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more potent 4-hydroxytamoxifen which binds to the ER in breast tissue, and prevents ER 
mediated gene expression and growth of cancer cells. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Non-steroidal analogues of sex steroids in clinical use for cancer treatment. 
 
 
Enzymes involved in the biosynthesis and metabolism of steroids are also attractive targets 
for the development of non-steroidal drugs. Non-steroidal compounds are of great interest 
for inhibiting steroid 5α-reductase, the enzyme that converts testosterone to DHT (see 
Scheme 1.5). Abnormal levels of DHT are implicated in several disease states, including 
prostate cancer, BPH, androgenetic alopecia and acne. Reducing the levels of DHT by 
inhibiting 5α-reductase activity is a logical strategy for treating these disorders. To date 
there are no non-steroidal inhibitors approved for clinical use, but some classes of 
compounds are currently involved in clinical trials. Chapter Three will discuss steroid 5α-
reductase inhibition by non-steroidal compounds in more detail, and work towards this 
thesis on the design, synthesis, and testing of non-steroidal inhibitors of this enzyme.  
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1.7 WORK DESCRIBED IN THIS THESIS 
 
The information provided in this introduction gives an overview of the importance of 
steroids and mechanisms for their biological activity within cells. The chemical structure 
of a steroid is recognised by steroid receptors and metabolising enzymes, interactions 
which are critical for mediating steroid activity within cells and tissues. However steroid 
receptors and metabolising enzymes also recognise and bind non-steroidal compounds, the 
effect of which may be the alteration of endogenous steroid activity. The consequences of 
altering steroid activity may be harmful, due to unintentional effects of steroid mimics (e.g. 
EDCs), or beneficial, for example treating disease with drugs designed to mimic steroids. 
This thesis investigates the effect of non-steroidal analogues on the biological activity of 
sex steroids from two perspectives; the interaction of non-steroidal compounds with a sex 
steroid receptor and an enzyme involved in sex steroid metabolism. 
 
Chapter Two describes a study investigating the estrogen-like activity of non-steroidal 
compounds through their interaction with the human ER (hER). Exogenous chemicals 
which mimic estrogen are of concern as they may alter estrogen activity and disrupt 
endocrine systems. Endocrine disruption by exogenous chemicals is reviewed, including 
their mechanisms of action and the evidence observed in wildlife and humans that links 
these chemicals with adverse effects on endocrine systems. The non-steroidal chemicals 
investigated in this study were pyrethroid insecticide metabolites, which were proposed to 
interact with the ER due to structural features mimicking those of 17β-estradiol. Whilst 
some were available commercially, a number of metabolites were synthesised. A 
biological assay was established and used to determine the activation of hER-mediated 
gene expression by these pyrethroid metabolites relative to that of 17β-estradiol. This 
assay involves a recombinant yeast strain which expresses hERα and possesses a lacZ 
reporter gene construct to allow detection of estrogen stimulated gene expression. The 
results are put into context by considering the estrogenic activity of metabolites in relation 
to the likelihood of exposure to these compounds. 
 
Chapter Three is concerned with the inhibition of a sex steroid metabolising enzyme by 
novel non-steroidal compounds. Steroid 5α-reductase converts testosterone to DHT and 
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abnormal levels of DHT are associated with prostate and skin disorders. Regulating DHT 
activity by 5α-reductase inhibition is a logical strategy for drug therapy. A review of non-
steroidal compounds already known to inhibit this enzyme is presented, which leads to a 
discussion on efforts in this thesis towards the rational design of novel inhibitors, with 
focus on investigating structure-activity relationships (SAR). The synthesis of proposed 
non-steroidal inhibitors is detailed, followed by a discussion on their activity against 
steroid 5α-reductase expressed by transfected human embryonic kidney cells. 
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2.1 INTRODUCTION 
 
Endocrine systems of the body provide means to enable target tissue responses to 
hormonal signals originating in another organ. Steroid hormones play essential roles within 
the endocrine system, which were discussed in detail in Chapter One. The objective of 
endocrine systems is to maintain homeostasis within the body, avoiding significant 
changes in hormone levels and responses which may have detrimental effects on 
metabolism.1 Increased or decreased hormone activity in endocrine systems can lead to 
potentially debilitating and life threatening disease involving different organs and 
functions. Chapter One discussed the potential adverse consequences of altering normal 
sex steroid hormone activity using target tissue cancers as an example (see Chapter One, 
section 1.4). There is significant concern for chemicals in the environment which mimic 
sex steroids and thus may alter endogenous sex steroid activity by interacting with sex 
steroid hormone receptors and enzymes. The following section discusses these endocrine 
disrupting chemicals (EDCs); their mechanisms of action and their history, which includes 
evidence for the implication of EDCs in endocrine abnormalities observed in wildlife and 
humans. 
 
 
2.1.1 Endocrine disruption 
 
The last two decades have witnessed growing concern about chemicals in the environment, 
including those that may interfere with the endocrine systems of wildlife and humans 
(EDCs). EDCs come from a wide range of chemical classes and sources, which include 
natural and synthetic hormones, plant constituents, pesticides, chemicals used for plastic 
and consumer product manufacture, industrial by-products and other pollutants. They are 
widely dispersed in the environment, where some are persistent. Others are rapidly 
degraded in the environment or human body, or may be present for short periods of time 
but at critical periods of development. Although they often display weak hormonal activity, 
their lipophilic nature allows them to accumulate in the fatty tissues of the body. This 
increases their concentration and bioavailability. 
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EDCs may interfere with endocrine systems by mimicking hormone action (particularly 
steroid hormones), preventing the action of hormones, altering hormone biosynthesis and 
metabolism, or by affecting the level of hormone receptors within the cell. Upon 
recognition of EDCs and their potential adverse health effects, laws were introduced in the 
United States. These laws required the Environmental Protection Agency (EPA) to develop 
and implement a screening strategy to assess risk from estrogenic endocrine disruptors, as 
the binding of molecules, other than estrogen, to the ER was already known to be a major 
mechanism of endocrine disruption. Androgenic and thyroid-active chemicals were also 
included and active chemicals were to be subjected to rigorous animal studies. Several 
methods have been established for screening and detecting endocrine disruptors, including 
the measurement of receptor-dependent responses, structure-activity relationship (SAR) 
based priority assessment, as well as a number of in vitro and in vivo assays. These will be 
discussed further in sections 2.1.7-2.1.8. 
 
There are several critical points that must be considered when assessing the potential 
impact of endocrine disruptors:1  
i) There may be no significant or observable effect if adult exposure is compensated for 
by normal homeostasis; 
ii) Permanent change to endocrine function can occur if EDC exposure is during foetal 
development; 
iii) Various effects may be observed if exposure to an EDC is at different life stages or 
seasons;  
iv) Endocrine pathways are connected intimately and the effects of EDCs may be 
unpredictable for systems not included in the assessment;  
v) Caution needs to be taken when extrapolating results from in vitro hormonal activity 
to the situation in vivo. 
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2.1.2 EDC mechanisms of action  
 
An EDC is defined by Kavlock et al.2 as “an exogenous agent that interferes with the 
production, release, transport, metabolism, binding, action, or elimination of natural 
hormones in the body responsible for the maintenance of homeostasis and regulation of 
developmental processes.” This interference is believed to be from chemicals mimicking 
endogenous hormones (in particular sex steroid hormones), antagonising endogenous 
receptors, altering the biosynthesis and metabolism of hormones, and modifying hormone 
receptor levels. The focus in this thesis is on chemicals that mimic 17β-estradiol by 
activating the ER.  
 
 
Interaction with hormone receptors 
 
Interaction with cellular hormone receptors is widely recognised as a major EDC mode of 
action. The role of receptors in hormone mediated gene expression (see Fig. 2.1) was 
discussed in detail in Chapter One, section 1.3.1. EDCs can mimic endogenous hormones 
and potentially induce hormone directed effects by activating a particular receptor 
(agonist) or by blocking the receptor (antagonist). This results in changes to gene 
expression characteristics for a certain hormone. Change in gene expression is a critical 
step in the regulation of a biological function, which could therefore be altered by an EDC. 
There are several systems used to evaluate the interaction of exogenous chemicals with 
hormone receptors, in particular those interacting with the ER, AR, thyroid, and aryl 
hydrocarbon receptors.1 Binding and activation of the ER by chemicals (other than the 
endogenous hormone 17β-estradiol) has been well studied and will be discussed in detail 
in section 2.1.6. However, there is a growing knowledge that exogenous chemicals may 
interact with other hormone receptor systems. These include the retinoic acid receptor, 
cytokine systems and orphan receptors (with unknown ligands and/or functions).  
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Figure 2.1. Key steps in steroid hormone action which may be sensitive to EDCs (adapted 
from WHO report1):  
The steroid hormone (H) is synthesised in an endocrine cell, then transported in the 
bloodstream bound to SHBG to the target cell. The steroid diffuses into the target cell and 
binds to nuclear receptor proteins (R). Steroid-receptor binding induces a conformational 
change in the receptor, increasing its affinity for specific DNA regions. Binding of the 
steroid-receptor complex to DNA initiates mRNA synthesis and translation to give proteins 
(enzymes, hormones, receptors and growth factors) which can initiate proliferative 
responses in the target cell. 
 
 
Interaction of chemicals with hormone biosynthesis and metabolism 
 
EDC research has focussed on interactions of exogenous chemicals with sex hormone 
receptors, particularly the ER. However alternative modes of action for EDCs have been 
investigated. Some chemicals, for example PCBs, exhibit estrogenic activity in 
experimental animals, but have little or no affinity for the ER.3 Therefore their estrogenic 
action cannot be due to ER mediated gene expression. An alternative mechanism of EDCs 
includes altering the function of key enzymes in steroid hormone biosynthesis and 
metabolism. Cytochrome P450 enzymes are of interest as they are responsible for the 
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highly specific reactions in steroid biosynthetic pathways, in which potent endogenous 
steroid hormones are formed. 
 
A key cytochrome P450 enzyme in steroidogenesis is aromatase (CYP19). Aromatase 
catalyses both the conversion of testosterone (2.2) to estradiol (2.3), and androstenendione 
(2.1) to estrone (2.4) (Scheme 2.1). This enzyme is of particular interest as it catalyses the 
final rate-limiting step in estrogen formation which occurs in ovarian granulosa cells, 
adrenal cortex, and in tissues such as brain, adipose and placenta. Aromatase plays a 
critical role in sexual differentiation, reproduction, and behaviour, as well as in disease 
such as estrogen-dependent cancer.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1. Aromatase catalysed metabolism of testosterone (2.2) and androstenedione 
(2.1). 
 
 
EDCs may interfere with the activity or expression of aromatase and disrupt processes 
such as the estrous cycle, sperm production and maturation, onset of puberty, development 
of sexual behaviour, as well as the inhibition or stimulation of breast, ovary and prostate 
hormone-dependent tumours. Several classes of pesticides that persist in the environment 
are suspected or have been shown to alter aromatase activity, including organotin 
compounds (used as antifouling agents on ship hulls), DDT and several metabolites, some 
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azole fungicides, and several triazine herbicides.4 In particular, azole fungicides have been 
shown to inhibit aromatase activity in rainbow trout, which may indicate their ability to 
block estrogen mediated responses.5 More experimental evidence is required to determine 
the exact mechanism of interference that chemicals have with aromatase activity. There 
has been some attempt to determine whether the enzyme is being induced or inhibited, or 
whether aromatase mRNA expression is altered, but this is still not completely clear. 
However, this area warrants further investigation to increase understanding in the 
complexity of the mechanisms by which EDCs may act.  
 
Enzymes are also responsible for regulating steroid hormone metabolism, another potential 
target for EDC activity. Metabolism of chemicals in cells usually occurs via Phase I and II 
reactions.6 Phase I metabolism, carried out by cytochrome P450 enzymes, introduces 
hydroxyl groups to a molecule. These hydroxyl groups are then conjugated, via Phase II 
metabolism, with charged groups such as sulfate, glucuronide, or amino acids. Circulating 
estrogens are metabolised extensively in the body, especially in the liver. They are either 
conjugated with sulfate alone (Phase II) or after hydroxylation by P450 enzymes (Phase 
I).4 They can also be conjugated to glucuronide moieties. Both metabolic processes render 
them hormonally inactive. A small fraction of estrogens are hydroxylated by P450 
enzymes, which convert them to catechol estrogens. Some of these Phase I metabolised 
estrogens have been implicated in estrogen-mediated genotoxic carcinogenesis.7 
Polyhalogenated and polycyclic aromatic hydrocarbons are capable of affecting the 
catalytic activity of these metabolising enzymes by inducing certain P450 enzymes that 
hydroxylate estrogens.4 
 
 
2.1.3 History and evidence for endocrine disruption  
 
Rachel Carson’s book Silent Spring8 first raised concerns about chemicals and their 
potential to cause unpredicted effects on wildlife and the environment. Since the 
publication of Silent Spring in 1962, there has been increasing awareness of chemicals in 
the environment that might have profound adverse effects on wildlife, even decades after 
their use (such as the case for DDT). A significant amount of literature has surfaced on the 
hormone-like effects of environmental chemicals in fish, wildlife and humans. 
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Unfortunately, these effects were discovered following the release of chemicals into the 
environment. Research into endocrine disruption has only been active over the last 15 
years since Theo Colborn and coworkers presented the notion at a conference in the USA 
in 1991.9 Research has since focussed on chemicals that mimic reproductive hormones, 
especially estrogens. The insecticide DDT was the first intentionally released chemical to 
be identified as an estrogen mimic years later. A link between aviation crop dusters 
handling DDT and reduced sperm counts was put forward in 1949.10 Other cases of 
occupational exposure to pesticides gave further evidence that these compounds may be 
having adverse effects on workers. Further experiments in animals demonstrated that these 
chemicals were able to mimic the biological activity of estrogens.11 In 1994 Guillette et al. 
published a significant paper reporting the relationship between the reproductive 
development of alligators and contamination in Lake Apopka, Florida.12 This lake 
contained pollution from a spill of the pesticides dicofol and DDT (an intermediate in 
dicofol manufacture), which were implicated in their findings that male alligators had 
depressed plasma testosterone concentrations and abnormally smaller phalli, compared to 
alligators in nearby uncontaminated Lake Woodruff. 
 
Many studies have focussed on establishing cause and effect relationships for chemicals 
and effects observed in wildlife, but it is difficult to prove that certain chemicals have 
directly caused defects. The cause is defined as the chemical suspected to induce an effect. 
The effect is defined as the biological response to the cause. Biological responses include 
those at the molecular, cellular, tissue, organ, individual, population, and ecosystems. 
Cause and effect relationships can have varying strengths of association. There is also 
awareness for the ‘cocktail effect’ of chemicals in the environment, where exposure to 
multiple chemicals may carry certain risks compared to those of a single chemical.  
 
 
Wildlife effects 
 
Adverse reproductive effects observed in wildlife have been linked to exposure from 
mixtures of chemicals in the environment. Fish, birds, reptiles, mammals and other species 
inhabiting areas contaminated with pollutants have been observed to have reproductive 
problems. Lower organisms such as the invertebrates exhibit anatomical and physiological 
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traits that are under endocrine control, so have unique susceptibilities to EDCs and are 
important indicators of hormonal imbalance. The following are examples of abnormalities 
(particularly reproductive) observed in wildlife, and whilst there are many more than 
mentioned here, they clearly demonstrate why chemicals in the environment are suspected 
of causing endocrine disruption. 
 
i) Invertebrates: An important example of endocrine disruption by environmental 
contaminants is the exposure of molluscs to tributyltin (TBT). This compound is used as an 
antifouling paint applied to boat hulls. The condition of imposex (imposition of male sex 
organs onto females) was observed in marine gastropods exposed to TBT with increasing 
frequency.13 Supporting work showed that TBT induced penis formation when injected 
into female dogwhelks (Nucella lapillus), and high levels of testosterone were measured.14 
Recent work suggests that TBT oxide interferes with hormone metabolism, presumably by 
inhibiting aromatase and therefore increasing androgen levels.15 
 
ii) Fish: Impairment of reproductive functions in fish was studied in areas downstream 
of sewerage treatment works effluent discharge in the UK. Male fish were found to 
produce a female specific egg-yolk protein precursor, vitellogenin, indicating estrogenic 
compounds were present in the water. This was also observed in rainbow trout exposed to 
treated sewerage.16 Populations of wild fish in English rivers have been found to be 
intersex (a phenomenon induced by estrogen exposure).17 Many causative agents, 
including estrogenic compounds, have been suggested.18 Waterborne bisphenol A has been 
demonstrated to affect transcription of estrogen responsive genes transfected into tadpoles 
and fish.19 
 
iii) Amphibians: This class of vertebrates may be subject to EDC exposure during 
different life stages, and therefore be particularly at risk from EDC effects. However, while 
scientists agree that amphibian population levels are decreasing, there is insufficient data to 
link this to EDCs. Studies are now focussing on understanding amphibians as potential 
targets for endocrine disruption.1 Recent laboratory studies have shown that amphibians 
can be feminised or demasculinised by EDCs.20 
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iv) Reptiles: Alligators (Alligator mississippiensis) inhabiting Lake Apopka in Florida 
provide one of the most publicised examples of EDC effects on wildlife. The lake was 
contaminated with dicofol and DDT , and alligators were observed to have reduced penis 
size, lowered testosterone levels, and elevated 17β-estradiol levels.12 These observations 
were made in comparison with alligators inhabiting another Florida lake, Lake Woodruff, a 
relatively uncontaminated site. Further studies have led to hypotheses on the mechanism of 
effect that DDT has on reproductive systems in alligators.21 Later reports suggested that the 
effect observed in Lake Apopka was also apparent in other Florida lakes, after further 
studies at lake sites and in the laboratory. 22,23 
 
v) Birds: Populations of gulls in the Canadian Great Lakes area and California have 
been exposed to great concentrations of organochlorines, including DDT, from the 1950s 
until the 1970s. Exposure to these chemicals has been implicated in observed reproductive 
problems, including egg shell thinning, abnormal parental behaviour and poor hatching.1 
Gull embryos exposed to organochlorines via injection into eggs showed signs of abnormal 
male and female reproductive system development, suggesting these chemicals may be the 
causal agent of defects observed in wildlife. Male chicks were found to possess oviducts 
and sexual organs resembling ovaries. Female chicks were found to have abnormally 
developed oviducts.24 Current hypotheses for a mechanism to explain egg shell thinning in 
some birds involves prostaglandin inhibition, but this remains undetermined.25 
 
vi) Mammals: Declining populations of mink and otter have also been observed in the 
organochlorine polluted Great Lakes Basin area, as has reproductive failure in 
commercially reared mink which were fed fish collected from the Great Lakes. These 
observations led to the suggestion that organochlorines were having an effect on these fish 
eating mammals.26 Trends in the Swedish European otter population from 1968-1999 have 
also been examined. The observed decline in otter population during this period was 
associated with exposure to PCBs, due to an increase in the population since PCB 
concentration has decreased.27 Reproductive failure in Baltic grey seals has also been 
linked to PCBs.28 Recently sperm concentration and motility was found to be reduced in 
male rats exposed to xenoestrogen-contaminated fish during lactation.29 
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Human health effects 
 
Evidence for endocrine disruption in wildlife has led to concerns for possible effects in 
humans. There are several examples of chemicals suspected to influence human health 
effects, but cause and effect relationships are difficult to ascertain, as for wildlife. Research 
into the relationship between EDCs and human health has focussed on particular areas; 
reproduction, neurobehaviour, immune function, and cancer. Health effects observed are 
related to the level of exposure; high human exposure to environmental chemicals can 
clearly demonstrate adverse effects, whereas for low levels of exposure the data is much 
less clear. It is difficult to draw conclusions in relating EDCs to human disease by 
comparing human, laboratory, and epidemiological studies. The lack of exposure data, 
especially during development, is also highlighted when trying to draw associations 
between the cause and effect of environmental chemicals. The following section describes 
human health effects which have been associated with EDC exposure. 
 
i) Reproductive effects: The male reproductive system is of concern when considering 
the impact of EDCs on humans, and many studies have investigated variations in sperm 
count and quality. In 1992 Carlsen et al. examined 61 separate studies on sperm count in 
men in different countries and concluded the mean sperm count of healthy men had 
declined within a period of 50 years (between 1938 and 1991).30 However, the paper was 
heavily criticised on the basis that men included in the studies could hardly be compared 
due to differences in location, age, and fertility. Additionally the sample sizes in some 
studies were very small, and thus did not permit useful comparisons. To date most studies 
have been retrospective and data analysed may have been collected for other reasons (e.g. 
infertility studies). In 1993 Sharpe and Skakkebaek proposed that environmental 
chemicals, interfering with the normal development of reproductive systems by an 
endocrine mechanism, may be related to observed increases in male reproductive 
disorders.31 They argued that increased exposure to environmental estrogens in utero may 
contribute to male reproductive abnormalities. These disorders included decreased sperm 
count and quality, testicular cancer, cryptorchidism (undescended testes), and 
malformations, e.g. hypospadias (developmental abnormality where the urethra opens on 
the underside of the penis). In 2003 Sharpe and Skakkebaek concluded that environmental 
estrogens probably pose little risk to male reproductive development.32 However when the 
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mechanisms by which estrogen acts are more understood the role of environmental 
chemicals in male reproductive development disorders could be redefined. 
 
The effects of EDCs on fertility have been widely studied and occupational exposure to 
chemicals is often analysed for evidence. Studies have focussed on maternal exposure to 
agricultural chemicals (e.g. pesticides), for example an increased risk of infertility was 
associated with women working in the agricultural industry.33 PCBs and pesticides are 
thought to account for this reduced fertility. To date no clear association with endocrine 
disruption has been demonstrated, but fertility has decreased in some occupational groups 
exposed to pesticides, which warrants further investigation to better characterise the 
association.1  
 
ii) Neurobehaviour: The brain contains steroid receptors, so it is a potential target for 
EDC related effects. Epidemiological studies have implicated exposure to environmental 
chemicals in neurobehavioural alterations. These chemicals include pesticides (DDT and 
DDE, kepone), fungicides (methoxychlor, fenamirol), polychlorinated dibenzodioxins 
(PCDDs), PCBs and dibenzofurans.1 Concern is especially focussed on exposure in utero. 
The mechanisms responsible for effects observed remain to be determined. 
 
iii) Immune function: The immune system interacts with the neuroendocrine system, so 
there is potential for environmental chemicals to influence immune function by interfering 
with endocrine mechanisms. However, there are few compounds proven to cause immune 
alterations by disrupting endocrine mechanisms. Diethystilbestrol (DES) was related to 
weak immunological changes after in utero exposure in animals, as were PCBs, PCDFs 
and PCDDs.1 DES was recently found to reduce the level of circulating lymphocytes in 
rhesus monkeys.34  
 
iv) Cancer: Increased rates of cancer worldwide are used as evidence for the impact of 
of EDCs on human health. Cancer incidence in hormonally sensitive tissues has increased 
in Europe and North America, including cancer of the breast (since the 1940s), prostate 
(1980s), and testis (1960s).1 These increased cancer rates have been associated with an 
increasing use and release of chemicals in the environment, with many acting as hormone 
mimics in vitro and in vivo. However, cause and effect relationships between chemicals 
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and cancer are extremely difficult to identify. While there is not enough information in the 
literature to completely reject endocrine disruptors as a causal factor in cancer, further 
research is needed, especially on the effect of EDC exposure at critical periods in relation 
to cancer incidence. 
 
 
2.1.4 Xenoestrogens 
 
Endogenous estrogens are involved in foetal development and organ development in the 
female genital tract and other tissues (see Chapter One, section 1.4.1). They are responsible 
for female development and reproductive processes such as maintaining the menstrual 
cycle, pregnancy and lactation. Other chemicals with estrogenic action have been known 
since the 1930s when DES was first synthesised.35 DES is an estrogen mimic and is still 
one of the most potent synthetic estrogens. In 1946 it was reported by Bennetts et al. that 
breeding problems in ewes from Western Australia were associated with their diet of 
clover.36 Infertility, dystocia and prolapsed uterus were linked to the phytoestrogens (plant 
based estrogenic compounds) formononetin, biochanin A and genistein.37 Chemicals from 
many different sources are now understood to have the capability to mimic endogenous 
estrogens. These mimics are termed xenoestrogens. The prefix ‘xeno’ is derived from the 
Greek word ‘xenos’ meaning foreign.  
 
The estrogenicity of some chemicals was accidentally discovered. Experiments conducted 
to study the effects of natural estrogens were disrupted by compounds exhibiting 
estrogenic activity. In 1991 nonylphenol (2.6, Fig. 2.2) was found to be estrogenic when an 
estrogen-like substance was being released into plasma stored in plastic centrifuge tubes.38 
Nonylphenol is used as an antioxidant in plastic manufacture. Bisphenol A (a plasticiser) 
(2.5) was accidentally discovered to be estrogenic when researchers, who were searching 
for an estrogen binding protein in yeast, found an estrogenic chemical was released into the 
yeast culture medium during autoclaving of the polycarbonate plastic-ware for 
sterilisation.39  
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Figure 2.2. Xenoestrogens bisphenol A (2.5) and p-nonylphenol (2.6). 
 
 
The interaction of xenoestrogens with the ER is considered to be a major mechanism of 
endocrine disruption, and is the mechanism focussed on in this thesis. Non-genomic effects 
of estrogen have also recently been characterised, involving rapid modulation of signal 
transduction pathways.40 Overall, estrogen action with respect to the mechanism and role 
of non-genomic activity remains to be determined. Other proposed mechanisms of action 
of xenoestrogens include: 
i) Activation or suppression of the AR 
ii) Activation of the aryl hydrocarbon receptor 
iii) Inhibiting steroid hormone synthesis, transport, and metabolism 
iv) Interaction with neurotransmitter receptors. 
 
There is concern for the ‘additive’ activity of xenoestrogens in humans and wildlife as they 
may affect the levels of endogenous estrogens already present in target cells. The normal 
level of 17β-estradiol in human females ranges from 20-350 ng/L (premenopausal), 10-30 
ng/L (postmenopausal), and 100-3000 ng/L (pregnant).41 In human males the level of 
estradiol ranges between 10-50 ng/L. Exposure to natural estrogens is a principal risk 
factor in the development of breast and endometrial cancer. Adult human males exposed to 
estrogens can result in gynecomastia and abnormalities of the endocrine system, such as 
reduced libido, impotence, decreased blood levels of androgens and lowered sperm 
count.11 If exposure is in utero, then cryptorchidism (undescended testes, from the Greek 
‘kryptos’ - hidden, and ‘orchidos’ - testes), enlarged prostates, malformations of the female 
genital tract, and cancer of the vagina may occur as a result of over exposure to 
estrogens.11 For these reasons xenoestrogens are of significant importance, as they may 
alter the level of exposure to estrogens and promote the onset of the aforementioned 
disease states. 
HO OH
2.5 2.6
HO
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2.1.5 Estrogen receptor 
 
A major mechanism of endocrine disruption is considered to be via the binding of 
xenoestrogens to the ER. This receptor is normally activated by endogenous estrogens. 
Estrogens were first isolated in the 1920s,42 and by the 1950s synthetic estrogens were 
used as oral contraceptives. The biochemical basis for the action of estrogens was revealed 
in the early 1960s when Jensen et al discovered a protein (subsequently named the ER) 
with high affinity for estrogen that migrated to the cell nucleus.43 Incidentally this work 
also led to the study of other nuclear receptors. Upon its discovery, it became apparent that 
the ER was part of a larger protein complex before activation by estrogens.44 This 
activation significantly increased the binding of the receptor to DNA,45 providing a 
rationale for how the receptor has specific effects on DNA transcription. The isolation, 
purification and characterisation of major steroid receptors followed.  
 
The ER belongs to the steroid/thyroid nuclear hormone receptor superfamily. There are 
two subtypes of ER, ERα which was discovered in 1962 and the more recently discovered 
ERβ, cloned from rat prostate in 1996.46 Both receptors contain features common to this 
family of receptors. These include a two zinc finger motif DBD and C-terminal LBD 
composed of 12 alpha helical structures. Each receptor subtype contains two activation 
functions (AF), AF-1 in the N-terminus and AF-2 in the C-terminus within the LBD. The 
ERα and β receptors are only 47% identical. ERα is a slightly longer protein with 595 
amino acids compared to 530 in ERβ. The most conserved region between them is the 
DBD (differing only by three amino acids), and the most divergent is the N-terminal AF-
1.47 The LBD shows only 59% homology. With the distinct pharmacology and differences 
in tissue distribution and expression levels of the two subtypes, complexity is added to the 
biological role of 17β-estradiol. ERβ is expressed predominantly in the urogenital tract, 
and the central nervous system, where ERβ seems to have great significance in brain 
function, and in the testis. However ERα is mainly involved in reproductive events.48 This 
thesis will focus solely on the effects of ERα. 
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ERα pharmacology 
 
17β-Estradiol has a molecular volume of 245Å3, with an O-O distance of 10.9 Å. From X-
ray studies, the A-ring is planar, while the B, C, and D rings are distorted. The 
conformational flexibility of the molecule lies in the B ring, which has a half-chair 
conformation.49 The ERα is activated upon binding by estradiol within the LBD (with an 
approximate Kd of 0.3 nM50), found between amino acids 303-533. The contact sites for 
estradiol-ER interaction define the orientation of estradiol within the binding pocket (see 
Fig. 2.3). The phenolic hydroxyl of the A-ring lies between helices 3 and 6. Hydrogen 
bonds connect the phenolic hydroxyl to the carboxylate of glutamate 353, the guanidinium 
group of arginine 394, and a water molecule. The 17β-hydroxyl group of the D ring makes 
a single hydrogen bond with histidine 524 in helix 11.51 The rest of the molecule 
participates in a number of hydrophobic contacts. Estradiol binds diagonally across this 
cavity between helices 3, 6, and 11 and adopts a low energy conformation.51 Estradiol is 
completely enclosed by ERα, forming a hydrophobic core in the protein.  
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Figure 2.3. Binding of 17β-estradiol to the ERα:  
i) Ribbon representation of estradiol in LBD nestled in between helices 3, 6, and 11 (taken 
from51).  
ii) Amino acids involved in ER-estradiol interaction with hydrogen bonding (dotted line).  
(i) (ii) 
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Binding of estradiol to the ER initiates specific conformational changes in the LBD which 
promote receptor homo-dimerisation. The ER dissociates from heat shock protein hsp90, 
and allows co-activator recruitment. Hyperphosphorylation of the ER follows, revealing 
the DBD. This region of ER recognises short (13-15 base pairs) DNA sequences named 
estrogen response elements (EREs) in upstream flanking regions of estrogen responsive 
genes. Binding to EREs stimulates gene transcription and mRNA synthesis resulting in 
increased or decreased expression of estrogen responsive genes (Fig. 2.4). This series of 
events describes the agonistic effect of estradiol, but some chemicals can act as antagonists 
of the receptor. Helix 12 (Fig. 2.3) is pivotal in distinguishing between agonists and 
antagonists. Antagonists block access to a groove located in between helices 3, 4, and 5, 
which is the binding site for co-activators during transcription. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Mechanism of estradiol (E) action. 
Estradiol dissociates from its transport protein (SHBG) and diffuses across the cell 
membrane and binds to ER. Estradiol binding causes dissociation of the hsp, which allows 
the estradiol-ER complex to bind as a dimer to EREs and activate transcriptional 
machinery to alter gene activity. 
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2.1.6 ER and xenoestrogens 
 
17β-Estradiol stimulates the maximum ER response as it naturally has the best fit into the 
binding site of the protein, initiating maximum receptor conformational change. It is now 
widely recognised that other chemicals (xenoestrogens) fit into this site as they share 
common structural features with estradiol. However, they don’t fit as well and elicit a 
lesser ER-mediated response compared to estradiol. The ER has a relatively 
accommodating binding pocket and is often termed ‘promiscuous,’ with respect to the 
nature of the binding ligand. In general planar compounds with phenolic character and two 
electronegative moieties approximately 11-12Å apart can fit in the ER binding pocket.52 
These include synthetic or natural compounds which can also be non-steroidal, for 
example, DES, PCBs, alkylphenols, triphenylethylenes, phytoestrogens, pesticides and 
others (Fig. 2.5). Xenoestrogens have quite different chemical structures compared to 
estradiol, yet they can bind to the ER and presumably activate receptor mediated processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Examples of chemicals that bind to the ER.53 All possess the main features 
required for ER binding, two electronegative groups separated by a hydrophobic region. 
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2.1.7 SAR of xenoestrogens 
 
As a wide variety of natural and synthetic chemicals are capable of acting as hormone 
receptor agonists and antagonists, there is a need for screening techniques to aid in human 
health and environmental risk assessments. SAR could serve as a primary screening tool to 
prioritise chemicals, which potentially may act as estrogen mimics, for more intense and 
costly evaluations. There is a reality that there are not sufficient resources to carry out in 
vitro or in vivo assessments to screen for example, the existing 70,000 industrial organic 
chemicals (not including pharmaceuticals and pesticides), as well as the approximately 
2000 new industrial chemicals submitted each year in the United States for evaluation 
under their Toxic Substances Control Act.54 SAR and now QSAR (quantitative structure-
activity relationships) are considered useful and credible tools for predicting the ecological 
effect and fate of chemicals when there is little experimental data available. 
 
SAR are useful for predicting the potential estrogenicity of a chemical. Major efforts have 
been made to determine the structural requirements for a chemical to exhibit estrogen 
receptor binding, so the ‘estrogenicity’ of a chemical may be predicted. Fang et al. have 
completed a comprehensive SAR study into the binding of a large set of natural and 
synthetic xenoestrogens to the ER.53 A total of 230 chemicals were investigated to develop 
structure-activity relationships. An ER binding assay was used to generate relative binding 
affinities for test chemicals, covering a 10-6 range. Five key features were deemed essential 
for estrogenic activity, and the more key structural features a chemical contained, the more 
active it was found to be. The key features were: 
i) Hydrogen bonding ability of a phenolic ring mimicking 3-OH 
ii) Distance between 3-OH and 17β-OH 
iii) Steric hydrophobic groups at 7α- and 11β-positions 
iv) Overall hydrophobicity 
v) Rigid ring structure. 
 
If a chemical contains a phenolic ring and other key features then it is likely to be an ER 
ligand. The binding potential for chemicals without a phenolic ring is dependent on other 
features, such as the presence of a heteroatom required for hydrogen bonding. Whilst this 
study has provided a lot of information about SAR for xenoestrogens and ER binding, it 
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fails to determine whether a chemical acts as an agonist or antagonist. However SAR 
studies, such as this, are essential in identifying important features so that potential 
xenoestrogens may be identified for further biological based analysis. 
 
 
2.1.8 Methods for assessing estrogenicity 
 
SAR are useful for predicting estrogenic compounds but they require further testing to 
determine their biological effect. Estrogens are defined by their biological activity, so 
bioassays must be used to identify them. There are several types of assays used to assess 
the estrogenicity of chemicals. These include in-vitro and in-vivo assays. Determining the 
different degrees of estrogenicity of xenoestrogens (potency) relative to estradiol is 
important in assessing their potential effects on animals, humans, and the environment. 
 
 
In vitro assays 
 
There are three main types of in-vitro assays used to determine the estrogenicity of a 
chemical. Each of them represents a step in the ER-mediated pathway of estrogen action. 
i) Receptor binding assays which measure the affinity a chemical has for the ER. 
ii) Receptor-dependent gene expression assays, which measure the ability of a 
chemical to stimulate gene expression and protein synthesis via binding to the ER. 
iii) Cell proliferation assays, which measure a whole cell estrogenic response. 
 
 
Receptor binding assays  
 
A competitive binding assay measures the binding of radiolabelled estradiol in the 
presence of competing unlabelled ligand. It is a rapid method for determining the affinity 
of a chemical for the ER.55 Receptors are obtained from various tissues (bovine, rat, or 
MCF-7 human breast cancer cell line), or as purified recombinant protein. If the test 
chemical competes with the labelled estradiol, then it will displace a fraction of estradiol. 
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A relative binding affinity is generated so the affinity of test chemicals for the receptor can 
be compared with each other and with estradiol. 
 
 
Receptor-dependent gene expression assays 
 
These assays are based on the ability of a test chemical to bind to the ER and activate DNA 
binding and transcription, leading to gene expression. Assays of this type include: 
 
 a) Yeast based receptor assays – yeast cells have been transfected with human ERα 
(hER) DNA, and EREs linked to the lacZ reporter gene.56 This gene codes for the 
expression of β-galactosidase. If a test chemical binds to the ER and activates gene 
expression, then β-galactosidase is synthesised and released into the assay medium, where 
it cleaves a yellow galactoside dye (chlorophenol red β-D-galactopyranoside). 
Chlorophenol red is produced as a result, and can be measured spectrophotometrically. A 
luciferase reporter gene can also be used, the luminescent product of which can be 
measured. A yeast two-hybrid method has also been developed, which detects a test 
chemical-dependent interaction between ERα and a coactivator required for DNA 
transcription (coactivators interact with the ER LBD in the presence of estrogens).57 β-
Galactosidase activity is measured as an end-point. 
 
 (b) Mammalian based receptor assays – the cell either contains the ER (such as MCF-
7 cells), or hER DNA is transfected into the cell via a vector, along with a reporter gene 
linked to EREs (such as in transfected HepG2 cells). These cells synthesise β-galactosidase 
or luciferase as a result of estrogen activated reporter gene expression, and their activity is 
measured.58 MCF-7 cells have also been incubated with human and rat S9 or liver 
microsomes, which are capable of metabolising test compounds.59 
 
 HeLa cells have been transfected with a vector (pRSV) containing mouse ER cDNA, and 
an estrogen responsive vector (ERET81CAT) with EREs linked to a reporter gene coding 
for chloramphenicol acetyl transferase (CAT). Upon estrogenic activation, the amount of 
CAT produced is measured via the ELISA method.55  
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 Ishikawa Var-1 human endometrial cancer cells are rich in ER and express the enzyme 
alkaline phosphatase in response to estrogens. This enzyme converts p-nitrophenyl 
phosphate (added to the exposed cells) to p-nitrophenol which is detected 
spectrophotometrically.60 
 
 The levels of pS2 mRNA in MCF-7 cells can be measured to determine estrogenic activity. 
The cells are exposed to test chemicals and the amount of pS2 mRNA produced in 
response to estrogen activity is measured via hybridising radiolabelled probes and northern 
analysis.61 
 
 
Cell proliferation assays 
 
The hallmark of physiological estrogen action is the proliferation of estrogen-responsive 
cells. Cell proliferation assays measure the ability of chemicals to induce cell proliferation 
as an end point of interaction with the ER. The proteins synthesised as a result of DNA 
transcription and translation effect cell growth. The E-Screen assay was developed by Soto 
et al. and is one of the most commonly used estrogenic assays.62 In this assay MCF-7 cells 
(an estrogen responsive human breast cancer cell line) are used, and cells are counted upon 
incubation with a test chemical and compared to control cell growth. 
 
 
In vivo assays 
 
Diverse animal models and assays have been utilised for determining estrogenic activity. 
In vivo assays are more meaningful as they allow the full physiological effects of 
estrogenicity to be observed, i.e. they allow interactions between different parts of the 
endocrine system in the animal, which is more comprehensive than just a particular cell 
type based assay. Assays of this type include: 
i) Measuring the proliferative effect of estrogens in the female genital tract. For 
example the uterotrophic assay measures uterine weight in ovariectomised 
rodents.63 Other estrogen endpoints are also measured, such as uterine and vaginal 
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epithelium height.64 Ovariectomised mice or rats are used to minimise the effect of 
endogenous estrogens. 
ii) Measuring the effect of xenoestrogens on testicular size and sperm quality in male 
rodents, including reduction in testicular size, reduction in ventral prostate weight, 
and reduction in sperm production in male rats.65 
iii) Induction of vitellogenin in fish. Vitellogenin is a protein normally produced in 
response to estrogens in female fish. The induction of vitellogenin synthesis in 
male rainbow trout after exposure to xenoestrogens has been measured.66 
 
 
2.1.9 Metabolism of xenoestrogens 
 
SAR can be used to predict potential xenoestrogens for further biological analysis. 
However SAR do not take into account whether the chemical is an agonist or antagonist of 
the ER, and possible metabolic conversion in test assays and animals. For several 
chemicals, the products of their metabolism/environmental degradation, rather than the 
parent compound itself, are estrogen mimics. Compounds of this type include metabolites 
of phthalate plasticisers, PCBs and some insecticides.67-69 The effect of metabolism might 
explain the ‘hidden’ estrogenicity of compounds whose activity is not detected in assays 
incapable of metabolising chemicals. 
 
Information regarding a chemical’s metabolism is important in assessing its toxic potential, 
including estrogenicity. Metabolism of chemicals occurs endogenously in animals, 
humans, and also in the environment (environmental degradation) via microbes. Chemicals 
can be converted to a more or less estrogenic form than the parent compound (see Fig. 
2.6). These conversions involve Phase I oxidation reactions that are catalysed mainly by 
many of the CYP (cytochrome P450) family of enzymes. These oxidations are followed by 
Phase II conjugations of the oxidised moiety with highly polar groups such as glucose, 
sulphate, methionine, cysteine or glutathione, aiding in the excretion of hydrophobic 
molecules. These reactions occur endogenously in living organisms, as well as in the 
environment via microbes. 
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Figure 2.6. Cytochrome P450 catalysed metabolism of chemicals. 
 
 
2.1.10   Pyrethroid insecticides 
 
Insecticides are chemicals used to control insects that attack crops and other plants, and for 
domestic public health purposes. Concern has arisen that some insecticides may possess 
the ability to mimic the action of 17β-estradiol through interaction with the hER. An 
example is the association between the concentration of dicofol, and DDT and its 
metabolites, in Lake Apopka, Florida, USA, and developmental abnormalities in the lake 
alligators.12,21,22  
 
There is evidence to indicate that exposure to pyrethroids may also cause effects linked to 
hER mediated responses.60 Synthetic pyrethroids (such as those in Fig. 2.7) are commonly 
used insecticides around the world being the 4th major group used after organochlorines, 
organophosphates, and carbamates.70 Pyrethroids are used in forestry, on vegetable and 
fruit crops, wheat and barley, targeting many types of insects.71 Many of these are 
synthetic analogues of the naturally occurring pyrethrins found in the flowers of 
Chrysanthemum cinerariaefolium. They are highly toxic to insects, and the level of toxicity 
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greatly decreases in the order of amphibia, fish, mammals and birds. These compounds act 
on target insect nervous systems at sodium channels within lipophilic membranes. They act 
by stimulating Na+ gate proteins to open and close, leading to depolarisation of the cell and 
therefore death by neurotransmission inhibition. In the past they have been widely 
regarded as safe with a favourable insect to mammalian toxicity ratio.  
 
 
 
Figure 2.7. Examples of pyrethroid insecticides. 
 
 
However, an increase in the awareness for xenoestrogens in the environment has led to the 
testing of pyrethroid insecticides for potential estrogenic activity by several different 
methods. Highly variable results have been reported for the activity of pyrethroids in 
receptor binding assays, receptor-dependent gene expression assays, or varying cell 
proliferation assays. Cypermethrin and permethrin are commonly used pyrethroids that 
have been tested by these methods; a summary of reported results is shown in Table 2.1. 
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Table 2.1. Estrogenic activity of cypermethrin and permethrin in various estrogenicity 
assays (NA denotes no estrogenic activity observed, A denotes estrogenic activity). 
 
 
Cypermethrin and permethrin were among the pyrethroids that Kim et al. tested using three 
assays (ER binding, pS2 mRNA from MCF-7 BUS cells, and E-screen).72 Neither 
compound displayed any estrogenic activity compared to 17β-estradiol. Saito et al. also 
observed no significant estrogenicity when both pesticides were subjected to three in-vitro 
assays (ER binding, luciferase reporter gene, yeast two hybrid).74 A study by Garey and 
Wolff revealed that permethrin did not enhance cell proliferation in an endometrial cell 
line.60 Go et al. found that permethrin did not stimulate pS2 (estrogen responsive gene) 
mRNA levels in MCF-7 cells.61 In an in-vivo assay (uterotrophic), Kunimatsu et al. saw no 
increase in ovariectomised rat uterine weight when orally exposed to permethrin.63 Tyler et 
al. tested both cypermethrin and permethrin in the yeast receptor assay. Permethrin 
displayed weak agonistic activity while cypermethrin did not.75 Sumida et al. tested both 
also in a reporter gene assay (MCF-7 and HeLa cells with a luciferase endpoint).59 Neither 
was found to be estrogenic. Kojima et al. tested both pyrethroids in a luciferase reporter 
gene assay. Neither displayed activity in this assay. 76 
 
Several results reported are contrary to the above. Chen et al. tested both pyrethroids in 
three types of assay (E-screen, ER binding, and pS2 expression).73 Both were active in all 
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three assays. Go et al. reported that permethrin had a noticeable effect on cell proliferation 
in MCF-7 cells.61 
 
Pyrethroid insecticides are readily metabolised and environmentally degraded from the 
parent compound into smaller compounds. Cypermethrin (2.7) and permethrin (2.8) have 
similar mammalian metabolic pathways (Scheme 2.2), which produce metabolites with 
chemical similarity to 17β-estradiol. 
 
 
 
Scheme 2.2. Mammalian metabolism of cypermethrin (2.7) and permethrin (2.8).77 
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The pathways of metabolism and degradation in insects, fish, birds and mammalian 
animals are well understood.70,77 The metabolism of permethrin (2.8) and cypermethrin 
(2.7) follow a very similar route. The ester bond of the parent insecticide is enzymatically 
cleaved by an oxidase for the cis disubstituted cyclopropane of permethrin, and an esterase 
for the trans. Both isomers of cypermethrin are hydrolysed by an esterase. The resulting 
cyclopropyl acids in both series are then further metabolised and conjugated with 
glucuronide or glycine moieties to aid in excretion. The cyanohydrin 2.10 and the aromatic 
alcohol 2.11 are oxidised and hydroxylated in different positions as shown in Scheme 2.2. 
These hydroxylated compounds are finally conjugated with glucuronide, glycine, taurine or 
sulphate groups. This can occur at either the carboxyl or hydroxyl groups.  
 
Although the parent compounds show little obvious structural resemblance to 17β-
estradiol, and limited estrogenicity as discussed, the metabolites are potentially more 
estrogenic based on proposed SAR.53 To study whether metabolites are more active than 
the parent compound, an assay with metabolic capability needs to be utilised, or the 
metabolites themselves can be tested. Kojima et al. recently found that permethrin had 
weak estrogenic activity after exposure to rat liver S9 homogenate (it was inactive before 
exposure), suggesting the products of permethrin metabolism were more estrogenic than 
permethrin itself.76 The products of metabolism were not identified. Only one paper to date 
has examined the ability of three permethrin metabolites to activate the estrogen receptor.75 
The cyclopropyl acid 2.9 was inactive, whereas 3-phenoxybenzyl alcohol (2.11) was 
weakly estrogenic (105 fold less potent than 17β-estradiol). 3-Phenoxybenzoic acid (2.13) 
was also analysed, and found to behave as an antiestrogen (antagonist) by blocking the 
action of estradiol in an anti-estrogen screen. The cyclopropyl acid 2.9 also showed anti-
estrogenic behaviour. However metabolites 2.14 and 2.15, which are potentially more 
estrogenic than 2.9, 2.11, and 2.13, were not investigated. Known SAR,53 suggest that the 
3-(4-hydroxyphenoxy)benzyl alcohol (2.14) metabolite of permethrin would be more 
active in the yeast assay than 2.11, due to the presence of the aromatic hydroxyl group 
which is known to be favoured for receptor binding. 3-(4-Hydroxyphenoxy)benzoic acid 
(2.15) (metabolite of both permethrin and cypermethrin) also contains an aromatic 
hydroxyl, suggesting a potential greater estrogenicity than 2.13 also.  
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The lack of data on the estrogenicity of permethrin and cypermethrin metabolites 
stimulated the research described in this chapter, which concerns the synthesis and 
estrogenicity of other cypermethrin and permethrin metabolites not tested by Tyler et al. 
For the reasons discussed in the previous paragraph, metabolites 2.14, 2.15, N-3-
(phenoxybenzoyl)glycine (2.16), and 3-phenoxybenzaldehyde (2.12) were chosen for 
exposure to a yeast based receptor assay (see section 2.1.8) to determine their 
estrogenicity, along with previously tested metabolites 3-phenoxybenzyl alcohol (2.11), 
and 3-phenoxybenzoic acid (2.13). Metabolite 2.16 is a glycine conjugate of 2.13, which is 
biosynthesised in the final step of permethrin metabolism. Conjugation with a glycine 
molecule increases the molecular length of the metabolite, so it was included in the assay 
for investigations into the relationship between the molecular dimensions of the 
metabolites and their estrogenic activity. The synthesis of three metabolites, 2.14-2.16, was 
required before they could be assayed. Their synthesis is discussed in section 2.2. 
Metabolites 2.11, 2.12, and 2.13 were purchased from SigmaAldrich. The estrogenicity of 
these six metabolites was determined with a yeast based reporter assay which detects 
estrogen-dependent gene expression. Details of the assay and results will be discussed in 
section 2.3. The estrogenicity of metabolites 2.12, 2.14, 2.15, and 2.16 has not previously 
been reported. 
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2.2 SYNTHESIS OF PYRETHROID METABOLITES  
 
The following section describes the synthesis of pyrethroid metabolites 2.14 and 2.15 
(Scheme 2.3) which was guided by the synthesis of Unai and Casida.78 The synthesis of N-
(3-phenoxybenzoyl)glycine (2.16) is discussed in section 2.2.2. 
 
 
2.2.1 Synthesis of metabolites 2.14 and 2.15 
 
The first step in the reaction scheme (Scheme 2.3) involved an Ullman coupling between 
methyl-3-bromobenzoate (2.17) and the sodium salt of p-methoxyphenol (2.18) in DMF in 
the presence of copper(I)chloride to give the key biaryl ether intermediate 2.19 in 31% 
yield. Hydrolysis of the methyl ester of 2.19 was accomplished with potassium hydroxide 
in equal volumes of THF and water to give the acid 2.20 in 90% yield. The methyl aryl 
ether of 2.20 was cleaved with equal volumes of aqueous hydrobromic acid and acetic acid 
to give the product (pyrethroid metabolite) 2.15 in 88% yield. The acid group of 2.15 was 
reduced with lithium aluminium hydride in ether to give pyrethroid metabolite 2.14 in 33% 
yield. 
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Scheme 2.3. Reagents and conditions: (i) NaH, DMF, rt, 30 min, then CuCl, reflux, 6 h 
(31%). (ii) KOH, 1:1 THF in H2O, reflux, 4 h (90%). (iii) 1:1 48% aq. HBr in AcOH, 
reflux, 7 h (88%). (iv) LiAlH4, Et2O, rt, 16 h (33%). 
 
 
2.2.2 Synthesis of glycine-conjugated metabolite 2.16 
 
Scheme 2.4 outlines the synthesis of 2.16.79 3-Phenoxybenzoic acid (2.13) was reacted 
with glycine methyl ester hydrochloride in DCM under EDCI coupling conditions to give 
the ester 2.22 in 85% yield. Hydrolysis of the methyl ester of 2.22 was carried out in THF 
and water in the presence of potassium hydroxide to give the glycine conjugate 2.16 in 
65% yield. 
 
 
 
 
 
MeO
O
Br HO
OMe
O
OMe
MeO
O
O
OMe
HO
O
O
OH
HO
O
O
OH
HO
(i)
(ii)
(iii)
(iv)
2.17 2.18 2.19
2.202.15
2.14
Chapter Two – Estrogenic activity of pyrethroid insecticide metabolites in a yeast estrogen screen 
 
 
 
58
 
 
Scheme 2.4. Reagents and conditions: (i) DIPEA, GlyOMe.HCl, EDCI HOBt, DCM, rt, 
16 h (85%). (ii) KOH, 1:1 THF in H2O, reflux, 4 h (65%). 
 
 
2.2.3 HPLC analysis of metabolites  
 
Assessing the purity of metabolites for assay was important to avoid false results that may 
have arisen from the presence of estrogenic impurities. Analytical HPLC was performed to 
assess the purity of synthesised metabolites 2.14 and 2.15. Samples of these compounds 
were run through an analytical C-18 reverse phase column eluting with various 
concentrations of water (containing 0.05% trifluoroacetic acid) in acetonitrile. Figure 2.8 
shows the HPLC trace of metabolites 2.14 and 2.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. HPLC analysis of synthesised metabolites 2.14 (black trace) and 2.15 (blue 
trace). The metabolites were detected by absorbance at 254 nm. 
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Two of the synthesised metabolites, 2.14 and 2.15, were analysed by HPLC to investigate 
their purity. Further purification (preparative HPLC) was planned for metabolites found to 
contain any impurities so the possibility of false positive results could be avoided. The 
black trace in Figure 2.8 is comprised of one major peak and low levels of impurities. The 
major peak was assumed to be metabolite 2.14 and this was confirmed by the 1H and 13C 
NMR spectra of 2.14, in which only 2.14 was observed (see Chapter Four, section 4.2.1). 
The blue trace in Figure 2.8 is comprised of one major peak and several impurities. The 
major peak was assumed to be metabolite 2.15 and this was confirmed by the 1H and 13C 
NMR spectra of 2.15 (see Chapter Four, section 4.2.1). In the YES screen, metabolite 2.14 
was active, whilst metabolite 2.15 was not (the assay and results will be discussed in the 
following section). The negative result for 2.15 suggests that it was not estrogenic, and 
thus was not purified further, but there is a possibility that the impurities present may be 
antagonists of the hER and thus block its activation. However, this possibility is remote as 
ER antagonists are usually large molecules, e.g. tamoxifen, which possesses three aromatic 
rings (see Chapter One, Fig. 1.5). The very slight shoulder of the peak corresponding to 
2.14 was assumed to be 2.15 by comparison with the blue trace (2.15 was the precursor in 
the synthesis of 2.14). As 2.15 was inactive, 2.14 was not purified further. The purity of 
metabolite 2.16 was not analysed by HPLC as it was inactive in the YES screen. 
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2.3 YEAST ESTROGEN SCREEN (YES) 
 
As previously discussed (in section 2.1.8) there are different assays available for assessing 
the estrogenicity of a chemical. In vitro assays include receptor binding, yeast and 
mammalian cell reporter gene, and cell proliferation. In vivo assays include the rodent 
uterotrophic assay, measuring the effects on male rodent testicular size and sperm quality, 
and the induction of vitellogenin in trout. A yeast based reporter gene assay was chosen for 
this research, as it not only determines whether a chemical binds to hERα, but also if 
estrogen-dependent gene expression is stimulated. Yeast (Saccharomyces cerevisiae) has 
proven to be a good model for studying more complex eukaryotic processes, such as 
steroid receptor function. The advantages of using yeast include the relatively short culture 
period, and the ability to use well defined culture conditions. Yeast based assays are 
considered robust, sensitive and relatively inexpensive to screen chemicals for in vitro 
estrogenic activity. 
 
The yeast estrogen screen (YES) developed by Arnold et al.56 (depicted in Fig. 2.9) was 
used in this research. The yeast is recombinant and was developed by integrating the DNA 
sequence for the hERα into the main chromosome of Saccharomyces cerevisiae. The 
recombinant yeast cells also contain a plasmid that possesses the lacZ reporter gene. This 
gene codes for the expression of β-galactosidase, an enzyme which modifies a galactoside 
dye added to the assay medium [see (i), Fig. 2.9]. The binding of a compound to hERα 
results in a complex that binds to EREs on the plasmid. β-Galactosidase is expressed and 
secreted into the assay medium, where it modifies the yellow galactoside dye, 
chlorophenol red β-galactopyranoside (CPRG). CPRG is converted to chlorophenol red by 
enzymatic activity [see (ii), Fig. 2.9], and the release of chlorophenol red can be monitored 
spectrophotometrically at 540nm. A background reading at 620nm is taken to record the 
optical density of the assay solution (reflecting the yeast growth). The absorbance of 
chlorophenol red measured at 540 nm is indicative of the degree of ER binding by the test 
chemical. Sigmoidal ‘S’ curves (typical for ligand-receptor binding) are obtained when the 
absorbance at 540 nm is plotted against a range of different concentrations of estrogenic 
chemical. The relative responses of different chemicals in the yeast assay can be compared 
by taking a concentration value at a common point on the curve. This value makes it 
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possible to measure the relative estrogenicity of one compound to another. Therefore, an 
EC550 value is generated for estrogenic chemicals, and is defined as the statistically 
derived molar concentration of a test chemical (agonist) which generates 50% of the 
maximum possible response for that chemical (in this case absorbance). Data points 
obtained from the assay are fitted to a curve determined by a computer programme, and the 
mathematical equation for the fit curve is used to calculate the concentration of estrogenic 
chemical (EC50) where the absorbance is half the maximum value obtained. 
 
 
 
Figure 2.9. (i) Schematic of yeast estrogen screen:  
Estrogenic chemical binds to hER and the complex binds to EREs on the plasmid, 
initiating synthesis of β-galactosidase enzyme, which cleaves the CPRG substrate in the 
assay medium, resulting in a yellow to red colour change.  
(ii) β-galactosidase catalysed cleavage of CPRG substrate. 
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2.3.1 Yeast preparation 
 
The recombinant yeast was donated by John Sumpter of Brunel University, UK. All 
preparation and storage of the yeast, and assay procedures were followed from those 
described by Routledge and Sumpter.80 Personal communications with the Sumpter 
research group also provided more detailed procedures. Five vials of agar slopes 
containing the yeast were obtained, and they were each recultured on to agar plates, and 
two samples from each vial were transferred to cryovials with sterile glycerol and frozen at 
-80°C. 
 
To prepare the yeast as required for assay, a 10 x concentrated yeast stock was prepared 
(see Chapter Four section 4.2.2). This involved growing the yeast for 3 days (when it 
became turbid). A small aliquot of this yeast was transferred to two flasks of yeast growth 
medium, in which the yeast was grown separately for a further 24 h. Both cultures were 
centrifuged and re-suspended in media and sterile glycerol for storage at -20°C. 
 
 
2.3.2 Yeast assay establishment 
 
The yeast assay required establishing and validation, due to differences that might arise 
when biological systems are in new hands. Initial assays were carried out to check results 
were comparable with literature values (see Chapter 4, section 4.2.2 for assay procedure). 
Early work on establishing the assay was carried out in collaboration with Dr Barbara 
Thomson at ESR (Institute of Environmental Science and Research). Briefly, the assay 
involves incubating test chemicals in a solution of yeast, growth media and CPRG. 17β-
Estradiol was used as the standard and included on each assay plate. A blank control row 
was also included on each plate, each well in the row consisted of the yeast, growth media 
and ethanol (no test chemical). Two known xenoestrogens (genistein and daidzein) were 
included in initial assays, to be used for further validation of the assay. In the protocol 
followed, the optical density of the yeast culture in the assay plates was recorded at 620 
nm. The plate reader used for this research required fixed wavelength light filters, and only 
several different wavelength filters existed for use. Amongst these filters was a 610 nm 
filter so this wavelength was used to record the optical density of the assay plates, instead 
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of at 620 nm as described in the protocol. A 540 nm filter was purchased specifically for 
this assay out of necessity. Early assay attempts were unsuccessful. Upon removal from the 
incubator after 48 h (our standard assay time), high absorbances at 540 nm (wells were 
observed to be an intense red colour) were recorded for all wells containing test chemicals, 
indicating significant production of chlorophenol red as a result of hERα activation. Even 
the row of blank wells with no test chemical present displayed estrogenic activity, 
suggesting there was estrogenic contamination of some sort present in the assay.  
 
 
2.3.2.1  Experiments in detecting source of assay contamination 
 
Assay runs were designed to investigate why the all the well solutions in assays performed 
so far were displaying a high absorbance at 540 nm. Estrogenic contamination was 
suspected to be the cause. The yeast minimal media was identified first as a possible source 
of estrogenic contamination. Therefore a new batch of yeast minimal media was prepared. 
An assay was then attempted using the new media, with a new control included. This 
control contained growth media and yeast, as well as the CPRG dye, to assess the 
possibility there were microbes in the media also exhibiting β-galactosidase activity. After 
48 h, high absorbances at 540 nm were again recorded, except for the new control wells 
which remained yellow. The presence of wells displaying high absorbance at 540nm 
indicated there was still an estrogenic contaminant. The yellow control wells indicated that 
there were no microbes with β-galactosidase activity present. 
 
Further sources of the estrogenic contamination were postulated. The yeast culture was 
considered next. A new 10 x concentrated yeast stock was prepared and an assay run. 
Again high absorbances at 540 nm were recorded for all well solutions on the plate. The 
next possible source of contamination considered was the CPRG dye. The dye solution was 
stored in plastic tubes, and it was thought that the solution may be contaminated with 
plasticisers. Phthalate compounds are used as plasticisers and have been shown to be 
estrogenic in the YES by Harris et al.81 Despite awareness for this potential problem, it 
was thought that small plastic tubes would be suitable for storing the aqueous dye solution. 
We didn’t think this would promote plasticiser leaching. However, some interesting results 
were obtained when the next assay was run with CPRG stored in glass vials (Fig. 2.10). 
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Figure 2.10. Assay plate comparing CPRG stored in plastic and glass vials. 
Key to rows: A - empty 
           B - estradiol (CPRG in glass) 
           C – estradiol (CPRG in plastic) 
           D – ethanol blank 
           E – 10 x estradiol dilution (to check sensitivity; CPRG in glass) 
           F – genistein (CPRG in plastic) 
 
 
When rows B and C were compared, it appeared that the CPRG stored in plastic vials was 
contaminated with an estrogenic substance, most likely plasticiser. This result also 
prompted us to store the 10 x concentrated yeast stock in glass tubes as well. 
 
From the results obtained in the previous assay, it seemed the contamination source had 
been identified. Therefore, selected pyrethroid metabolites (2.11, 2.13, and 2.14) were 
introduced into the next assay run. However, high absorbances at 540 nm were recorded 
for all wells after 48 h again. We then tested for the possibility that the ethanol used to 
dissolve the test chemicals was contaminated, by incubating a sample containing only 
growth medium, yeast and dye in a sterilised glass bottle. This sample also displayed high 
absorbance at 540 nm, without ethanol, which was therefore ruled out as a contamination 
source. 
 
From the results above, it became clear that the CPRG was not the only problem affecting 
the assay. The effect of the amount of yeast added to the assay media was investigated 
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next. The addition of too many yeast cells to the assay was a likely explanation for the 
over-activity observed in the attempted assays as described. A review of the literature 
associated with the assay procedure revealed that the optical density (OD) at 640 nm of the 
yeast assay culture was important. The optical density of a solution was used to determine 
the number of microbes in a culture solution. Microbes present in a solution are able to 
scatter light, and a spectrophotometer was used to measure the amount of light that reaches 
the detector upon passing through a culture solution. Therefore the number of cells present 
is proportional to the optical density of the culture solution (the optical density will 
increase as the concentration of cells increases). The optical density is measured at a 
particular wavelength of light that minimises absorption by biomolecules in microbial 
cells; around 600 nm is generally suitable. The assay protocol followed stated that between 
0.5 mL and 2 mL of yeast culture or 4 x 107 cells was required to seed the assay medium. 
To investigate the concentration of yeast cells in our yeast culture, the number of yeast 
cells in a 24 h assay culture was counted by Nicola Turner of ESR at three time intervals 
over 24 h and the OD640 measured concurrently. The results are shown in Figure 2.11. 
After 24 h of growth the yeast was found to be in the stationary growth phase with an 
optical density of 2.5. 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Growth of hER yeast over 24 h. Bars indicate CFU/mL and data points 
indicate OD at 640 nm. 
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The 24 h yeast culture contained 1.5 x 107 colony forming units (CFU) per mL which 
corresponded to an optical density of 2.5 at 640 nm. In the attempted assays described 
previously, 1 mL of 24 h yeast culture was added to the assay medium (which corresponds 
to about 1.5 x 107 cells as guided by the information in Figure 2.11). Although this is about 
the same number of cells as suggested by the protocol followed, high absorbances were 
obtained at 540 nm for all the assay well solutions (indicating significant chlorophenol red 
production). Therefore it was decided to add slightly fewer cells than the suggested 
number, so 0.25 mL of yeast culture (which corresponds to 3.75 x 106 cells according to 
the cell count in Fig. 2.11) was added to the assay medium from this point on. The addition 
of fewer cells to the assay medium had a profound effect on subsequent assays. For assay 
wells containing test chemicals, sensible absorbances at 540 nm (between 1 and 2.5) were 
obtained, and the blank control wells (with no test chemical present) appeared yellow and 
displayed low absorbance at 540 nm as desired. From this point on, the OD of the 24 h 
yeast culture at 640 nm was measured before each assay. By monitoring the OD of the 
culture solution, the number of cells being added to the assay could be controlled.  
 
 
2.3.3 Activity of pyrethroid metabolites 2.11-2.16 in yeast assay 
 
A total of 12 various assay runs were done before reproducibility was obtained and the 
plate wells were no longer all turning red. We were hopeful that reasonable results could 
now be obtained from assaying the metabolites. Standard solutions of metabolites in 
AnalaR ethanol were prepared at a concentration of 2 x 10-2 M as suggested by the 
protocol. Estradiol was prepared at a concentration of 2 x 10-7 M. As estrogenic potency is 
different for different compounds, varying concentrations of starting solutions are needed 
to generate a spread of absorbance readings. Therefore chemicals were added to the assay 
plates and diluted by a factor of 2 sequentially across rows, giving a range of 12 
concentrations. One row was left between each chemical to prevent the creeping effect 
described by Beresford et al.82 The ethanol was allowed to evaporate and then 200 µL 
assay media was added. The final concentrations for estradiol ranged from 0.0048 nM to 
10 nM, and for the metabolites, 0.488 µM to 1000 µM.  
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Of the metabolites tested, 2.15, 2.14, and 2.16 were synthesised, while 2.11, 2.12, and 2.13 
were purchased from Sigma-Aldrich. Each of these six metabolites was assayed at least 4 
times to assess variation between assays and the reproducibility of data. To show variation 
between assays, data from four estradiol samples from different assay runs are presented in 
Figure 2.12. 
 
 
2.3.3.1  Assay results 
 
The following graphs (Fig. 2.13) were constructed from assay data. Plates were read in a 
plate reader after 48 h of growth in a 30˚C incubator. Absorbances at 540 nm and 610 nm 
were recorded. The 540 nm absorbance was corrected for by the following equation: 
Corrected absorbance = chem. abs. (540) – [chem. abs. (610) – blank abs. (610)]. 
This equation corrects for absorbance arising from the turbidity of the assay solution due to 
the presence of yeast cells. The corrected absorbance values are plotted against the range 
of concentrations for each metabolite as shown in Figure 2.13 (the plots are semi-log). 
Typical (ligand-receptor binding) sigmoidal ‘S’ curves were obtained for the estradiol 
standard. 
 
EC50 values were calculated for estradiol and the estrogenic metabolites, 2.11, 2.12, and 
2.14. These values were determined using SigmaPlot and Microsoft Excel (see Chapter 
Four, section 4.2.2). The reported EC50 for each chemical was an average of EC50 values 
calculated from various assay runs. A relative potency for each chemical was calculated by 
dividing the EC50 by the estradiol EC50 and inversing the obtained number. This was done 
to report the relative estrogenic activity of the metabolites as less than estradiol (Table 2.2).  
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Figure 2.12. 17β-Estradiol EC50 values calculated from different assays. 
 
 
 
 
 
 
Assay #19 Estradiol
Concentration estradiol per well (nM)
0.001 0.01 0.1 1 10
C
or
re
ct
ed
 a
bs
.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
EC50 = 0.107
R2 = 0.9926
Assay #15 Estradiol
Concentration of estradiol per well (nM)
0.001 0.01 0.1 1 10
C
or
re
ct
ed
 a
bs
.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
EC50 = 0.331
R2 = 0.9910
Assay #16 Estradiol
Concentration of estradiol per well (nM)
0.001 0.01 0.1 1 10
C
or
re
ct
ed
 a
bs
.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
EC50  = 0.311
R2 = 0.9969
Assay #14 Estradiol
Concentration of estradiol per well (nM)
0.001 0.01 0.1 1 10
C
or
re
ct
ed
 a
bs
.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
EC50 = 0.165 
R2 = 0.9935 
Chapter Two – Estrogenic activity of pyrethroid insecticide metabolites in a yeast estrogen screen 
 
 
 
69
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Estrogenic activity of pyrethroid metabolites determined by the YES screen 
(data from sample assays). 
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Table 2.2. Estrogenic activity (relative potency) of pyrethroid metabolites measured by 
calculated EC50 values [NA denotes no estrogenicity detected at a concentration less than 
the minimum concentration of 17β-estradiol (5 x 10-3 nM)]. The activity of 17β-estradiol 
was 0.229 ± 0.11 nM (mean ± SD). 
 
 
 
 
 
 
 
 
Pyrethroid Metabolite Estrogenic Activity  EC50 (µM) 
Relative Potency 
(Estradiol=1) 
 
O
HO  2.11
 
 
6.67 ± 3.11 
 
 
3x10-5 
 
 
O
HO
OH
 2.14
 
 
 
6.75 ± 2.28 
 
 
 
3x10-5 
 
 
O
HOOC  2.13
 
 
 
NA 
 
 
 
- 
 
 
O
HOC  2.12
 
 
 
4.32 ± 1.70 
 
 
 
5x10-5 
 
 
O
HOOC
OH
 2.15
 
 
 
NA 
 
 
 
- 
 
 
O
O
H
N
O
HO
 2.16
 
 
 
NA 
 
 
 
- 
Chapter Two – Estrogenic activity of pyrethroid insecticide metabolites in a yeast estrogen screen 
 
 
 
71
 
 
 
 
 
 
 
 
 
Table 2.3. Mean calculated EC50 for 17β-estradiol. 
 
 
Yeast assay protocol 17β-Estradiol EC50 (nM) 
This thesis 0.229 
Tyler et al.75 0.21 
Beresford et al.82 0.22 
Gaido et al.83 0.225 
 
 
Table 2.4. Comparison of 17β-estradiol EC50 with those from the literature. 
 
 
Table 2.2 illustrates that 2.11, 2.14 and 2.12 have weak estrogenic activity of five orders of 
magnitude less than estradiol. Metabolites 2.13, 2.15, and 2.16 show no activity (see 
graphs in Fig. 2.13). To validate the assay, the estradiol EC50 determined here was 
compared to values reported in the literature (Table 2.4). Our EC50 value is in excellent 
agreement with literature data. 
 
The assay concentration for the test chemicals was quite high (the highest concentration 
was 1000 µM), and this is reflected in the graphical curves obtained for the estrogenic 
metabolites (2.11, 2.14, and 2.12, Fig. 2.13). Instead of the sigmoidal curve seen for the 
estradiol standard, the metabolite curves rise in absorbance and then fall as the 
concentration increases. This may indicate that the metabolite concentration was high 
Assay # 17β-Estradiol EC50 (nM) 
14 0.165 
15 0.331 
16 0.311 
19 0.107 
 Mean = 0.229 
 SD = 0.11 
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enough to kill the yeast. Yeast growth in this assay is shown by the turbidity (yeast cell 
concentration) of the solution, which was measured at 610 nm for all wells containing test 
chemicals. The absorbances measured at 610 nm for the highest concentration of 
metabolites were often very low due to the absence of turbidity, shown by clear yellow 
wells which indicated the cells were lysed. These cells are non-viable and therefore not 
synthesising β-galactosidase, so chlorophenol red is not produced as a result. Lysed cells 
present in wells containing high concentrations of the active metabolites displayed low 
absorbances at 540 nm, hence the observed decline in absorbance with increasing chemical 
concentration (e.g. 2.11, Fig. 2.13). Therefore, in determining an EC50 for each of the 
active metabolites, only the first eight data points were fitted to a curve in SigmaPlot (as 
described above), as these points formed a sigmoidal curve characteristic of ligand-
receptor binding. 
 
Lysed cells in the first 2 or 3 wells of rows on the assay plates (chemicals were present in 
decreasing concentration across the plate) indicated that the assay concentration was too 
high in these wells and toxic to the yeast. This result suggested that the test chemical 
concentration needed to be diluted to reduce yeast cell toxicity. Each well across the row 
represents a subsequent decrease in concentration by 0.5. From about the third well 
reasonable absorbances were measured, so the three estrogenic metabolites were diluted by 
0.1 to give a concentration similar to the concentration of the chemical in the third well. 
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2.4 DISCUSSION 
 
In order to determine the estrogenicity of pyrethroid metabolites, either the pyrethroid 
needs to be tested in an assay with metabolic capability, or the actual metabolites need to 
be tested in an assay such as YES. Six metabolites (three of which were synthesised in this 
work) of cypermethrin and permethrin were tested with a recombinant YES expressing 
hERα. Estrogenic activity resulted from the test chemical forming a complex with hER, 
which binds to EREs found on the plasmid present in the yeast cell. Binding of the ligand-
receptor complex to EREs induces lacZ expression and synthesis of β-galactosidase. 
Activity of this enzyme was measured by recording the absorbance of chlorophenol red at 
540 nm. 
 
The yeast assay required validation due to differences that might arise with biological 
systems in different circumstances. Initially the assay was not reproducible (the test 
chemicals and blank appeared bright red on the assay plate after 48 h) due to various 
problems as discussed in section 2.3.2.1; contamination of the CPRG solution stored in 
particular plastic tubes by an estrogenic compound (most likely plasticiser), and by the 
addition of what seemed to be too many yeast cells (presumably leading to over-expression 
of β-galactosidase, hence the high absorbance recorded at 540 nm for all well solutions). A 
cell count of the 24 h yeast culture was carried out and it was determined that there were 
1.5 x 107 CFU per mL of culture, corresponding to an OD640 of 2.5. This result revealed we 
were not adding to many yeast cells, but due to the over-activity observed in assays 
performed before the cell count, it was decided to add slightly fewer cells than the protocol 
suggested (4 x 107 cells). In subsequent assays, 0.25 mL of 24 h yeast culture (containing 
3.75 x 106 cells) was added to the assay medium, resulting in sensible absorbance 
responses. The yeast culture in our hands seems to be more active, as fewer cells provided 
similar responses to literature reports. The number of hERs being expressed by the yeast 
cell may be higher which might explain these observations. To validate the assay, the EC50 
of the assay standard, 17β-estradiol, was compared to literature EC50 values. Our value of 
0.229 nM was in excellent agreement with three other estradiol EC50 values from the 
literature (see Table 2.4).  
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Cypermethrin and permethrin hydrolyse under enzymatic or high UV conditions to 
products 2.10 or 2.11 respectively (Scheme. 2.2). Metabolite 2.11 has estrogenic activity 
(Table 2.3), and both are very likely to be further metabolised by hepatic first pass 
metabolism following ingestion with food. Results from this work show that the Phase I 
first pass metabolites 2.12, (for cypermethrin) and 2.14 (for permethrin) respectively, are 
also both weakly estrogenic. Following oral ingestion of the estrogenic environmental 
degradation product (2.11), the first pass Phase I metabolites (2.12 and 2.14) are also 
estrogenic so increasing the risk of xenoestrogenic pharmacological effects on the 
consumer.  
 
From known SAR studies, we predicted 2.14 would be more estrogenic in the assay than 
2.11 due to the presence of two hydroxyl groups at both ends of the molecule (see section 
2.1.10 for reasoning). This structural arrangement is well known to be preferred for 
binding to the estrogen receptor, as well as the presence of phenolic rings.53 However, 
based on the assay results reported here, the activity of 2.14 was of the same order of 
magnitude as that of 2.11. The presence of a phenol did not increase the estrogenic activity 
of 2.14 when compared to 2.11. It is noted that the SAR,53 from which our predictions 
were made, are based on receptor binding assays and computational calculations, whereas 
the yeast assay used in this work measures the effects of gene expression, further down the 
effect pathway than receptor binding alone. This is a likely reason as to why we see a 
difference in our predicted activity compared to the observed, and also reiterates the fact 
that determining absolute SAR for xenoestrogens is complex and dependent on the type of 
assay utilised as well as the mechanism of action. The yeast assay measures an estrogenic 
response further down the effect pathway, but only the response of a single gene in a 
genetically modified cell system, unlike the complex system of an animal or human. It is 
for this reason that this assay is considered a simple screen to prioritise candidates that 
might require further biological testing. 
 
Of the two assays discussed, each has their own advantages and limitations. The receptor 
binding assay measures the relative binding affinity of chemicals for the estrogen receptor. 
They are easy and rapid to carry out, making large scale screening a possibility. However 
binding assays are unable to determine the difference between agonistic and antagonistic 
chemicals. As there is no cellular system present, there are no metabolic processes that 
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could produce xenoestrogens upon metabolism. Reporter gene assays (as used in this 
study) test the ability of a chemical to activate transcription and therefore reporter gene 
expression. The yeast cells are easy to grow over short time frames, possessing some 
metabolic capability. However, the number of receptors expressed may alter the sensitivity 
of the assay, as well as the type of reporter gene used. Some test chemicals may not 
penetrate the yeast cell to effect a response, resulting in false negatives.84 Although the 
yeast assay is further along the effect pathway than receptor binding, neither of these in 
vitro assays are particularly appropriate for modelling cellular effects in wildlife or 
humans. The yeast assay measures the response of a single gene in a genetically 
engineered cell system. This is a long way from a whole animal or human. Complicating 
this matter further is the emergence of new mechanisms by which estrogen may act in 
target cells, which are not mediated by the ER. 
 
There are two main sources of the metabolites shown to be estrogenic in this study. 
Microbial enzymes that can hydrolyse the parent pyrethroid to produce the metabolites are 
widely found in the environment (e.g. in the bacteria of aquatic silts). Therefore the 
metabolites are more likely to be found in the environment than the parent compound. 
Metabolites might then form residues in food crops and so be ingested with food.85 The 
other source of these metabolites is internal mammalian metabolism, 2.13 and 2.15 have 
been detected in human blood and urine.86-88 These compounds are end products of 
cypermethrin and permethrin metabolism after ingestion. Phase I enzyme reactions 
produce the estrogenic metabolites via hydroxylation (2.11, and 2.14) and oxidation (2.12) 
of the inactive parent. Subsequent Phase II enzyme reactions are responsible for 
conjugating molecules to metabolites to lower toxicity and aid in excretion. Phase I 
enzymes are mostly localised on the endoplasmic reticulum, while phase II enzymes are 
found in the cytoplasm.89 Thus the estrogenic insecticide metabolites produced from phase 
I reactions are then available for conjugation by phase II enzymes or interaction with hER 
in the cell. Therefore Phase II metabolism could lower the concentration of estrogenic 
metabolites, thus decreasing possible interaction with hER. Conjugation with glycine 
inactivates the metabolite (as shown by the non-activity of 2.16). 
 
The synthetic pyrethroid insecticides were designed to be relatively unstable to minimise 
their toxicological impact on both the environment and humans. For this reason food 
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residues are infrequent and very low even though their usage is relatively high.90 The 
major environmental degradation products of the pyrethroids (Scheme. 2.2) are not 
normally measured as part of pesticide residues surveillance programmes and therefore 
there are few, if any data, from which exposure estimates, can be made. The finding that 
several of these breakdown products are estrogenic brings into question their impact on 
humans. This risk assessment cannot be carried out without food residues data. However it 
is likely that the breakdown products do occur as residues in food since pyrethroid 
insecticides are applied directly to crops, e.g. tomatoes.85 Pyrethroid degradation occurs 
on/in the crop and so the breakdown products are likely to remain as residues. This 
reasoning suggests that there will be an impact on human health, but the magnitude of the 
impact cannot be assessed without detailed residue data. 
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2.5 CONCLUSION AND FUTURE WORK 
 
Six metabolites of the pyrethroid insecticides, cypermethrin and permethrin, (2.11-2.16) 
were exposed to the YES. Metabolites 2.14-2.16 were synthesised in this thesis for this 
purpose. Three metabolites, 2.11, 2.12, and 2.14, have been shown to be weakly estrogenic 
in the recombinant yeast assay. Even though the standard concentration of the metabolites 
was much higher than 17β-estradiol and not likely to be indicative of environmental 
concentrations, the yeast assay allows for estrogenic potencies to be compared for potential 
risk assessment. The fact that 2.11, 2.12, and 2.14 were about 105 less active than 17β-
estradiol suggests that a large amount of metabolite would have to be ingested or produced 
internally to observe any estrogenic effect. Pyrethroids are also metabolised rapidly, being 
renally excreted with a half life of about 6 hours.88 Upon evidence to date our opinion is 
that these insecticide metabolites are not contributing significantly to the xenoestrogenic 
impact on humans, but might be more significant to animals in the environment, 
contributing to total estrogenic exposure. 
 
Future work in this area would involve assessing the risk posed to humans and the 
environment from exposure to cypermethrin and permethrin metabolites. To carry out this 
assessment, exposure data for cypermethrin and permethrin would be required, such as 
how much insecticide is used in the environment. As these insecticides are sprayed on food 
crops (such as grains, fruit and vegetables), ingestion by mouth is the likely exposure route 
for humans. Data for the average amount of crops eaten, which have been sprayed with 
cypermethrin and permethrin, would be needed to estimate how much insecticide is eaten. 
Finally, an estimate of the amount of metabolites produced by internal metabolism would 
be required, as it is these metabolites (such as 2.11, 2.12, and 2.14) which interact with the 
ER. 
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3.1 INTRODUCTION 
 
The major circulating androgen testosterone is metabolised to DHT in a reaction catalysed 
by steroid 5α-reductase. Like other steroid hormones, both testosterone and DHT activate 
the expression of responsive genes by binding to the AR. The genomic action of steroid 
hormones was discussed in Chapter One, section 1.3.1. However, the action of these two 
androgens differs from other steroid hormones because both interact with the AR but 
induce different physiological effects, which were described in Chapter One, section 1.4. 
DHT has been proposed as a causative factor in some disease states, so there has been 
intense interest in developing inhibitors of steroid 5α-reductase to lower the levels of DHT 
synthesised. The following section details the mechanism of steroid 5α-reductase, diseases 
associated with DHT, and the development of 5α-reductase inhibitors to date. 
 
 
3.1.1 Mechanism of steroid 5α-reductase 
 
Steroid 5α-reductase (3-oxo-5α-steroid:∆4-oxidoreductase) is a membrane bound, 
NADPH-dependent enzyme that catalyses the irreversible reduction of testosterone. The 
mechanism for this reduction has been has been investigated, and is believed to proceed 
via binding of the substrate followed by release of the product DHT.1 NADPH firstly binds 
to the enzyme to give a binary complex that binds testosterone (3.1), forming a ternary 
complex (see Scheme 3.1).2 Upon formation of the ternary complex, the enone system is 
activated by a strong interaction with an electrophilic residue present in the active site 
(proton or proton donor), giving a delocalised carbocation at C5. A hydride from NADPH 
is transferred stereospecifically to the 5α-position of testosterone (3.1), forming the enolate 
3.3 of DHT (3.4). Protonation on the α-face of 3.3 gives 3.4 which is released from the 
active site. 
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Scheme 3.1. Steroid 5α-reductase catalysed conversion of testosterone (3.1) to DHT (3.4); 
(i) a molecular mechanism and (ii) kinetic mechanism. 
 
 
3.1.2 Steroid 5α-reductase isozymes 
 
Steroid 5α-reductase is a hydrophobic and unstable intrinsic membrane protein which is 
present at trace levels in tissue. These properties created difficulty in early work to study 
the enzyme’s biochemistry and regulation. These problems have now been largely 
overcome with the use of expression cloning technology to isolate cDNA that encodes 5α-
reductase. Several observations led to the suggestion that more than one isoform of 5α-
reductase existed.3 These were the fact that cDNA for 5α-reductase was found to be 
present in individuals with 5α-reductase deficiency, and the enzyme was inhibited poorly 
by finasteride, a known potent inhibitor of 5α-reductase in human prostate. Two isozymes 
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of steroid 5α-reductase have subsequently been cloned, expressed, and these are termed 
type 1 and type 2.4 Type 1 is a hydrophobic protein of 259 amino acids, while type 2 
consists of 254 amino acids (with 45% homology to the type 1 isozyme).5 The DNA 
sequences coding for type 1 and 2 are found on separate chromosomes. The isozymes have 
different expression patterns in various tissues and also different enzyme kinetics. 
Testosterone has high affinity for the type 2 enzyme (Km = 4-50 nM), but its affinity is 
lower for the type 1 isozyme (Km = 1-5 µM).1 These differing affinities suggest that there 
are sequence differences in the enzyme binding domains. 
 
The tissue localisation of type 1 and 2 differs. When the two isozymes were first cloned in 
the early 1990s, type 2 was only identified in prostate tissue whilst type 1 was identified in 
skin and liver. However, techniques used to detect proteins or their corresponding mRNAs 
have since become more sensitive and reliable. Both isozymes have now been identified in 
almost all the target tissues with different ratios and distribution in target organs. Overall, 
the type 2 isozyme is found predominantly in the prostate, genital skin, seminal vesicles 
and dermal papilla. Type 1 is predominantly found in non genital skin, scalp, sebaceous 
gland, and in the liver and brain (see Occhiato et al. and references therein).1 
 
 
3.1.3 DHT-related pathologies 
 
DHT-related pathologies are associated with the tissues and organs discussed in the above 
paragraph. Information regarding the role of the two isozymes in DHT disorders arose 
from clinical evidence of type 2 deficiency. Total or part deficiency of the type 2 isozyme 
has been found in an inherited form of male pseudohermaphroditism.6 At birth these male 
individuals have female-like external genitalia, and at puberty, the genitalia enlarge and the 
testes descend, but the prostate remains undeveloped. Facial and body hair growth remains 
similar to that of female patterns. This finding suggested the isozyme is required for 
differentiation of the male external genitalia in the foetus.7  
 
Type 2 is the main 5α-reductase isozyme found in the prostate and it is involved in 
prostate pathology. Prostate cancer is one of the main causes of cancer deaths in Western 
males, and was discussed in Chapter One, section 1.4. DHT is implicated as a causative 
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factor, due to the well founded link between androgens and prostate cancer.1 DHT is also 
implicated in BPH, a condition where benign prostate enlargement occurs (also discussed 
in Chapter One). Men with deficiencies of the type 2 isozyme do not develop BPH. 
 
Type 1 is implicated in skin and hair conditions as these tissues predominantly express this 
isozyme. The hair follicle and sebaceous gland together form the pilosebaceous unit, 
whose development and function is dependent on the androgens. Therefore DHT is 
implicated in disorders of the pilosebaceous unit, such as androgenetic alopecia (male hair 
pattern baldness), hirsuitism, and acne.8 It has recently been established that the rate of 
DHT production is higher in bald men than non-bald men.9 However, the local production 
of DHT is dependent on the distribution of the two isozymes throughout the hair follicle, 
which is currently not fully understood.1 In the second component of the pilosebaceous 
unit, the sebaceous gland, there is more indication that only the type 1 isozyme is 
expressed.10 In skin areas prone to acne, androgens can cause the sebaceous gland to 
enlarge greatly. DHT is responsible for the hyper production of sebum, which causes acne. 
 
As a consequence of the role of DHT in these conditions, there has been much interest in 
developing inhibitors of steroid 5α-reductase as potential therapeutics. Inhibition of 5α-
reductase is an ideal strategy, as the enzyme catalyses the final step in DHT synthesis, 
avoiding a decrease in testosterone levels and its beneficial effects. By decreasing prostatic 
DHT levels through 5α-reductase inhibition, prostatic volume may be reduced, a desirable 
effect which has been shown in human trials with finasteride.11 Finasteride is now 
marketed as a treatment for BPH and hair loss. The interest of 5α-reductase inhibitors in 
prostate cancer is in its prevention. Long term androgenic stimulation is associated with 
causing prostate cancer,1 so manipulating androgen levels (by inhibiting 5α-reductase) 
may have the best influence at the initial stages of tumour development and progression. 
Lowering DHT levels through 5α-reductase inhibition is also potentially useful for treating 
hirsutism and acne (perhaps by selective inhibition of the type 1 isozyme). 
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3.1.4 Inhibitors of steroid 5α-reductase 
 
Scientists at Merck initiated projects in the 1980s to identify inhibitors of prostatic 5α-
reductase activity, after realising the significance of the finding that male 
pseudohermaphrodites with underdeveloped prostates were type 2 deficient (see section 
3.1.3). The development of enzyme inhibitors usually requires information about the 
enzyme active site structure; however the two 5α-reductase isozymes have yet to be 
isolated and purified from tissues or cells. The only available information comes from the 
primary sequence derived from their cDNAs. The first inhibitors of 5α-reductase were 
therefore designed by modifying the structure of the natural substrates. Potent inhibitors 
have been identified using both rational design and compound screening approaches. Both 
steroidal and non-steroidal inhibitors have been reported. The following section briefly 
discusses steroidal inhibitors, which leads to a review of the non-steroidal inhibitors 
reported to date, with focus on their SAR and the key structural features responsible for 
inhibitory potency. 
 
 
3.1.4.1  Steroidal inhibitors 
 
Potent steroidal inhibitors of steroid 5α-reductase were discovered by Merck in the 1980s 
as a result of modifying the natural substrates. Such modification included substituting a 
carbon atom in the A or B ring (see 3.5, Fig. 3.1) of the steroid backbone with a 
heteroatom. Substitution of a carbon with a nitrogen atom at the 4-position in the A ring 
resulted in the 4-azasteroid inhibitor class, to which finasteride (3.5) belongs. Finasteride 
(PROSCAR®) was the first 5α-reductase inhibitor approved for BPH treatment. It 
preferentially inhibits the type 2 isozyme (IC50 = 9.4 nM), and can reduce the level of 
prostatic DHT by 80-90%, and serum DHT by 70-80%.12 Finasteride is also FDA 
approved for treating male pattern baldness by reducing the level of DHT in human scalp, 
and decreasing apoptosis of hair follicles. Other classes of steroidal inhibitors discovered 
were the 6-azasteroids (3.6), 10-azasteroids (3.7), and steroidal carboxylic acids (3.8-3.10). 
The steroidal pharmacophore provides a tether between the A ring and the C17 substituent 
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of the D ring. The C17 substituent aids in binding within a lipophilic pocket in the enzyme, 
which differs for the two isozymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Early steroid based inhibitors of 5α-reductase. 
 
 
The exact structure of the transition state in the conversion of testosterone to DHT is 
unknown; however inhibitors (including the above) have been designed as mimics of the 
proposed enolate 3.3 in the biosynthesis of DHT. This has been a major theme in the 
design of 5α-reductase inhibitors, where their electrostatic properties and A ring geometry 
mimic that of enolate 3.3. The 4-azasteroids, 6-azasteroids, and 10-azasteroids mimic the 
enolate 3.3 and are competitive inhibitors with respect to testosterone as they interact with 
the enzyme-NADPH complex (see Scheme 3.2). The steroidal carboxylic acids are also 
enolate mimics but are uncompetitive inhibitors as they interact with the enzyme-NADP+ 
complex. 
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Scheme 3.2. Interaction of steroid 5α-reductase inhibitors (I) with enzyme mechanism. 
 
 
On the basis of the enzyme mechanism (Scheme 3.1), two possible transition states for the 
enzymatic process have been postulated, in considering how substrate competitive 
inhibitors act as transition state analogues (Fig. 3.2).13 In the substrate-like transition state 
3.11, C5 is sp2 hybridised like the carbocation (3.2, Scheme 3.1), and for the product-like 
transition state 3.12, C5 is sp3 hybridised as for the enolate of DHT (3.3, Scheme. 3.1). 4-
Azasteroids (3.5) are sp3 hybridised at C5, as in product-like transition state 3.12, so they 
may be thought of as analogues of the DHT enolate. However the 6-azasteroids (3.6) and 
10 azasteroids (3.7) are sp2 hybridised at C5, so can be thought of as analogues of the 
substrate-like transition state 3.11. 
 
 
 
 
 
 
 
 
 
Figure 3.2. Postulated transition states (TS) in the biosynthesis of DHT (taken from 
Occhiato et al.1). 
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Glaxo and Merck have recently demonstrated how finasteride (3.5), and other related 4-
azasteroids, behave as irreversible inhibitors (Scheme 3.3).1 Irreversible inhibition results 
from alkylation by NADP+of the enolate (3.13, Scheme 3.3), formed after 1,4-reduction of 
the A ring. The resulting enzyme-NADP-dihydrofinasteride complex is very stable, 
making finasteride extremely potent and selective. The enzyme-NADP-dihydrofinasteride 
complex has a dissociation constant (Ki) of less than 10-13 M, which ranks finasteride 
amongst the most potent non-covalently bound inhibitors known for any enzyme. The high 
affinity is due to adduct 3.14 acting as a bi-substrate inhibitor. The adduct fits in both 
cavity sites of the enzyme normally bound by testosterone and NADPH. 
 
 
Scheme 3.3. Formation of NADP-dihydrofinasteride adduct 3.14 in the mechanism of 
irreversible inhibition of steroid 5α-reductase by finasteride (3.5). P = phosphoadenosine 
diphosphoribose. 
 
 
The steroidal based carboxylic acid inhibitors (3.8-3.10, Fig 3.1) were also designed to 
mimic the postulated enolate intermediate (3.3, Scheme 3.1). The negatively charged 
carboxylate ion mimics the enolate oxygen binding to the enzyme active site. These 
charged inhibitors show uncompetitive kinetics (Scheme 3.2) as they bind to the enzyme-
NADP+ complex. Epristeride (3.8, Fig. 3.1) is of this class, and is a potent and selective 
inhibitor of the type 2 isozyme. The carboxylate and double bond between C3 and C4 
mimic the negative charge and planarity of the enolate. Isozyme selectivity of steroidal 
inhibitors is apparently due to the nucleophilic potency of the substituent at the C3 
position.14 Faragalla et al. proposed a 5α-reductase pharmacophore from molecular 
modelling and suggested the type 2 isozyme requires a negatively ionisable group, while 
the type 1 requires only a hydrogen bond acceptor, plus hydrophobic and hydrophobic-
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aromatic features.15 This would explain the observed selective type 2 activity of the aryl 
carboxylic acids which can be ionised. 
 
Selectivity towards the type 1 isozyme by steroidal inhibitors has been achieved with the 
inclusion of an appropriate substituent at C17. For the 4-azasteroids, selectivity towards the 
type 1 isozyme was found to increase with increasing lipophilicity at C17. The first 
inhibitor reported to address type 1 selectivity was MK38616 (3.15, Fig. 3.3), which has the 
side chain present in cholesterol at C17, however further development was abandoned due 
to its hepatotoxicity.  
 
 
 
 
 
 
 
 
Figure 3.3. Steroidal inhibitor of type 1 5α-reductase MK386 (IC50 = 0.9 nM). 
 
 
Steroidal dual inhibitors of 5α-reductase have also been developed. These inhibitors are 
able to inhibit both isozymes. A drug which has this property is desirable for potentially 
further reducing the serum concentrations of DHT (finasteride, which is type 2 selective, 
reduces these levels by only approximately 70%). Dual inhibitors have the potential to 
enhance therapeutic effect, as they would inhibit not only the type 2 isozyme but also slight 
type 1 activity in the prostate. An example is that of dutasteride (GG745) (Fig. 3.4), which 
has been marketed by GlaxoSmithKline and is FDA approved for treating BPH. Greater 
reductions in serum and tissue levels of DHT compared to finasteride have been observed, 
but clinical efficacy is comparable to that of finasteride.12 
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Figure 3.4. Dutasteride (GG745). 
 
 
3.1.4.2  Non-steroidal inhibitors 
 
The development of non-steroidal inhibitors of steroid 5α-reductase has gained importance 
recently due to the side effects associated with steroidal inhibitors. It is generally accepted 
that some of the side effects of steroidal compounds are related to the fact that they are 
recognised by steroid receptors.17 Problems relating to sexual function have been reported 
as side effects from taking finasteride.18 The design of non-steroidal inhibitors is based on 
the steroidal inhibitors, via removal of one or more rings from the steroid structure. 
Examples include benzo[f]quinolinones, pyridones and quinolinones, 
benzo[c]quinolinones, and benzo[c]quinolizinones. Most other types of non-steroidal 
inhibitors are carboxylic acids also derived from steroidal equivalents. Non-steroidal 
inhibitors provide the most potent and selective type 1 inhibitors to date. 
 
 
Benzo[f]quinolinones 
 
A series of benzo[f]quinolinone compounds were the first reported non-steroidal mimics of 
steroidal inhibitors.19 These compounds are related to the 4-azasteroids (see Fig. 3.5), the 
steroidal D ring is absent and the steroidal C ring is replaced with an aromatic ring. 
Inhibitors within this class are generally selective for type 1 steroid 5α-reductase, some of 
which are extremely potent. 
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Figure 3.5. Non-steroidal benzo[f]quinolinone structure derived from the 4-azasteroid 
series. 
 
 
For benzo[f]quinolinone inhibitors, potency is enhanced by a halogen substituent (in 
particular Cl, as inhibitory potency decreases with Br or F substitution) at the 8-position of 
the aromatic ring, and with a methyl group attached to the lactam nitrogen. This is in 
analogy with the 4-methyl substitution of the nitrogen in MK386 (Fig. 3.3). Potency 
decreases dramatically in this series with the removal of the methyl from the lactam 
nitrogen. A QSAR study of benzo[f]quinolinone inhibitors has investigated the effect of 
the 8-substituent on the aromatic ring, proposing that it interacts with a lipophilic pocket in 
the enzyme.20 The property space of a Cl atom was proposed to be optimal for occupation 
of the lipophilic pocket.  
 
A variety of substituents have been introduced at the 8-position to modulate isozyme 
selectivity. This work led to the discovery of dual inhibitors, and also potent selective type 
1 inhibitors (Fig. 3.6).19,21 Interestingly the cis 8-styryl compound 3.19 is a potent selective 
type 1 inhibitor, but the trans 8-styryl isomer 3.20 displays dual activity.21 In the 
benzo[f]quinolinone inhibitor series, compound LY191704 (3.17) has progressed into the 
clinical trial phase of pharmaceutical development. 
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Figure 3.6. Benzo[f]quinolinone inhibitors. 
 
 
Each of the four stereoisomers of LY191704 [(±)-3.21 and (±)-3.22] and LY266111 [(±)-
3.23 and (±)-3.24] were separated by preparative chiral HPLC, and the inhibitory activity 
of each stereoisomer against both type 1 and 2 5α-reductase was determined.22 This 
important study revealed that the trans enantiomers of 3.21 (Ki = 6 and 4 nM) and cis 
enantiomers of 3.22 (Ki = 15 and 15 nM) displayed similar and potent activity against the 
type 1 isozyme, as did the trans enantiomers of 3.23 (Ki = 9 and 10 nM). In contrast, the 
cis enantiomers of 3.24 showed much reduced type 1 activity (Ki = 4000 and 7000 nM). 
These results were explained by conformational analysis. The extended planar nature of 
the trans compounds 3.21 and 3.23 allowed excellent overlay of the enantiomeric pairs. 
The structures of the cis enantiomers of 3.22 also showed good overlay with the trans 
enantiomers of 3.21. This was explained by the absence of the constraints of the angular 
methyl group. The poor activity of the cis enantiomers of 3.24 was explained by the bowl 
shaped cis ring junction decreasing the overall planarity in both enantiomers, resulting in 
poor overlay with the trans enantiomers of 3.23. All eight stereoisomers were poor type 2 
inhibitors. 
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Figure 3.7. Trans and cis isomers of inhibitors LY191704 (3.21, 3.22) and LY266111 
(3.23, 3.24). 
 
 
Pyridones and derivatives 
 
5-Aryl substituted pyridones and piperidones typified by 3.25-3.27 (Fig. 3.8) have been 
prepared as non-steroidal analogues of the 4-azasteroids (3.5, Fig. 3.1) to test for steroid 
5α-reductase inhibition. Pyridone and piperidone inhibitors 3.25 and 3.26 lack the steroidal 
B and D rings of the 4-azasteroids. The absence of the steroidal B and D rings results in a 
decrease in inhibitory potency against the type 1 isozyme, when compared to the tricyclic 
benzo[f]quinolinones (in which only the steroidal D ring is absent) (Fig. 3.6). For 
compounds of type 3.25-3.26, the highest inhibitory activity was associated to the presence 
of a Cl atom at the R1 position on the aromatic ring of 3.26 (IC50 = 1690 nM).23 The 
steroidal B and D ring of the 4-azasteroid backbone have been replaced with an acyclic 
linker in 5-aryl substituted piperidones such as 3.27. These compounds display poor 
inhibition against both type 1 and 2 5α-reductase.24,25 6-Aryl substituted quinolinones such 
as 3.28 have also been reported to inhibit the type 1 isozyme.26 Here only the steroidal C 
ring of the 4-azasteroids is absent, which is associated with better inhibitory activity 
compared to compounds 3.25-3.27. An IC50 of 510 nM was observed for 3.28. A methyl 
group on the quinolinone nitrogen is important for type 1 inhibition. When the methyl 
group on the quinolinone nitrogen of 3.28 is removed, there is almost a complete loss of 
activity against type 1, but inhibition of the type 2 isozyme was observed (83% at 10 µM).  
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Figure 3.8. Aryl substituted pyridone/piperidone and quinolinone inhibitors. 
 
 
Benzo[c]quinolinones 
 
This class of tricyclic non-steroidal inhibitor mimics the 6-azasteroid compounds (3.6, Fig. 
3.9). They are selective but weak type 1 inhibitors.27 Their structure is similar to the 
benzo[f]quinolinones (Fig. 3.7), but they fail to show the same potent activity, even with 
the presence of a Cl atom on the aromatic ring. Compound 3.29 has a Ki of 920 nM 
towards type 1, and 49% inhibition of type 2 (at 20 µM). 
 
 
 
 
 
 
 
 
Figure 3.9. Non-steroidal phenanthridin-3-one mimic of 6-azasteroids. 
 
 
The presence of a methyl group on the A ring is important for inhibition potency. Removal 
of the A-ring methyl group of 3.29 resulted in an inhibitor with a Ki greater than 10000 
nM. The same effect is seen with the benzo[f]quinolinones and benzo[c]quinolizinones 
(Fig. 3.10), and can be accounted for by the presence of a postulated small hydrophobic 
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pocket in the enzyme active site. This pocket is thought to accommodate a small alkyl 
group at the 4-position of the A ring of these tricyclic inhibitors.1 
 
 
Benzo[c]quinolizinones 
 
The tricyclic benzo[c]quinolizinones are based on the 10-azasteroids (3.7, Fig. 3.10). 
Potent and selective type 1 inhibitors are found within this class (e.g. 3.31, Fig. 3.10).28-31 
There are two major series within this class; one with the double bond located between C1 
and C2 (4aH series, 3.30), and the second between C4 and C4a (1H series, 3.31). 
 
 
 
Figure 3.10. Benzo[c]quinolizinone inhibitors of type 1. 
 
 
As for the 10-azasteroid inhibitors, the presence of a double bond between the carbonyl 
group and the nitrogen atom is essential for potency. Removal of the double bond results in 
a significant decrease in activity against the type 1 isozyme (3.31 compared to 3.32). The 
1H series of inhibitors with the double bond between C4 and C4a generally displays higher 
activity (10 fold) than those with the double bond between C1 and C2 (4aH series). A 
thorough investigation into the effects of substituents on the different positions of this 
tricyclic system has been discussed by Occhiato et al.1 A Cl atom at position 8 generally 
increases the potency observed for both series, in analogy with the previously mentioned 
tricyclic inhibitors. Substitution with a methyl group in the same position also increases 
potency when combined with one or two methyl groups on the aliphatic rings. A 4-methyl 
substituent enhances inhibitory activity, the same effect seen for the benzo[f]quinolinones 
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and benzo[c]quinolinones. A 6-methyl substituent also enhances potency, while a methyl 
group at position 1 or 5 generally reduces the potency. 
 
The higher inhibitory activity toward the type 1 isozyme displayed by compounds of the 
1H series (e.g. 3.31) compared to inhibitors of the 4aH series (e.g. 3.30) has been 
associated to their more extended planarity.28 This effect is analogous to that discussed for 
the benzo[f]quinolinones (Fig. 3.7). However, molecular planarity is not the only important 
feature when evaluating inhibition data. For example, the large difference in potency of 
3.34 and 3.35 (Fig. 3.11) cannot be explained by differences in molecular planarity. A 
molecular modelling study showed that the two inhibitors possessed similar overall 
extended planarity.1 As a consequence Occhiato et al. have suggested that the difference in 
inhibitory activity is associated with an important interaction between the double bond 
between C6a and C10a of 3.34, with an aromatic amino acid side chain in the enzyme 
active site.1 This hypothesis arose from the relatively recent report that residues 26-29 
(AVFA) in the type 1 isozyme sequence are involved in inhibitor-substrate binding, and 
contain an aromatic residue.32 
 
 
 
 
 
 
Figure 3.11. Inhibition of type 1 by benzo[c]quinolizinone 3.34 containing 6-10a/10-10a 
double bond (isomers in 10:1 ratio, IC50 = 58 nM for type 1) compared to the saturated 
trans-fused compound 3.35 ( IC50 = 20000 nM).33 
 
 
Non-steroidal acids 
 
A range of non-steroidal aryl acids has been synthesised and tested for 5α-reductase 
inhibition. Tricyclic aryl acids of the type 3.36 and 3.37 (Fig. 3.12) are related to the 
steroidal carboxylic acid inhibitors (3.8 and 3.10, Fig. 3.1). The steroidal D ring is absent 
in this tricyclic series. In contrast to the steroidal carboxylic acid inhibitors, the tricyclic 
N
O
1
4
6
10a
6a
8
3.34
N
O
3.35
H
H
Chapter Three – Design, synthesis and testing of non-steroidal inhibitors of steroid 5α-reductase 
 
 
 
100
acids are selective type 1 inhibitors.34 The introduction of a Cl atom to the aromatic ring 
(3.39, IC50 = 320 nM) does not increase the potency when compared to inhibitor 3.38 (IC50 
= 310 nM). This observation is in contrast with the enhanced potency usually seen with Cl 
substitution at the corresponding position in the other classes of tricyclic non-steroidal 
inhibitors. Instead enhanced potency is observed with a Br atom on the aromatic ring (3.37, 
IC50 = 26 nM). These carboxylic acid inhibitors act by a different mechanism to the aza-
inhibitors, supposedly interacting with the enzyme-NADP+ complex (see Scheme 3.2) in 
an uncompetitive manner versus testosterone (in analogy to the mechanism of the steroidal 
carboxylic acid inhibitors). 
 
 
 
 
 
 
 
 
Figure 3.12. Tricyclic aryl acid inhibitors derived from steroidal carboxylic acids. 
 
 
Other non-steroidal aryl acid inhibitors related to the steroidal carboxylic acids have been 
reported. While the tricyclic aryl acid inhibitors (Fig. 3.12) are selective for the type 1 
isozyme, non-steroidal aryl acids (summarised in Fig. 3.13, 3.14, and 3.15) are generally 
selective for the type 2 isozyme. In compound 3.40 the steroidal B and D rings are absent; 
while in compounds 3.42 and 3.43 the steroidal B and C rings have been replaced by an 
acyclic linker (Fig. 3.13). Compounds with inhibition values in the nanomolar range are 
found within the three classes of compounds in Figure 3.13. Inhibitor 3.40 was reported by 
Holt et al. to have a Ki of 60 nM.35 Picard et al. investigated the effect on inhibition by 
varying the substituent at the R1 position of 3.40.36 Inhibitor 3.41 with a dicyclohexyl 
group present has an IC50 of 220 nM. The presence of benzyl or alkyl carbonyl groups at 
the 4’-position (e.g. 3.40 and 3.41) was found to enhance potency in comparison to 
compounds with the corresponding amide present (for 3.40, where R1 = N(cyclohexyl)2, 
IC50 = 4.7 µM). Hydrophobic and bulky substituents (e.g. methyldicyclohexyl and benzyl 
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groups) at the R1 position were also found to increase inhibition of type 2, which supports 
the hypothesis for a hydrophobic pocket in the enzyme. N-Piperidine-4-(benzylidene-4-
carboxylic acid) compounds such as 3.42 have been reported. Substitution at the R1 
position with bulky groups also enhances potency. Inhibitor 3.42 has an IC50 of 60 nM, but 
when the methyldicyclohexyl group was replaced with a t-butyl group, an IC50 of 75 µM 
was observed.37 
 
 
 
 
 
 
 
 
Figure 3.13. Non-steroidal biaryl acid inhibitors. 
 
 
Some particularly potent aryl acid inhibitors of the type in Figure 3.14 have been reported. 
An IC50 of 53 nM was obtained for inhibitor 3.44 with selective activity against the type 2 
isozyme.38 The ether linkage of 3.44 is important for potency since substitution of the 
phenoxy group with the amide group as in 3.45 results in a 10 fold decrease in potency 
(IC50 = 820 nM). A very potent inhibitor containing an ether linkage was reported (3.46, 
IC50 = 6 nM).39 Replacing the ether linkage in 3.46 with a methylene linker results in a 10 
fold decrease in inhibition of the type 2 isozyme. 
 
 
 
Figure 3.14. Benzophenone and biaryl ether carboxylic acid inhibitors. 
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Lesuisse et al. have reported biaryl acid inhibitors such as 3.49 (Fig. 3.15) that are among 
the most potent selective inhibitors of type 2 with IC50 values in the low nanomolar 
range.40 The inhibition behaviour of compounds was studied by LeSuisse et al. by 
introducing various linkers between the aromatic ring and the amide portion (see 3.47, Fig. 
3.15). Inhibition of type 2 isozyme activity increased from 32.5% (3.47) to 57.5% (3.48) 
(at 10-6 M) with the introduction of an OCH2 linker between the aromatic ring and the 
amide of 3.47. The effect of substitution of the aromatic rings towards inhibition was also 
investigated. No significant effect on inhibition was observed when the carboxylic acid 
containing ring of 3.48 was substituted with various groups (F, Cl, Me, CF3). However 
when the phenxoyacetamide ring of 3.48 was substituted with various groups ortho to the 
acetamide, a dramatic effect on inhibition was observed. A F atom and a nitro group in 
these positions resulted in a very potent type 2 inhibitor (3.49, IC50 = 9.8 nM). The 
diisopropyl amide of 3.49 is important for potency. A 10 fold decrease in inhibitory 
activity (IC50 = 92 nM) was found when a trityl amide was substituted for the diisopropyl 
amide of 3.49. 
 
 
 
Figure 3.15. Biaryl carboxylic acid type 2 inhibitors. 
 
 
Dual non-steroidal inhibitors 
 
Steroidal dual inhibitors have been developed including dutasteride (see Fig. 3.4). 
Therefore the synthesis and inhibition profile of non-steroidal dual inhibitors is currently of 
interest. Streiber et al. have reported methyl esters of N-(dicyclohexyl)acetyl-piperidine-4-
(benzylidene-4-carboxylic acids) (e.g. 3.50, Fig 3.16) that were initially designed as 
prodrugs to enhance cell permeability, but were discovered to be potent inhibitors of type 1 
in human plasma.14 The ester 3.50 displays an IC50 of 1494 nM against type 1 in human 
plasma, but is metabolised to the acid 3.51 in human prostate tissue, where selective type 2 
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inhibition is observed (IC50 = 11 nM). Guarna et al. have reported dual inhibitors of the 
benzo[f]quinolizinone type.31 Inhibitor 3.52 (Fig. 3.16) inhibits both isozymes with similar 
potency. Compounds such as 3.50 and 3.52 present the future possibility of dual inhibition 
of steroid 5α-reductase by administering one drug, which would potentially achieve nearly 
complete suppression of serum DHT levels.  
 
 
 
 
 
 
 
 
Figure 3.16. Dual inhibitors of type 1 and 2 isozymes. 
 
 
3.1.5 SAR of non-steroidal inhibitors 
 
Despite a diversity of structures amongst the known classes of non-steroidal inhibitors, 
there are general structural features which influence potency. A structural feature common 
to inhibitors is a lipophilic scaffold incorporating a ring which mimics the geometry and 
electrostatic properties of the A ring in the DHT enolate 3.3. The potency and selectivity of 
non-steroidal inhibitors depends greatly on the nature and position of ring substituents. 
Features which influence non-steroidal inhibitor potency are summarised below. 
 
Ring substitution 
 
The nature of the substituent present at the 8-position (tricyclic inhibitors, see Fig. 3.5) or 
the 4’-position (biphenyl inhibitors, see Fig. 3.15) of non-steroidal inhibitors has a 
profound effect on potency against the type 1 isozyme. An 8-Cl substituent is found in 
some very potent inhibitors within the benzo[f]quinolinone and benzo[c]quinolizinone 
classes, for example 3.17 (IC50 = 8 nM) and 3.31 (IC50 = 7.6 nM). Replacement of the 8-Cl 
of 3.17 (for example) with other substituents decreases the potency against type 1 5α-
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reductase (Me, IC50 = 11 nM; Br, IC50 = 35 nM; H, IC50 = 560 nM). However, in the 
related tricyclic aryl acids (Fig. 3.12), potency is dependent on an 8-Br substituent (3.37, 
IC50 = 26 nM) and activity decreases 10 fold with either an 8-Cl (3.39) or 8-H substituent 
(3.38). For biaryl acid inhibitors of the type depicted in Figure 3.13, hydrophobic and 
bulky groups (e.g. benzyl, methyldicyclohexyl) at the R1 position of 3.40-3.43 enhance the 
potency of type 2 inhibition compared to compounds with smaller alkyl R1 substituents 
(replacement of the methyldicyclohexyl group of 3.41 with an isopropyl group results in a 
decrease in IC50 from 220 nM to 10 µM). The same influence is seen with the biaryl acid 
inhibitors depicted in Figures 3.14 and 3.15, where potent type 2 inhibition is also 
observed for compounds with bulky groups at the 4’-position [e.g. phenyl (3.44 has an IC50 
of 6 nM), diisopropylacetamide (3.49 has an IC50 of 9.8 nM)]. The presence of substituents 
at other positions on the phenxoyacetamide ring of 3.49 greatly enhances type 2 inhibition. 
Electron-withdrawing groups such as F and NO2 ortho to the acetamide group influence 
inhibitory potency dramatically, as shown by the difference in activity between 3.49 and 
3.48 (57.5% inhibition of type 2 activity at 10-6 M). 
 
Position and nature of unsaturation 
 
The influence of ring unsaturation on type 1 inhibitory potency for the tricyclic aza-
inhibitors (benzo[f]quinolinones, benzo[c]quinolinones, and benzo[c]quinlizinones) has 
been widely investigated. Potent inhibitory activity for these compounds depends on the 
presence (and position) or absence of unsaturation. For the benzo[c]quinolinones (Fig. 3.5) 
potency is observed with the absence of a double bond in the lactam ring (see 3.17, IC50 = 
8 nM). However, for the benzo[c]quinolizinones (Fig. 3.10) the presence of conjugation 
between the nitrogen and the carbonyl is essential for potency (see 3.31 vs 3.32), where a 
double bond between C4 and C4a (1H series) is preferred. Inhibitor 3.31 has an IC50 of 7.6 
nM, in comparison to 3.30 (IC50 = 141 nM) which has a double bond between C1 and C2. 
A double bond between C6a and C10a in the benzo[c]quinolizinones (see Fig. 3.11) is also 
influential on inhibitory potency (see Fig. 3.11), as it supposedly interacts with an aromatic 
amino acid in the enzyme active site. Potency has been associated to extended molecular 
planarity which is present in potent isomers of benzo[f]quinolinones LY191704 (3.21, Ki = 
6, 4 nM, and 3.22, Ki = 15, 15 nM) and LY266111 (3.23, Ki =9, 10 nM). 
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Lactam N-alkylation and angular methyl groups 
 
The presence of a 4-methyl group influences the potency of non-steroidal inhibitors of type 
1. Methylation of the lactam nitrogen enhances the potency of compounds within the 
benzo[f]quinolinone, pyridone and piperidone (3.25-3.27, Fig. 3.8), and quinolinone (3.28, 
Fig. 3.8) classes. The most dramatic effect can be seen by comparing the activity of 
compound 3.28 (IC50 = 510 nM) with that of its derivative in which the N-methyl group is 
absent (almost no inhibition of type 1). The presence of an angular methyl group at the 4-
position of the benzo[c]quinolinones (3.29, Fig. 3.9) and benzo[c]quinolizinones (3.31, 
Fig. 3.10) also influences the potency of these tricyclic aza-inhibitors. For example, 
removal of the 4-methyl group of 3.29 (Ki = 920 nM) results in a compound with a Ki 
greater than 10000 nM. Potent inhibition is observed for the trans enantiomers of 
LY266111 (3.23, IC50 = 9, 10 nM) in which the angular methyl group is trans to the H at 
C4. In the benzo[c]quinolizinone series of inhibitors, the presence of an angular methyl 
group at the 6-position either maintains or enhances potency against the type 1 isozyme. 
For example, incorporation of a methyl group at the 6-position of 3.31 (IC50 = 7.6 nM) 
results in an inhibitor with similar potency (IC50 = 8.5 nM).  
 
 
3.1.6 Biological testing of steroid 5α-reductase inhibitors 
 
SAR studies of inhibitors depend on the reliability and reproducibility of the biological 
inhibition assay. Methods have been developed to assess the activity of inhibitors versus 
human steroid 5α-reductase using either the native isozymes (sourced from tissue 
homogenates or human cell lines), or recombinant isozymes expressed by transfected cells. 
Tissue homogenates contain both isozymes in different amounts, complicating the testing 
procedure and hence the interpretation of results. When assessing the inhibition of a 
compound against both isozymes in tissue homogenates, it is necessary to selectively 
activate one of the isozymes in the presence of the other. Different concentrations of 
testosterone have been used to activate either 5α-reductase type 1 or 2 on the basis of the 
different affinities of the substrate (testosterone has higher affinity for the type 2 isozyme 
than type 1). 
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Human derived cell lines, which predominantly express the type 1 isozyme, can be used to 
test inhibitors. These include tumour cell lines originating from the prostate, such as PC3, 
DU145, and LnCaP, or lines from skin, like SZ95.41-43 However, tumour lines are difficult 
to grow and maintain in culture. Transfected cell lines expressing recombinant isozymes 
have also been used to test inhibitors. These cell lines avoid the problems associated with 
tissue homogenates, as each isozyme is tested separately. A biological test for assessing 
5α-reductase inhibitors should be chosen carefully.1 Human isozymes are essential for 
determining the potency and selectivity of novel inhibitors, especially if they are clinical 
study candidates. The structural difference of the isozymes between species can cause 
different responses to inhibitors. This is often the case with rat versus human isozymes. For 
example, finasteride is a weak inhibitor of human type 1 (Ki = 300 nM), but a potent 
inhibitor of rat type 1 (Ki = 5 nM).1 
 
A number of different classes of non-steroidal 5α-reductase inhibitors have appeared in the 
literature, which has made the definition of SAR within and across classes desirable. The 
aim of the work presented in this chapter was to investigate SAR across different classes of 
non-steroidal inhibitors of steroid 5α-reductase. Several non-steroidal inhibitor scaffolds 
were identified for synthesis in this thesis. A 5-aryl 1-methyl-2-pyridone scaffold [related 
to the 4-azasteroids (3.5)], was chosen so that SAR for novel inhibitors of this type could 
be investigated further and compared with SAR from another series of inhibitors. There is 
a lack of reported information which compares SAR for 4’-substituents of this pyridone 
scaffold (see 3.55, Fig. 3.18) with SAR for 4’-substituents of biaryl acid inhibitors (see 
Fig. 3.13 and Fig. 3.15). Potent type 2 inhibitors are found within the biaryl acid series of 
compounds, so it was of interest to see if 4’-substituents influencing potency have a similar 
effect when incorporated into the pyridone scaffold. 5-Aryl 1-methyl-2-pyridone based 
inhibitors have been reported previously (and are generally type 1 inhibitors) however this 
thesis investigates SAR for substituents at the 4’-position in particular, because the nature 
of the 4’-substituent is known to influence potency. A 1-aryl 2-substituted 2,3-dihydro-4-
pyridone scaffold [related to the 10-azasteroids (3.7) and benzo[c]quinolizinones (e.g. 
3.30)] was also chosen (see 3.61, Fig. 3.20), as it is a novel non-steroidal scaffold with 
which to investigate 5α-reductase inhibition. SAR for substituents at the 4’-position of 
inhibitors of this type were also of interest, for reasons discussed for the 5-aryl 1-methyl-2-
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pyridone scaffold. Activity comparison between the two different series of pyridones was 
also desirable.  
 
A further aim was to conjugate an inhibitor to a long carbon chain olefin-containing tether 
by a novel method using cross metathesis. Conjugates such as these are useful for attaching 
to a gold surface, so that biological interactions (e.g. between an inhibitor and enzyme) 
may potentially be studied by the use of a solid support. A sulfur atom at the tether 
terminus is required to facilitate attachment of a conjugate to a gold surface. Self-
assembled monolayers (SAMs) occur when a gold surface is modified by an organic 
substance, such as an inhibitor-tether conjugate.44 SAMs provide well defined systems for 
investigating biomolecular recognition, for example the interaction between an enzyme 
and an inhibitor. Steroid 5α-reductase has not been isolated (see section 3.1.2), so we 
proposed that SAM technology may be a possible method to isolate the enzyme for further 
investigation into its molecular conformation, as well as inhibition kinetics. 
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3.2 DESIGN OF NOVEL NON-STEROIDAL INHIBITORS 
OF STEROID 5α-REDUCTASE  
 
Novel non-steroidal inhibitors of steroid 5α-reductase, consisting of a 5-aryl 1-methyl-
pyridone scaffold, were based upon particular structural features of literature inhibitors 
(e.g. 3.53 and 3.48, Fig. 3.17). Pyridones of this nature have been reported to be weak 
inhibitors of type 1 5α-reductase (discussed in section 3.1.4.2). The 5-aryl 1-methyl-
pyridone scaffold of 3.53 was chosen as a non-steroidal skeleton for the synthesis of novel 
inhibitors, so SAR for substituents at the 4’-position could be further investigated and 
compared to SAR for the biaryl acid type inhibitors. Section 3.1.5 discussed the important 
structural features that influence inhibitor potency, one of which was ring substitution. It 
was also of interest to determine whether the potency of particular 5-aryl 1-methyl-
pyridones from the literature could be enhanced by incorporating particular groups from 
potent known biaryl acid inhibitors in the scaffold at the 4’-position. The selection of 
groups to attach to the aromatic ring at the 4’-position of the pyridone scaffold (see 3.53) 
was based on those from inhibitors reported by Hartmann and Reichert24 (3.53 and 3.54, 
Fig. 3.17) and Lesuisse et al.40 (3.47-3.49, Fig. 3.17). The N,N-diisopropylamide group of 
3.53 and 3.54 was used as it is known to influence the potency of type 1 inhibitors 
previously reported by Hartmann.25 Lesuisse et al. reported potent inhibition of the type 2 
isozyme also using an N,N-diisopropylamide group but on a biaryl acid scaffold, e.g. 3.49 
(Fig. 3.17). However, the potency of 3.49 is also due to the presence of an OCH2 linker 
between the aromatic ring and the diisopropyl amide. The presence of the OCH2 linker 
results in enhanced activity for compound 3.48 compared to 3.47.  
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Figure 3.17. Inhibition values (% inhibition at 100 µM) for 4’-substituted benzamides 3.53 
and 3.54 [BPH (type 2) and RVP (pH 6.6 type 1) denote the enzyme source, benign 
prostatic hyperplasia tissue, or rat ventral prostate]. % Inhibition values for 3.47 and 3.48 
were obtained at 10-6 M. 
 
 
Because of the effect of the OCH2 linker on potency for 3.48 and 3.49, we decided to 
incorporate it into literature inhibitors 3.53 and 3.54 to give the novel compounds 3.55 and 
3.56 (Fig. 3.18). The inhibitory activity of these novel compounds allows the evaluation of 
SAR for the N,N-diisopropylacetamide group at the 4’-position for 5-aryl 1-methyl-2-
pyridone/piperidone based compounds. Compound 3.49 is a potent inhibitor of the type 2 
isozyme, so inhibition data for 3.55 and 3.56 would provide useful information on whether 
SAR for 4’-substituents of 5-aryl 1-methyl-pyridones/piperidones correlate with SAR 
derived from the biaryl acid inhibitors. The N-allylacetamide of 3.57 was incorporated on a 
similar basis to the diisopropylacetamide of 3.55. However, the allyl group was chosen 
specifically to facilitate conjugation with a long chain olefin-containing tether, for the 
potential attachment of inhibitor-tether conjugates to a gold surface (which will be 
discussed in further detail later in this section).  
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Figure 3.18. Structures of initial targets for synthesis. 
 
 
To evaluate SAR for substituents at the 4’-position of the pyridone scaffold, it was 
necessary to incorporate groups other than the acetamides already discussed. A potent 4’-
benzoyl biaryl carboxylic acid inhibitor of the type 2 isozyme (3.58, Fig. 3.19) was 
reported by Holt et al.35 Interest in related benzophenone aryl acid compounds stemmed 
from previous work which indicated potency was related to the benzophenone moiety. 
Therefore the benzoyl group of 3.58 was incorporated into the pyridone/piperidone 
scaffold under investigation in this thesis, resulting in novel compounds 3.59 and 3.60. The 
presence of the bulky benzoyl group at the 4’-position (see 3.59) allows for evaluation of 
SAR in relation to compounds 3.55-3.57 which have an N-substituted acetamide. 
Iinhibition data for 3.59 and 3.60 would also indicate whether SAR for the pyridone type 
compounds correlate with those of the biaryl carboxylic acids. 
 
 
 
Figure 3.19. Potent reported benzoyl inhibitor 3.58 and novel inhibitors 3.59 and 3.60. 
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After the design of initial targets 3.55-3.57 and 3.59-3.60, further compounds were 
developed for synthesis. The 5-aryl 1-methyl-2-pyridone type inhibitors represent non-
steroidal derivatives of the 4-azasteroids, with two of the steroidal rings (B and D) missing. 
Inhibitors related to the 10-azasteroids (3.7, Fig. 3.1) with the steroidal B and D rings 
absent have not been reported to date. The 10-azasteroid related tricyclic 
benzo[c]quinolizinones (3.30, Fig. 3.10) have been reported, in which a steroidal D ring is 
absent. A 1-aryl 2-substituted 2,3-dihydro-4-pyridone (e.g. 3.61, Fig. 3.20) represents a 
non-steroidal derivative of the 10-azasteroids and was used as a novel scaffold for the 
design of inhibitors. In analogy with compounds 3.55-3.57, N,N-diisopropyl- and N-
allylacetamide groups were incorporated at the 4’-position of the dihydro-4-pyridone 
scaffold to give 3.61 and 3.62. Inhibition data for dihydro-4-pyridones 3.61 and 3.62 would 
allow SAR comparisons with the corresponding 5-aryl pyridones 3.55 and 3.57, as these 
series differ by the position of the N atom relative to the carbonyl in the pyridone rings. 
Compounds 3.61 and 3.62 also have unsaturation between C2 and C3 of the pyridone ring, 
a structural feature which is known to influence the inhibitory potency of the related 
tricyclic benzo[c]quinolizinone inhibitors (see 3.30, Fig. 3.10). The presence of angular 
methyl groups is also known to influence the inhibitory potency of the 
benzo[c]quinolizinone inhibitors, so a methyl group was incorporated at the 2-position of 
the pyridone ring (see 3.61). In the design of compounds 3.63 and 3.64, a phenyl group 
was incorporated at the 2-position of the pyridone ring in order to investigate the effect on 
inhibition that this bulky group has in comparison with a small 2-methyl group. 
 
 
 
 
 
 
 
 
 
 
Figure 3.20. Novel non-steroidal inhibitors related to the 10-azasteroids. 
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Another series of potential inhibitors was also designed in which compounds 3.57, 3.62, 
and 3.64 are conjugated to a long carbon chain tether with a protected thiol at its terminus 
(Fig. 3.22). The purpose of conjugating a thiol-containing tether to an inhibitor is to 
facilitate attachment of inhibitors to a gold surface. The sulfur atom at the tether terminus 
is required for reaction with a gold surface to form SAMs (see section 3.1.6). Long chain 
tethers which are suitable for conjugating to biological ligands (e.g. inhibitors) have been 
reported by Svedham et al.45 Poly-(ethylene glycol)-terminated alkane thiol amides (see 
3.65, Fig. 3.21) were synthesised to study the structure and stability of SAMs on gold for 
potential biosensing interfaces. Poly-ethylene glycol spacer units provide good anchors for 
biological receptors and ligands and are known to reduce the non specific binding of 
proteins and other bioactive molecules. In a series of tethers typified by 3.65, the alkane 
chain length (x) was varied from 2C to 15C. The number of ethylene glycol units (y) was 
also varied to investigate the conformations induced by different chain lengths when 
attached to the gold surface. The approach of Svedham et al. was used in the design of 
long chain tethers 3.66 and 3.67 (Fig. 3.21). For tethers 3.66 and 3.67, a 15C alkane chain 
was chosen, due to the readily available starting material, 16-mercaptohexadecanoic acid. 
The number of ethylene glycol units was also varied; 3.66 contains one unit, while 3.67 
contains two units. An allyl group was incorporated into the terminus of these tethers as it 
allows conjugation to compounds 3.57, 3.62, and 3.64 (which also possess an allyl group) 
by the cross metathesis reaction. This is a novel and mild method for conjugating a 
biological molecule to a long carbon chain tether for the purpose of gold surface 
attachment. Cross metathesis is the exchange of substituents between two alkenes; terminal 
alkenes are particularly favourable as the reaction is driven by the release of ethylene gas 
(Scheme 3.4).  
 
 
 
 
Scheme 3.4. Cross metathesis general reaction. 
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The reaction is catalysed by ruthenium compounds which tolerate a wide variety of alkene 
substrates. It is an ideal method for conjugating long chain tethers to biological molecules 
as the reaction conditions are generally mild (substrates are simply stirred in solvent in the 
presence of catalyst). The reaction can be done in a wide range of solvents including polar 
solvents (e.g. MeOH and water) without heating with an appropriate catalyst. These mild 
conditions are desirable for biological substrates. The inhibitor-tether conjugate targets 
initially designed for synthesis in this thesis are shown in Figure 3.22. 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. Long chain tethers 3.66 and 3.67 derived from 3.65. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. Inhibitor-tether conjugate targets. 
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3.3 SYNTHESIS OF 5-ARYL 1-METHYL-2-
PYRIDONES/PIPERIDONE INHIBITORS 3.55-3.57 
 
The following sections describe the synthesis of pyridones 3.55 and 3.57 and piperidone 
3.56. A key step in the scheme towards preparation of the 5-aryl 1-methyl-pyridone 
scaffold involved a Suzuki cross coupling to generate an aryl-substituted pyridine 
intermediate which could subsequently be converted into the 2-pyridone 3.77. Two 
different strategies were investigated for the synthesis of 3.77. An initial strategy is 
discussed in section 3.3.1, which was abandoned due to the low yielding nature of the N-
methylation/α-oxidation reaction [Scheme 3.5, step (ii)]. The synthetic route to inhibitors 
3.55-3.57 is discussed in section 3.3.2 in which 5-aryl-2-fluoropyridine (3.80, Scheme 3.6) 
was converted to the 2-pyridone 3.81 by facile acid hydrolysis. The N,N-diisopropyl- and 
N-allylacetamide groups of 3.83 and 3.84 (Scheme 3.7) were then introduced at the 4’-
position of phenol 3.78 to give pyridone target compounds 3.55 and 3.57. The piperidone 
target 3.56 was prepared by catalytic hydrogenation of 3.55. 
 
 
3.3.1 Attempted synthesis of pyridones/piperidone 3.55-3.57 
 
The reported synthesis24 of related literature inhibitors 3.53 and 3.54 was used for an initial 
attempt to prepare 3.55-3.57. Scheme 3.5 outlines the initial strategy used for the 
preparation of 3.55-3.57. A Suzuki cross coupling was utilised for the generation of key 
intermediate 3.76, which would be converted to the 1-methyl-pyridinium salt and then α-
oxidised to give the pyridone 3.77. Deprotection of 3.77 to give 3.78, followed by 
alkylation with an N-substituted bromoacetamide was envisaged to give pyridones 3.55 
and 3.57. 
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Scheme 3.5. Reagents and conditions: (i) KOH, nBu4NBr, Pd(PPh3)4, THF, reflux, 16 h 
(73%). (ii) (MeO)2SO2, 80˚C, 45 min, then K3[Fe(CN)6], KOH (at 0˚C), DCM, rt, 16 h 
(8% yield). 
 
 
The Suzuki cross coupling reaction of 3-bromopyridine (3.74) and p-methoxyphenyl 
boronic acid (3.75) (both commercially available) was performed in THF in the presence 
of tetrakis(triphenylphosphine)palladium(0) catalyst, potassium hydroxide and n-
tetrabutylammonium bromide to give 3.76 in 73% yield. 3-Arylpyridine 3.76 was N-
methylated with dimethyl sulfate, the resulting N-methylpyridinium salt was hydroxylated 
with potassium hydroxide and oxidised in situ with potassium ferricyanide to give the 1-
methyl-pyridone 3.77 in 8% yield. This compound was difficult to purify, requiring 
extended chromatography resulting in a very poor yield (8%). For this reason the synthesis 
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of 1-methyl-pyridone 3.77 by this method was abandoned and an alternative route to 
inhibitors 3.55-3.57 was sought. 
 
 
3.3.2 Synthetic route to pyridones/piperidone 3.55-3.57 
 
A revised route to inhibitors 3.55-3.57 is outlined in Scheme 3.6. Sutherland et al. have 
described the use of 5-bromo-2-fluoropyridine (3.79) in Suzuki cross couplings for the 
synthesis of 5-aryl-2-fluoropyridines.46 These fluorinated pyridines are converted to the 
corresponding 2-pyridones by acid hydrolysis. Therefore 3.79 was incorporated into the 
synthetic strategy for preparing 3.55-3.57. Suzuki cross coupling of 3.79 with 3.75 would 
give the key intermediate 3.80, which upon acid hydrolysis would give the pyridone 3.81. 
N-Methylation using lithium hydride and methyl iodide (coordination of lithium to the 
pyridone O atom supposedly promotes selective N-methylation),47 is followed by 
deprotection to give 3.78. Alkylation of phenol 3.78 with an N-substituted 2-
bromoacetamide (3.83 or 3.84) was envisaged to give the pyridones 3.55 and 3.57. 
Catalytic hydrogenation of 3.55 would produce the piperidone 3.56. 
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Scheme 3.6. Reagents and conditions: (i) Pd(PPh3)4, KOH, nBu4NBr, THF, reflux, 19 h 
(82%). (ii) 4 M aq. HCl in dioxane, H2O, reflux, 24 h (quantitative). (iii) LiH, DMF, 50˚C, 
1.5 h, then MeI, 50˚C, 16 h (68%). (iv) 1:1 48% aq. HBr in AcOH, reflux, 16 h (83%). (v) 
2 M aq. NaOH, DMSO, 80˚C, 30 min, then 3.83, 80˚C, 2 h (46%). (vi) 10% Pd/C/H2, 
EtOH, rt, 40 bar, 48 h (63%). (vii) 2 M aq. KOH, DMF, 80˚C, 1.5 h, then 3.84, 16 h (79%). 
 
 
 
 
 
Scheme 3.7. Reagents and conditions: BnNEt3Cl, ClCH2CH2Cl, HNiPr2 or 
NHCH2CHCH2, NaOH, 0˚C, then BrCH2COBr, rt, 16 h (3.83 75%, 3.84 67%). 
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Scheme 3.6 details the synthesis of 3.55-3.57. The Suzuki cross coupling reaction of 5-
bromo-2-fluoropyridine (3.79) with p-methoxyphenyl boronic acid (3.75) (both 
commercially available) was performed in THF in the presence of 
tetrakis(triphenylphosphine)palladium(0) catalyst, potassium hydroxide and n-
tetrabutylammonium bromide to give key intermediate 3.80 in 82% yield. Hydrolysis of 2-
fluoropyridine 3.80 was carried out in 4 M aqueous hydrochloric acid in dioxane and water 
to give the 2-pyridone 3.81 in quantitative yield. Pyridone 3.81 was deprotonated with 
lithium hydride and subsequently methylated with methyl iodide to give 3.77 in 68% yield. 
Cleavage of the methyl aryl ether of 3.77 was achieved in equal volumes of hydrobromic 
acid and acetic acid to give 3.78 in 83% yield. 
 
Scheme 3.7 outlines the synthesis of 2-bromo-N,N-diisopropylacetamide (3.83) and N-
allyl-2-bromoacetamide (3.84)48 required for the synthesis of 3.55 and 3.57. 
Bromoacetylbromide (3.82) was reacted with either diisopropylamine or allylamine in the 
presence of sodium hydroxide and benzyltriethyl ammonium chloride in 1,2-
dichloroethane to give the 2-bromoacetamides 3.83 and 3.84 in 75% and 67% yield 
respectively. 
 
The alkylation reaction of phenol 3.78 with 3.83 was performed in DMSO in the presence 
of aqueous sodium hydroxide to give phenoxyacetamide 3.55 in 46% yield. Compound 
3.78 was also alkylated with 3.84, but in DMF in the presence of potassium hydroxide, to 
give 3.57 in 79% yield. Catalytic hydrogenation of 3.55 was carried out in ethanol in a 
PARR hydrogenator with H2 at 40 bar and 10% palladium on charcoal to give the racemic 
piperidone 3.56 in 63% yield. The piperidone derivative of 3.57 was not synthesised due to 
probable hydrogenation of the allyl group. 
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3.4 SYNTHESIS OF BENZOYL INHIBITOR 3.59 
 
The following section describes work in the synthesis of benzoyl inhibitor 3.59. A key step 
in the synthetic strategy for preparation of the 5-aryl 1-methyl-pyridone scaffold (outlined 
in Scheme 3.8) was a Suzuki cross coupling of fluorinated boronic acid 3.85 and benzyl-4-
bromophenyl ketone (3.86). Several different cross coupling conditions were investigated 
before the 2-fluoropyridone 3.87 was successfully synthesised. Initial attempts to 
synthesise key intermediate 3.87 are discussed in section 3.4.1, while section 3.4.2 
describes the final synthesis of inhibitor 3.59. 
 
 
3.4.1 Attempted synthesis of key intermediate 3.87 
 
Initially it was envisaged that inhibitor 3.59 could be synthesised via the methodology 
developed for the pyridones 3.55 and 3.57 [see Scheme 3.6, steps (i) to (iii)]. Scheme 3.8 
outlines an initial strategy for the synthesis of benzoyl compound 3.59. Benzyl-4-
bromophenyl ketone (3.86) was identified as a reactant for Suzuki cross coupling to 
generate the key intermediate 2-fluoropyridine 3.87. 5-Bromo-2-fluoropyridine (3.79) 
required conversion to boronic acid 3.85, via bromine-lithium exchange and subsequent 
reaction with trimethyl borate, to faciliate cross coupling with 3.86. The remaining steps in 
Scheme 3.8 were derived from the methodology shown in Scheme 3.6. Acid hydrolysis of 
2-fluoropyridine 3.87 would give the 2-pyridone 3.88, which could be N-methylated to 
give 1-methyl-pyridone 3.59. Catalytic hydrogenation of 3.59 was envisaged to give the 
piperidone 3.60 in the final step. 
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Scheme 3.8. Reagents and conditions: (i) nBuLi, Et2O, -78˚C, 45 min, then B(OMe)3, 1 h 
(73%). (ii) KOH, nBu4NBr, Pd(PPh3)4, THF, reflux, 16 h. 
 
 
5-Bromo-2-fluoropyridine (3.79) was converted to an organolithium species in situ with n-
butylithium and reacted with trimethylborate to give boronic acid 3.85 in 73% yield.49 The 
work up for this reaction was important and involved slow addition of aqueous sodium 
hydroxide to the reaction mixture, followed by careful addition of aqueous hydrochloric 
acid at 0˚C to prevent protodeboronation. The cross coupling reaction of 3.85 and benzyl-
4-bromophenyl ketone (3.86) was carried out in THF in the presence of 
tetrakis(triphenylphosphine)palladium(0), potassium hydroxide and n-tetrabutyl 
ammonium bromide. However, when the crude product was analysed by 1H NMR, 
unidentified material was observed. From this observation it was assumed that the cross 
coupling of 3.85 and 3.86 did not proceed as desired. 
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Three equivalents of a strong base, potassium hydroxide, were used in the coupling 
reaction. Since 3.86 can be deprotonated α to the carbonyl, the base may have reacted with 
ketone 3.86. Organoboron species (such as 3.85) are poor nucleophiles and cross coupling 
with aryl halide electrophiles does not usually proceed unless a negatively charged base is 
present to enhance the nucleophilicity of the organic group on the boron atom.50 Reaction 
of potassium hydroxide with 3.86 would reduce the amount of base available to activate 
3.85, suggesting a possible reason as to why the coupling of 3.85 and 3.86 did not proceed 
as desired. The low solubility of potassium hydroxide in THF observed would also reduce 
the amount of hydroxide ion present in solution.  
 
As the cross coupling of 3.85 and 3.86 did not proceed under the conditions described in 
Scheme 3.8, a new strategy for the synthesis of key intermediate 3.87 was devised. It was 
envisaged that if potential α-deprotonation of 3.86 by potassium hydroxide could be 
prevented then cross coupling might occur. Protection of the carbonyl functional group in 
3.86 would remove the possibility of α-deprotonation. Carbonyl groups are easily 
converted to acetal derivatives, so the carbonyl of ketone 3.86 was protected through 
conversion to the acetal in 3.89. Scheme 3.9 presents a revised strategy for synthesising 
key intermediate 3.87. 
 
 
 
Scheme 3.9. Reagents and conditions: (i) CH(OMe)3, CF3SO3H, 4Å sieves, MeOH, rt, 16 
h (73%). (ii) KOH, nBu4NBr, Pd(PPh3)4, THF, reflux, 16 h. 
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Benzyl-4-bromophenyl ketone (3.86) was reacted with trimethylorthoformate in methanol 
in the presence of catalytic trifluoromethane sulfonic acid and 4Å molecular sieves to give 
the acetal 3.89 in 73% yield. The cross coupling reaction of boronic acid 3.85 and 3.89 was 
performed in THF in the presence of tetrakis(triphenylphosphine)palladium(0), potassium 
hydroxide and n-tetrabutyl ammonium bromide. Analysis of the crude product by 1H NMR 
revealed that only starting material was present, so it was assumed that the cross coupling 
did not proceed to give 3.90.  
 
Since cross coupling between the protected ketone 3.89 and boronic acid 3.85 did not 
proceed, a new strategy was devised to synthesise 3.87 (see Scheme 3.10). For the cross 
coupling depicted in Scheme 3.8 [step (ii)], a strong base (potassium hydroxide) was used 
for the activation of boronic acid 3.85. A weaker base than potassium hydroxide was 
thought to aid coupling with the suspected base sensitive starting material 3.86. Weakly 
basic conditions have been reported in the Suzuki coupling of triflates with boronic acids.50 
A triflate derivative of ketone 3.86 was therefore synthesised for coupling with boronic 
acid 3.85. Different reaction conditions are required when a triflate is used for coupling 
with a boronic acid. The reaction of triphenylphosphine (palladium catalyst ligand) with 
triflates is thought to cause catalyst decomposition.50 Potassium bromide is often added to 
prevent decomposition of the Pd catalyst (precipitating palladium black is observed at the 
early stage of reaction), which is proposed to cause failure of triflate mediated cross 
coupling. Addition of potassium bromide to the reaction prevents catalyst decomposition. 
A method using tetrakis(triphenylphosphine)palladium(0), tripotassium phosphate, and 
potassium bromide in dioxane40 was identified for use in an attempt to couple boronic acid 
3.85 with triflate 3.95 (Scheme 3.10). 
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Scheme 3.10. Reagents and conditions: (i) AlCl3, ClCH2CH2Cl, rt, 16 h (60%). (ii) 1:1 
48% aq. HBr in AcOH, reflux, 7 h (57%). (iii) Pyridine, (CF3SO2)2O, CH2Cl2, 0˚C, 45 min 
(59%). (iv) Pd(PPh3)4, K3PO4, KBr, dioxane, 85˚C, 16 h.  
 
 
Scheme 3.10 outlines the attempted synthesis of 3.87 via coss coupling of triflate 3.95 with 
boronic acid 3.85. Friedel-Crafts acylation of anisole (3.91) with phenylacetyl chloride 
(3.92) in 1,2-dichloroethane in the presence of aluminium trichloride gave benzoyl 
compound 3.93 in 60% yield.51 The methyl ether of 3.93 was cleaved with aqueous 
hydrobromic acid in acetic acid to give phenol 3.94 in 57% yield. Phenol 3.94 was reacted 
with triflic anhydride and a catalytic amount of pyridine in DCM to give triflate 3.95 in 
59% yield. The cross coupling of boronic acid 3.85 with triflate 3.95 was carried out in 
dioxane in the presence of tetrakis(triphenylphosphine)palladium(0), potassium bromide 
and tripotassium phosphate. However, when the crude product was analysed by 1H NMR, 
only starting material and unidentified material were observed. This method for coupling 
was subsequently abandoned. 
 
 
 
 
 
MeO
(i)
MeO
O
(ii)
HO
O
(iii)
TfO
O
(iv)
F
O
3.91 3.92 3.93 3.94
3.95
3.85
3.87
Cl
O
Tf = SO2CF3
Chapter Three – Design, synthesis and testing of non-steroidal inhibitors of steroid 5α-reductase 
 
 
 
124
3.4.2 Synthetic route to benzoyl inhibitor 3.59 
 
A literature search was conducted to find other possible conditions for synthesising key 
intermediate 3.87 via Suzuki cross coupling. A significant paper was identified in which 
Br-substituted aryl ketones were coupled to aryl boronic acids under mild conditions, using 
tetrakis(triphenylphosphine)palladium(0) with aqueous sodium carbonate in ethanol and 
toluene. The ketone and boronic acid starting materials for couplings described in the paper 
were similar to 3.86 and 3.85, so the reported mild conditions were of interest for 
synthesising 3.87. These conditions were used to couple 3.85 with 3.86 to successfully 
generate the desired 2-fluoropyridine 3.87 in excellent yield. Investigations into the 
synthesis of 3.87 described here have led to the conclusion that the choice of conditions for 
Suzuki cross coupling is critical. Scheme 3.11 outlines the synthesis of benzoyl inhibitor 
3.59. 
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Scheme 3.11. Reagents and conditions: (i) nBuLi, Et2O, -78˚C, 45 min, then B(OMe)3, rt, 
1 h (73%). (ii) Pd(PPh3)4, 2 M aq. Na2CO3, EtOH, toluene, reflux, 18 h (85%). (iii) 4 M aq. 
HCl in dioxane, H2O, reflux, 24 h (95%). (iv) LiH, DMF, rt, 1 h, then MeI, 16 h (52%). (v) 
10% Pd/C/H2, rt, 40 bar, 48 h. 
 
 
The cross coupling of boronic acid 3.85 with benzyl-4-bromophenyl ketone (3.86) was 
performed in ethanol/toluene in the presence of tetrakis(triphenylphosphine)palladium(0) 
and aqueous sodium carbonate to give 2-fluoropyridine 3.87 in 85% yield. The 1H NMR 
spectrum of 2-fluoropyridine 3.87 is shown in Figure 3.23. The presence of the product 
3.87 could be crudely determined by observing the chemical shift of the peak which 
represents the methylene protons adjacent to the carbonyl. This chemical shift was 
compared to that of the corresponding protons in the starting material 3.86 (Scheme 3.9). 
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In the 1H NMR spectrum of 3.86 (not shown here), a singlet representing the methylene 
protons was observed at 4.22 ppm, but in the spectrum of product 3.87 (Fig. 3.23), this 
singlet is present at 4.32 ppm. HRMS analysis also confirmed the presence of 3.87 by the 
accurate mass obtained for protonated product (C19H15NOF = 292.1132 g mol-1, calculated 
mass = 292.1138 g mol-1). Hydrolysis of 2-fluoropyridine 3.87 was carried out in 4 M 
aqueous hydrochloric acid in dioxane and water to give the 2-pyridone 3.88 in 95% yield. 
Pyridone 3.88 was deprotonated with lithium hydride at rt and subsequently methylated 
with methyl iodide to give 3.59 in 68% yield. Catalytic hydrogenation of 3.59 in methanol 
in the presence of 10% palladium on charcoal was attempted, but the expected piperidone 
product 3.60 was not obtained. When the crude product was analysed by 1H NMR, 
unidentified material was observed.  
 
 
 
Figure 3.23. 1H NMR spectrum (CDCl3, 500 MHz) of cross coupling product 3.87. 
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3.5 SYNTHESIS OF 1-ARYL 2-METHYL 2,3-DIHYDRO-4-
PYRIDONE INHIBITORS AND ATTEMPTED 
SYNTHESIS OF 2-PHENYL ANALOGUES 
 
The synthesis of 1-aryl 2-methyl 2,3,-dihydro-4-pyridone inhibitors 3.61 and 3.62 is 
discussed in the following section (see Scheme 3.13). A search of the literature revealed 
that 2-substituted 2,3-dihydro-4-pyridones (see 3.97, Scheme 3.12) can be synthesised by 
the aza Diels-Alder reaction of Danishefsky’s diene (3.96) with imines. An efficient 
protocol for this reaction was reported by Yuan et al. in which the reaction occurs in 
methanol at rt without acid catalysis (Scheme 3.12).52 
 
 
 
 
 
 
Scheme 3.12. Aza Diels-Alder reaction of Danishefsky’s diene with imines. 
 
 
3.5.1 Synthetic route to dihydro-4-pyridones 3.61 and 3.62 
 
A one pot aza Diels-Alder procedure was used to synthesise the 1-aryl 2-methyl 2,3-
dihydro-4-pyridone scaffold of 3.61 and 3.62 using an appropriate aldehyde (acetaldehyde) 
to incorporate the desired methyl functionality at the 2-position. Scheme 3.13 outlines the 
synthetic route to inhibitors 3.61 and 3.62. 
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Scheme 3.13. Reagents and conditions: (i) MeOH, rt, 2 h (89%). (ii) 1:1 48% aq. HBr in 
AcOH, 80˚C, 8 h (66%). (iii) 2 M aq. KOH, DMF, 80˚C, 1.25 h, then 3.84, 16 h (30%). 
(iv) 2 M aq. KOH, DMF, 80˚C, 30 min, then 3.83, 16 h (43%). 
 
 
To the imine (dienophile), generated in situ by reacting acetaldehyde with p-anisidine, was 
added Danishefsky’s diene (3.96) to give the racemic dihydro-4-pyridones 3.98 in 89% 
yield. Cleavage of the aryl methyl ether of 3.98 to give the phenols 3.99 was accomplished 
with equal volumes of aqueous hydrobromic acid and acetic acid in 66% yield. Phenols 
3.99 were alkylated with either bromoacetamide 3.84 or 3.83 in DMF in the presence of 
potassium hydroxide to give the 2-methyl 2,3-dihydro-4-pyridone inhibitors 3.62 and 3.61 
in 30% and 43% yield respectively.  
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3.5.2 Attempted synthesis of dihydro-4-pyridones 3.63 and 3.64 
 
The synthetic route to 2-phenyl 2,3-dihydro-4-pyridones 3.63 and 3.64 (Scheme 3.14) was 
devised by analogy to the synthesis of 3.61 and 3.62 (Scheme 3.13). Benzaldehyde was 
used for the key aza Diels-Alder step to incorporate the phenyl group at the 2-position of 
the dihydro-4-pyridone ring.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.14. Reagents and conditions: (i) MeOH, rt, 2 h, (64%).  
 
 
The key starting material, 2-phenyl 2,3-dihydro-4-pyridone 3.100, was synthesised via a 
one pot aza Diels-Alder reaction as shown in Scheme 3.14 step (i). A solution of 
benzaldehyde and p-anisidine in methanol was stirred to form the imine in situ, to which 
diene 3.96 was added to give the racemic 2-phenyl 2,3-dihydro-4-pyridones 3.100 in 64% 
yield. Cleavage of the methyl aryl ether of 3.100 with aqueous hydrobromic acid and acetic 
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acid was attempted. When the crude product was analysed by 1H NMR, an intractable 
mixture of compounds was observed. In order to find another method to cleave the methyl 
aryl ether group of 3.100, more of this starting material needed to be synthesised. However 
the synthesis of 3.100 could not be reproduced, so further synthetic work in this area was 
discontinued. 
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3.6 SYNTHESIS OF LONG CARBON CHAIN TETHERS 
AND INHIBITOR-TETHER CONJUGATES  
 
The design of novel steroid 5α-reductase inhibitor-tether conjugates was discussed in 
section 3.2. The following section describes the attempted synthesis of initial tether targets 
3.66 and 3.67. These tethers were not successfully synthesised so a different approach was 
required to generate alternative terminal olefin containing tethers for cross metathesis with 
inhibitors 3.57 and 3.62. Section 3.6.2 describes the synthesis of alternative tethers 3.107 
and 3.108. 
 
3.6.1 Attempted synthesis of initial tether targets  
 
A proposed synthetic route to tethers 3.66 and 3.67 is outlined in Scheme 3.15. Due to the 
high nucleophilicity of sulfur, the thiol group of 3.102 required protection to avoid inter- 
and intramolecular thioesterification during the coupling step [Scheme 3.15 step (ii)]. 
Ethanolamine or 2-(2-aminoethoxy)ethanol would then be coupled to the acid 3.103 to 
give the alcohols 3.104 and 3.105. Allylation of the alcohols 3.104 and 3.105 with allyl 
bromide was envisaged to give 3.66 and 3.67 as desired for conjugation to inhibitors 3.57 
and 3.62. 
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Scheme 3.15. Reagents and conditions: (i) Zn, CH2Cl2, AcOH, rt, 15 min, then AcCl, 0˚C, 
rt, 10 min (83%). (ii) EDCI, HOBt, ethanolamine, DCM, 16 h (93%). (iii) (a.) nBu4NBr, 
10% aq. NaOH, DCM, rt, 1 h, then allyl bromide, 16 h. (b) KOH, allyl bromide, DMF, rt, 3 
h. (c) NaH, THF, rt, 1 h, then allyl bromide, 16 h. 
 
 
Reduction of contaminant disulfide and subsequent acetylation of 3.102 was carried out in 
a one-pot reaction with zinc and acetyl chloride to give the thioacetylated acid 3.103 in 
83% yield. Ethanolamine was coupled to 3.103 under EDCI coupling conditions45 to give 
3.104 in 93% yield. Attempts were then made to allylate the alcohol of 3.104 with allyl 
bromide under various conditions. Firstly the alcohol was treated with 10% aqueous 
sodium hydroxide in DCM with n-tetrabutyl ammonium bromide, followed by the addition 
of allyl bromide to give a mixture of compounds by 1H NMR spectroscopy. Starting 
material 3.104 was observed in the 1H NMR spectrum, as well as unidentified material. 
However, analysis by electrospray LRMS indicated a mixture in which the desired 
protonated product was present (C23H43NO3S = 414.3204 g.mol-1). From this observation it 
was assumed that product 3.66 was present as a very minor constituent of the crude 1H 
NMR spectrum. Therefore, an alternative method was used to allylate alcohol 3.104 with 
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allyl bromide in DMF in the presence of potassium hydroxide. Starting material was 
observed in the 1H NMR spectrum of the crude product, as was confirmed by TLC. The 
desired product 3.66 was not evidentially obtained. A third method was attempted to 
allylate alcohol 3.104 with allyl bromide THF in the presence of NaH. Again a mixture of 
starting material and unidentified material was observed by 1H NMR spectroscopy. 
 
An alternative method was sought for allylating the alcohol of 3.104. Zumpe and Kazmaier 
reported a method for selective O-allylation of amino acid side chains with allyl 
ethylcarbonate (3.106) in the presence of π-allyl-palladium chloride dimer catalyst.53 The 
hydroxyl group of the side chain of serine (CH2OH) was selectively allylated over the NH 
group. Therefore, this method was attempted for allylating alcohol 3.104 (which also 
contains an NH group). Scheme 3.16 outlines the attempted synthesis of 3.66. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.16. Reagents and conditions: (i) Allyl alcohol, THF, 0˚C, 10 min, then ethyl 
chloroformate, rt, 3 h (47%). (ii) PPh3, [allylPdCl2]2, THF, rt, 16 h. 
 
 
Coupling of allyl alcohol and ethyl chloroformate gave the allyl carbonate 3.106 in 47% 
yield. O-allylation of 3.104 with the allyl carbonate 3.106 was attempted in THF with 
triphenylphosphine, in the presence π-allyl-palladium chloride dimer. However, only 
starting materials were observed in the 1H NMR spectrum of the crude product, which was 
confirmed by the presence of two spots by TLC which correlated with those of 3.104 and 
3.106. 
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3.6.2 Synthesis of alternative tethers 3.107 and 3.108 
 
Four different methods were utilised in the attempted synthesis of tether 3.66. Allylation of 
the hydroxyl group in 3.104 seemed to be difficult so a different approach was investigated 
to introduce an allyl group into the long chain tethers, as shown in Scheme 3.17. Instead of 
directly allylating the hydroxyl of 3.104, a terminal olefin could be introduced by coupling 
4-pentenoic acid to the alcohol 3.104, as depicted in Scheme 3.17. 4-Pentenoic acid was 
chosen as it was a readily available terminal olefin containing compound with a carboxylic 
acid group to facilitate esterification with the hydroxyl group of 3.104. 
 
 
 
Scheme 3.17. Reagents and conditions: (i) EDCI, HOBt, ethanolamine, DCM, rt, 16 h 
(93%). (ii) DMAP, 4-pentenoic acid, EDCI, DCM, rt, 3 h (49%). (iii) 2-(2-
Aminoethoxy)ethanol, EDCI, HOBt, DCM, rt, 16 h (95%). (iv) DMAP, 4-pentenoic acid, 
EDCI, rt, 16 h (62%).  
 
 
Ethanolamine was coupled to 3.103 under EDCI coupling conditions to give 3.104 in 93% 
yield. Esterification of 3.104 was carried out in DCM with 4-pentenoic acid, DMAP and 
EDCI54 to give the desired tether 3.107 in 49%. The acid 3.103 was also coupled to 2-(2-
aminoethoxy)ethanol under EDCI conditions to give the alcohol 3.105 in 95% yield. 
Esterification of 3.105 was accomplished with 4-pentenoic acid in DCM in the presence of 
DMAP and EDCI to give the desired tether 3.108 in 62% yield.  
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3.6.3 Synthesis of inhibitor-tether conjugates 3.110 and 3.111  
 
Conjugation of tethers 3.107 and 3.108 to inhibitor 3.57 and also 3.62 was attempted using 
cross metathesis methodology (which was discussed in section 3.2). Grubbs’ second 
generation ruthenium catalyst 3.109 was employed for the cross metathesis outlined in 
Scheme 3.18. This particular metathesis catalyst was used as it is tolerant to a wide range 
of substrates, and is more stable to air and water than the first generation catalyst. The 
second generation catalyst was also readily available. 
 
 
Scheme 3.18. Reagents and conditions: 20 mol% Grubbs’ 2nd gen. catalyst 3.109, 1,1,2-
trichloroethane, rt, 16 h, 3.110 (30%), 3.111 (52%). 
 
 
Tether 3.107 was reacted with inhibitor 3.57 in 1,1,2-trichloroethane in the presence of 20 
mol% Grubbs’ second generation catalyst 3.109 to give conjugate 3.110 in 30% yield. A 
flow of nitrogen was used to remove the ethylene gas side product to help drive the 
reaction to completion. Tether 3.108 was reacted with 3.57 in an analogous fashion to give 
conjugate 3.111 in 52% yield. The 1H NMR spectrum of conjugate 3.111 is shown in 
Figure 3.24. A characteristic multiplet at 5.57 ppm, which represents the vicinal hydrogens 
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of the double bond, indicated the formation of a new double bond from cross metathesis. 
The configuration of the double bond of conjugates 3.110 and 3.111 was assumed to be E 
for steric reasons. This assumption was confirmed by calculation of the vicinal coupling 
constant across the double bond for 3.111. A vicinal coupling constant of 15 Hz was 
extrapolated from the multiplet present at 5.57 ppm. It is possible that traces of the Z 
isomers were present but corresponding peaks were not observed in the 1H NMR and 13C 
NMR spectra of 3.110 and 3.111. A single set of signals was observed in the 13C NMR 
spectra of both 3.110 and 3.111, indicating that only one isomer was present. 
 
ppm234567  
 
 
Figure 3.24. 1H NMR spectrum (CDCl3, 500 MHz) of inhibitor-tether conjugate 3.111. 
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3.6.4 Attempted synthesis of inhibitor-tether conjugates 3.112 and 3.113 
 
The methodology described in section 3.6.3 was used in the synthetic strategy for 
conjugates 3.112 and 3.113, as shown in Scheme 3.19. 
 
 
 
Scheme 3.19. Reagents and conditions: as for Scheme 3.18. 
 
 
Inhibitor 3.62 was reacted with tether 3.107 or 3.108 in the presence of Grubbs’ second 
generation catalyst 3.109 in 1,1,2-trichloroethane, but the expected conjugate products 
3.112 and 3.113 were not evidentially obtained. The 1H NMR spectrum of both reactions 
revealed that starting materials were present. The reaction of 3.62 with 3.108 was repeated, 
but at 50˚C rather than rt. However, when the crude product was analysed by 1H NMR, 
starting material was again observed. From these observations it appears that cross 
metathesis of 3.62 with tethers 3.107 and 3.108 does not proceed under these conditions. 
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3.7 INHIBITION ASSAY 
 
Methods for the biological testing of steroid 5α-reductase inhibitors were discussed in 
section 3.1.6. The cell lines and methodology required for testing 5α-reductase inhibitors 
was beyond the scope of this project. Therefore inhibitors synthesised in this thesis (3.55-
3.57, 3.59, 3.61, 3.62, 3.110, 3.111, as well as 3.77 for SAR purposes) were sent for assay 
to the research group of Professor Rolf Hartmann at Saarland University, Germany. This 
group has recently developed an assay method using human embryonic kidney cells (HEK 
293) which have been transfected with either type 1 5α-reductase (HEK-I) or type 2 
(HEK-II) cDNA. An advantage in using these cell lines is that inhibition of type 1 and 2 
5α-reductase can be tested separately. All compounds were tested for inhibition against 
both isozymes using HEK-I and HEK-II cell free homogenates. The cells were grown, 
homogenised, and then incubated with NADP+, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, [3H]-androstenedione (substrate) and test compound. After 30 min the 
steroids were extracted and subsequently analysed by HPLC. Radioactivity was detected 
for separated substrates and products.55 
 
 
3.7.1 Inhibition results 
 
Results obtained for inhibition of type 1 and 2 steroid 5α-reductase from HEK cell-free 
homogenates, by 3.77, 3.55-3.57, 3.59, 3.61, 3.62, 3.110, and 3.111, are shown in Table 
3.1. These compounds were tested at a concentration of 10 µM, and results are expressed 
as % inhibition (calculated from the amount of enzyme reaction product recovered). 
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homogenate 
(% inhibition at 10 µM) 
 
 
 
 
 
                                                  3.77 
 
IC50 = 2.5 µM 
 
 
3% 
3.55 R1 = NiPr2 
3.57 R1 = NHCH2CHCH2
 
3.55 = 8% 
3.57 = 6% 
 
 
no inhibition 
 
3.56
 
 
6%  
 
 
no inhibition 
3.110 n = 1, 3.111 n = 2
 
 
 
3.110 = 43% 
3.111 = 33% 
 
 
 
no inhibition 
3.61 R1 = NiPr2
3.62 R1 = NHCH2CHCH2
 
3.61 = 3% 
3.62 = 8% 
 
no inhibition 
12% 
 
 
 
 
 
3.59
 
 
61% 
 
 
no inhibition 
 
 
Table 3.1. Inhibition of type 1 and 2 5α-reductase. 
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HEK-I: human embryonal kidney cell homogenate containing 5α-reductase type 1; 
substrate: 3H androstenedione 505 nM, reference compound: finasteride IC50 = 453 nM. 
HEK-II: human embyonal kidney cell homogenate containing 5α-reductase type 2; 
substrate: 3H androstenedione 505 nM, reference compound: finasteride IC50 = 25 nM. 
 
 
3.7.2 Discussion of inhibition results 
 
All compounds tested inhibited the type 1 isozyme. Weak inhibition was observed with 
inhibitors 3.55-3.57, 3.61, and 3.62, while more potent inhibition was observed with 
inhibitors 3.77, 3.110, 3.111, and 3.59. There was little difference in activity between 3.55 
and 3.56 (8% and 6% inhibition respectively at 10 µM) suggesting type 1 inhibition is not 
enhanced by the presence of a piperidone mimicking the steroidal A-ring, compared to a 
pyridone. This observation is consistent with the small difference in inhibition between 
literature compounds 3.53 and 3.54 (Fig. 3.17). There was no difference in activity when 
an N-diisopropylacetamide or N-allylacetamide group was present at the 4’-position of the 
5-aryl substituted 1-methyl-2-pyridones (3.55 vs 3.57). There was also little difference in 
activity between the 5-aryl 1-methyl-2-pyridones (3.55 and 3.57) and the 1-aryl 2-methyl-
2,3-dihydro-4-pyridones (3.61 and 3.62). The dihydro-4-pyridones 3.61 and 3.62 displayed 
3% and 8% inhibition respectively, which is comparable to the activity of 
pyridones/piperidone 3.55, 3.56, and 3.57. For the dihydro-4-pyridones 3.61 and 3.62, the 
presence of an N-diisopropylacetamide or N-allylacetamide group at the 4’-position made 
little difference to the inhibitory activity observed with inhibition values of 3% and 8% 
respectively. 
 
The two inhibitor-tether conjugates 3.110 and 3.111 were more potent inhibitors of type 1 
(inhibiting type 1 activity by 43% and 33% respectively) than the pyridones 33 and 35 
which have N-diisopropylacetamide and N-allylacetamide side chains at the 4’-position. 
This result is interesting as it provides further evidence that large hydrophobic groups are 
tolerated in the enzyme site not involved in reaction with the enzyme. A lipophilic group at 
the 4’-position is known to influence isozyme selectivity of inhibitors, so type 1 inhibitory 
activity by 3.110 and 3.111 correlates with that of the type 1 selective steroidal inhibitor 
MK386 (3.15, Fig. 3.3), which has a cholesterol moiety at C17 (steroidal numbering). The 
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presence of the long carbon chain tether in 3.110 and 3.111 enhances potency when 
compared to the activity of 3.57, in which the tether is absent. Comparisons can also be 
made between 3.110 and 3.111 which differ in the number of ethylene glycol units (n) in 
the tether. Inhibitor 3.110 has one ethylene glycol unit and inhibits type 1 activity by 43%, 
while 3.111 has two glycol units and inhibits type 1 activity by 33%.  
 
The most potent inhibitor of type 1 was the benzoyl compound 3.59 which inhibited 
enzyme activity by 61% (at 10 µM). The presence of the benzoyl group attached to the 
aromatic ring is clearly involved in enhancing potency when compared to inhibitors 
containing the N-substituted acetamide groups as in 3.55, 3.56, and 3.57, and also 3.61, and 
3.62. This observation correlates with that of Hartmann et al. who observed that the 
presence of bulky ketone groups at the 4’-position of 5-aryl substituted pyridones enhanced 
inhibitory potency in comparison to compounds with 4’-amide groups.24 
 
5-Aryl 1-methyl-2-pyridone 3.77, and 1-aryl 2-methyl-2,3-dihydro-4-pyridone 3.62 
inhibited type 2 steroid 5α-reductase activity by 3% and 12% respectively. None of the 
other compounds tested inhibited this isozyme. Interestingly the dihydro-4-pyridone 3.62 
showed slight dual inhibition of the isozymes, inhibiting type 1 activity by 8%, and type 2 
activity by 12%. The corresponding 5-aryl 1-methyl-2-pyridone 3.57 did not inhibit type 2 
at all.  
 
Compounds 3.55 and 3.56 were designed from reported inhibitors 3.53 and 3.54 (Fig. 
3.17). In these literature inhibitors, the amide is attached directly to the aromatic ring at the 
4’-position. Incorporation of an OCH2 linker into inhibitors 3.53 and 3.54 between the 
aromatic ring and amide resulted in novel compounds 3.55 and 3.56. Lesuisse et al. found 
enhanced potency with the OCH2 linker (see Fig. 3.25, 3.47 vs 3.48) for compounds 
containing an aryl carboxylic acid in place of the pyridone as in 3.53 and 3.54.40 Strikingly 
this ether linker did not result in enhanced potency for inhibitors 3.55 and 3.56, which 
inhibited the type 1 isozyme activity by 8% and 6% respectively.  
 
The Lesuisse compound 3.49 (Fig 3.25) is an extremely potent inhibitor of the type 2 
isozyme (IC50 = 9.8 nM). This compound contains a biphenyl scaffold consisting of an aryl 
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carboxylic acid attached to an aromatic ring with F, NO2 and 4’-OCH2 substitution, and 
was prepared after enhanced potency was seen for 3.48 compared to 3.47 (Fig. 3.25).  
 
 
 
Figure 3.25. Effect of OCH2 linker on inhibition (3.47 and 3.48 at 1 µM, 3.53 at 100 µM, 
3.55 at 10 µM). 
 
 
The non-steroidal inhibitors focussed on (5-aryl pyridones, 1-aryl 2,3-dihydro-4-pyridones, 
and the biaryl carboxylic acids) possess two rings as compared to the four of the steroidal 
inhibitors. The substituent present at the 4’-position of non-steroidal biaryl inhibitors is 
influential on both type 1 and 2 inhibition potencies, as discussed in section 3.1.5. This is 
clearly illustrated when comparing inhibition data for 3.47 with 3.48, and 3.49 (Fig. 3.25). 
The 4’-OCH2CONiPr2 group of 3.48 and 3.49 has a positive influence on potency for type 
2 inhibition, so we proposed that incorporation of the OCH2 linker into compound 3.53 to 
give 3.55 might have a similar effect on type 1 potency. The finding that 3.55 did not show 
greater type 1 inhibition than 3.53 (and also 3.56 compared to 3.54) is a significant result 
for defining SAR across different inhibitor classes. We can conclude that for the pyridone 
inhibitors, SAR for 4’-substituents do not correlate with SAR derived from the biaryl 
carboxylic acid inhibitors. 
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The design of inhibitor 3.59 was based on a potent compound 3.58 (Ki = 60 nM) reported 
by Holt et al. (Fig. 3.26) which possesses a benzoyl group at the 4’-position on the biaryl 
carboxylic acid scaffold.35 The substituent at the 4’-position is influential on the potency of 
non-steroidal inhibitors, so the 4’-benzoyl group of 3.58 was incorporated into the 4’-
position of the 5-aryl 1-methyl-pyridone scaffold to give 3.59. The literature compound 
3.58 had a Ki of 60 nM for the type 2 enzyme. Our compound 3.59 showed 61% inhibition 
of type 1 activity at a concentration of 10 µM. Whilst not as potent as 3.58, this result 
shows that the benzoyl group is favoured by the enzyme active site in both isozymes, as 
the presence of this group translated into potent type 2 inhibition and moderate type 1 
inhibition.  
 
 
 
 
 
 
 
 
Figure 3.26. 4’-Benzoyl group inhibitors (3.59 tested at a concentration of 10 µM). 
 
 
Inhibitors consisting of a 1-aryl 2-substituted 2,3-dihydro-4-pyridone scaffold (e.g. 3.61 
and 3.62) have not been reported to date, so direct comparison of inhibitory data for 3.61 
and 3.62 to that of literature compounds is impossible. This non-steroidal class of 
compounds is related to the 10-azasteroid inhibitors and the non-steroidal tricyclic 4aH-
benzo[c]quinolizinone inhibitors (Fig. 3.10). The pyridone and aromatic rings of 3.61 and 
3.62 mimic the A and C rings respectively of the 10-azasteroids and the 4aH-
benzo[c]quinolizinones. The 4aH-benzo[c]quinolizinones are good inhibitors of the type 1 
isozyme. Inhibitors 3.61 and 3.62 were designed on a similar basis to pyridones 3.55 and 
3.57. The N-diisopropylacetamide and N-allylacetamide groups of 3.55 and 3.57 were 
incorporated into the 2,3-dihydro-4-pyridone scaffold to give 3.61 and 3.62. The inhibition 
of steroid 5α-reductase by this novel class of inhibitor was of interest with focus on SAR 
for the substituent at the 4’-position. As for the pyridones 3.55 and 3.57, the presence of 
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the OCH2 linker in 3.61 and 3.62 did not translate into good inhibitory activity. Therefore 
it would seem that SAR for 4’-substituents of the 2,3-dihydro-4-pyridones do not correlate 
with SAR derived from the biaryl acid inhibitors. 
 
The presence of a long carbon chain tether enhanced the inhibitory activity of inhibitor-
tether conjugate 3.110 in comparison to 3.57. The conjugate 3.110 inhibited type 1 activity 
by 43%, while the non-conjugated compound 3.57 only inhibited the isozyme by 6%. This 
finding provides further evidence for the presence of a lipophilic pocket (see section 
3.1.4.2) in the enzyme active site that tolerates bulky hydrophobic groups at the end of the 
inhibitor not interacting with the active site region which facilitates the enzymatic reaction.  
 
Literature compounds 3.53 and 3.54 inhibit steroid 5α-reductase sourced from human BPH 
tissue and RVP.24 Compound 3.53 inhibited BPH enzyme activity by 34% and RVP 
enzyme activity by 45% (at 100 µM). Compound 3.54 inhibited BPH enzyme activity by 
37% and RVP enzyme activity by 41% (at 100 µM). The BPH tissue was used to test for 
type 2 inhibition while RVP was used for type 1. In the test protocol the BPH preparation 
was buffered at pH 5.5 to select for type 2 activity, while the RVP preparation was 
buffered at pH 6.6 to select for type 1 activity. Inhibitors synthesised in this thesis were 
tested with transfected cell line homogenates expressing either type 1 or type 2 5α-
reductase. It is not understood why the inhibitory activity of 3.55 and 3.56 was 
significantly lower than the activity of 3.53 and 3.54. The observed difference in activity 
might be accounted for by the method used to assay 3.53 and 3.54, where the activity of 
one isozyme was selected over the other in tissue homogenates by using pH 5.5 or pH 6.6 
buffer. Perhaps the RVP preparation used by Hartmann et al. did not specifically select 
type 1 activity, which would suggest some of the inhibition data was due to type 2 activity. 
These observations highlight the difficulty in using tissue preparations which contain both 
isozymes, such as RVP in this case. Inhibitors synthesised in this thesis were tested versus 
each single isozyme in cell-free homogenates of transfected HEK-I and HEK-II cells. This 
avoids the problems associated with tissue homogenates, but makes comparison to results 
derived from tissues difficult. 
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3.8 CONCLUSION AND FUTURE WORK 
 
Inhibitors of steroid 5α-reductase are of great pharmaceutical interest. Currently research is 
focused on developing non-steroidal inhibitors to avoid potential side effects associated 
with steroid based drugs. The appearance of a number of different classes of non-steroidal 
inhibitors of 5α-reductase has made it necessary to define the SAR within each class and 
across classes. SAR studies of literature compounds led to the design and synthesis of 
novel non-steroidal proposed 5α-reductase inhibitors in this thesis, with focus on 
establishing SAR. Compounds containing a non-steroidal substituted 5-aryl 1-methyl-2-
pyridone/piperidone scaffold (3.55-3.57 and 3.59) were synthesised. This scaffold is 
related to that of the 4-azasteroids which are potent inhibitors. The 5-aryl pyridone scaffold 
of 3.55-3.57 and 3.59 was constructed under Suzuki cross coupling conditions and was 
subsequently reacted under various conditions to give 3.55, 3.57, and the piperidone 3.56. 
Inhibitor 3.59 required slightly different conditions for the Suzuki cross coupling due to 
base sensitivity of the ketone starting material 3.86. Synthesis of the piperidone derivative 
3.60 was unsuccessful. 
 
A novel type of steroid 5α-reductase inhibitor possessing a 1-aryl 2-substituted 2,3-
dihydro-4-pyridone scaffold (3.61 and 3.62) was developed and synthesised. These 
compounds are related to the 10-azasteroids, and non-steroidal benzo[c]quinolizinones 
(e.g. 3.7 and 3.30 respectively). The 1-aryl 2,3-dihydro-4-pyridone scaffold of 3.61 and 
3.62 was constructed using aza Diels-Alder methodology. A methyl group was 
incorporated at the 2-position of the pyridone ring by the use of acetaldehyde in generating 
an imine with p-anisidine. An attempt was made to incorporate a phenyl group at the 2-
position of the pyridone ring (compounds 3.63 and 3.64) for SAR purposes but the aza 
Diels-Alder step was not reproducible in the synthesis of 3.63 so further work in this area 
was abandoned. 
 
Inhibitor 3.57 was conjugated with olefin containing tethers 3.107 and 3.108 by cross 
metathesis to give conjugates 3.110 and 3.111. These conjugates possess a thiol terminus 
for the purpose of future attachment to a gold surface. Attempts were made to attach the 
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tethers to the dihydro-4-pyridone 3.62 by the cross metathesis methodology already 
established for 3.110 and 3.111, but these were unsuccessful. 
 
The target compounds synthesised in this thesis (3.55-3.57, 3.59, 3.61, 3.62, 3.110 and 
3.111) were tested for inhibitory activity against both type 1 and 2 steroid 5α-reductase. 
Human embryonal kidney cells stably transfected with either type 1 or 2 cDNA (HEK-I or 
HEK-II) were used to evaluate inhibition of the isozymes separately. The compounds 
tested inhibited the type 1 isozyme to varying degrees at a concentration of 10 µM. The 5-
aryl pyridones 3.55, 3.57 and piperidone 3.56, inhibited the enzyme weakly (6-8% 
inhibition of isozyme activity). The 2,3-dihydro-4-pyridones 3.61 and 3.62 also inhibited 
the enzyme weakly (3% and 8% inhibition respectively). Conjugates 3.110 and 3.111 were 
moderate inhibitors displaying 43% and 33% inhibition respectively. The benzoyl 
compound 3.59 was the most active, inhibiting isozyme activity by 61%. One compound, 
dihydro-4-pyridone 3.62 showed slight inhibition of both isozymes (type 1 8%, type 2 
12%). 
 
Incorporation of an OCH2 linker into 3.53 and 3.54 at the 4’-position, resulting in 
compounds 3.55 and 3.56 did not enhance potency towards type 1 5α-reductase as 
predicted. Therefore SAR determined for substituents at the 4’-position of biphenyl 
carboxylic acid inhibitors do not correlate with the pyridone series of compounds as 
illustrated here. The benzoyl group of 3.59 is a more favoured substituent at this position 
for the type 1 isozyme. 
 
Future work in this area would involve attaching conjugates 3.110 and 3.111 to a gold 
surface. The thioester of 3.110 and 3.111 would require hydrolysis in situ to give a free 
thiol which is required for interaction with a gold surface. The development of inhibitor 
3.59 could be another area of future work. The synthesis of an inhibitor based on 3.59, but 
with substitution of the aromatic ring attached directly to the benzoyl group, would be of 
interest based on the influence of the F and NO2 groups of literature compound 3.49. 
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4.1 GENERAL METHODS AND EXPERIMENTAL 
 PROCEDURES 
 
Melting points 
All melting points were obtained on an Electrothermal apparatus and are uncorrected. 
 
 
Nuclear Magnetic Resonance 
Proton NMR spectra were obtained on a Varian Inova spectrometer, operating at 500 MHz. 
Carbon NMR spectra were obtained on a Varian Unity 300 spectrometer, operating at 75 
MHz, with a delay (D1) of 1 s. All spectra were obtained at 23°C. Chemical shifts are 
reported in parts per million (ppm) on the δ scale. Solvents used for NMR analysis 
(reference peaks listed) included: DMSO-d6 (CHD2SOCD3 at δH 2.60 ppm, (CD3)2SO at 
δC 39.6 ppm); CDCl3 (CHCl3 at δH 7.25 ppm, CDCl3 at δC 77.0 ppm); CD3OD (CHD2OD 
at δH 3.30 ppm, CD3OD at δC 49.3 ppm); acetone-d6 (CHD2COCD3 at δH 2.17 ppm, 
(CD3)2CO at δC 29.2 ppm). Two-dimensional NMR experiments included COSY and 
HSQC, and were obtained on the Varian Inova spectrometer operating at 500 MHz. 
 
 
Small Molecule Mass Spectrometry 
Electron impact mass spectra were obtained on a Kratos MS80 RFA mass spectrometer 
operating at 4000 V (accelerating potential) and 70 eV (ionisation energy). The source 
temperature was 200-250°C. Electrospray ionisation mass spectra were detected on a 
micromass LCT TOF mass spectrometer, with a probe voltage of 3200 V, temperature of 
150°C and a source temperature of 80°C. Direct ionisation used 10 µL of a 10 µg mL-1 
solution, using a carrier solvent of 50% acetonitrile/H2O at a flow rate of 20 µL min-1. 
Ionisation was assisted by the addition of 0.5% formic acid. 
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High Pressure Liquid Chromatography 
Analytical HPLC was performed on a Shimadzu LC-10AD VP liquid chromatograph 
coupled to a SIL-10A VP autoinjector, a CTO-10A VP column oven set to 40˚C and a 
SPD-M10A VP photodiode array detector. The system was controlled by Shimadzu 
CLASS-VP (Version 5.02) software. For reverse phase HPLC a Phenomenex Prodigy C18 
5-ODS (3µ, 250 x 4.6 mm) column was used with a flow rate of 1 mL min-1 with a 
standard HPLC solvent gradient system that was comprised of variable concentrations of 
H2O (Milli-Q) containing 0.05% trifluoroacetic acid and acetonitrile (HPLC grade). The 
gradient consisted of a 24 min run with the following steps - 2 min of 50% water in 
acetonitrile, followed by a linear gradient to 75% water in acetonitrile over 18 min, then 
returned to 50% water in acetonitrile over 2 min, which was maintained for 2 min to allow 
the column to re-equilibrate.  
 
 
Reagents, solvents and laboratory methodology 
Oven dried glassware was used in all the reactions that were carried out under an 
atmosphere of dry nitrogen. All starting materials were obtained commercially unless 
otherwise stated. “Removal of the solvent (or volatiles) by evaporation under reduced 
pressure” refers to the process of bulk solvent removal by rotary evaporation (low vacuum 
pump) followed by application of high vacuum (oil pump) for a minimum of 30 min. 
Analytical thin layer chromatography (TLC) was performed on plastic backed Merck 
Keisegel KG60F254 silica plates, and visualised using short wave ultra violet light, or AMC 
dip1. Flash chromatography was performed using 230-400 mesh Merck Silica Gel 60 
following established guidelines2 under positive pressure. THF and diethyl ether were 
distilled from sodium benzophenone ketyl under an inert atmosphere immediately prior to 
use. Dichloromethane (DCM), 1,2-dichloroethane, and toluene were distilled from calcium 
hydride under an inert atmosphere. Dimethyl sulfoxide (DMSO) was distilled from 
calcium hydride under reduced pressure and stored over 4 Å molecular sieves. “Super-dry” 
methanol and ethanol were prepared according to the literature procedure.3 Petroleum ether 
refers to the fraction collected between 50-70°C. Ethyl acetate, petroleum ether, and DCM 
were distilled from calcium hydride prior to their use in column chromatography. DMF 
was dried by placing over 4 Å molecular sieves, applying a high vacuum for 15 min, then 
flushed briefly with an inert atmosphere. This process was repeated twice over 24 h, after 
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which the DMF was stored over 4 Å molecular sieves under an inert atmosphere. All other 
reagents and solvents requiring purification prior to use were purified using literature 
procedures.4  
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4.2 EXPERIMENTAL WORK DESCRIBED IN CHAPTER 
TWO 
 
4.2.1 Synthesis of permethrin metabolites 2.14-2.16 
 
Methyl 3-(4-methoxyphenoxy)benzoate (2.19)5 
 
 
 
 
 
Sodium hydride (60% in oil, 270 mg, 5.58 mmol, 1.2 equiv) was added to a flask under N2 
atmosphere. This was washed with petroleum ether (stored over sieves) twice, DMF (2 
mL) was added and the resulting bubbly grey solution was stirred at rt. p-Methoxyphenol 
(577 mg, 4.65 mmol, 1 equiv) (recrystallised from toluene and used immediately) was 
dissolved in DMF (5 mL) in another flask under N2. The phenol solution was added 
dropwise over 10 min to the sodium hydride at 0˚C, resulting in a thick creamy solution 
which was stirred for 30 min. Methyl-3-bromobenzoate (1 g, 4.65 mmol, 1 equiv) and 
copper (I) chloride (23 mg, 0.23 mmol, 0.05 equiv) were stirred in DMF (5 mL) for 10 min 
before the phenol solution was added dropwise. The resulting dark brown mixture was 
heated at reflux for 6 h, and then cooled to rt. The reaction mixture was diluted with water 
(50 mL), and extracted with ether (3 x 50 mL). The organic phases were combined and 
washed with water (5 x 50mL). The ethereal solution was dried over MgSO4, and the 
solvent removed under reduced pressure. The resulting green/yellow oil was purified by 
column chromatography on silica (10% ethyl acetate/petroleum ether) to give 2.19 (370 
mg, 31%) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz) δ 3.81 (s, 3H, OCH3), 3.88 (s, 3H, COOCH3), 6.90 (d, 2H, J 
= 9.1 Hz, ArH), 6.98 (d, 2H, J = 8.7 Hz, ArH), 7.14 (dd, 1H, J = 2.8, 8.3 Hz, ArH), 7.36 (t, 
1H, J = 7.9, 15.9 Hz, ArH), 7.57 (d, 1H, J = 1.6 Hz, ArH), 7.71 (d, 1H, J = 7.9, ArH).  
13C NMR (CDCl3, 75 MHz) δ 52.16, 55.59, 114.97, 118.14, 120.93, 122.07, 123.51, 
129.58, 131.70, 149.52, 156.15, 158.62, 166.57. 
HRMS Found 258.0888 (Calcd. for C15H14O4 258.0892). 
O
MeO
O
OMe
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3-(4-Methoxyphenoxy)benzoic acid (2.20) 
 
 
 
 
 
The aryl ester 2.19 (153 mg, 0.59 mmol, 1 equiv) was heated with potassium hydroxide 
(132 mg, 2.36 mmol, 4 equiv) at reflux for 4 h in THF (2.5 mL) and water (2.5 mL). After 
cooling to rt, the solution was acidified with 10% aqueous hydrochloric acid until neutral 
pH (universal indicator paper), and extracted with ethyl acetate (3 x 20 mL). The combined 
organic phases were dried over MgSO4, and the solvent was removed under reduced 
pressure to give 2.20 (130 mg, 90%) as a white solid. The product was not purified further. 
mp 138-140˚C (Lit.6 141-143˚C). 
1H NMR (acetone-d6, 500 MHz) δ 3.93 (s, 3H, OCH3), 7.12 (d, 2H, J = 9.3 Hz, ArH), 7.17 
(d, 2H, J = 9.3 Hz, ArH), 7.34 (dd, 1H, J = 2.4, 7.8 Hz, ArH), 7.61 (t, 1H, J = 7.8 Hz, 
ArH), 7.64 (d, 1H, J = 2.4 Hz, ArH), 7.85 (d, 1H, J = 7.8 Hz, ArH). 
13C NMR (acetone-d6, 75 MHz) δ 53.76, 113.83, 116.31, 119.91, 120.55, 122.25, 128.7, 
130.95, 148.08, 155.34, 157.72, 164.93. 
HRMS Found 244.0740 (Calcd. for C14H12O4 244.0736). 
 
 
3-(4-Hydroxyphenoxy)benzoic acid (2.15) 
 
 
 
 
 
The methyl ether 2.20 (70 mg, 0.29 mmol) was heated at reflux for 7 h in 48% aqueous 
hydrobromic acid (2.5 mL) and acetic acid (2.5 mL). The mixture was cooled to rt, and the 
solvent removed under pressure. The orange residue was dissolved in ethyl acetate (25 mL) 
and washed with 1 M aqueous potassium hydroxide (3 x 15 mL). The aqueous washings 
were combined, acidified with 6 M aqueous hydrochloric acid until neutral pH (universal 
indicator paper), and extracted with ethyl acetate (3 x 20 mL). The organic phases were 
O
HO
O
OMe
O
HO
O
OH
Chapter Four – Experimental 
 
 
 
157
combined and dried over MgSO4. The solvent was removed by evaporation under reduced 
pressure to give a brown solid which was purified by column chromatography on silica 
(50% ethyl acetate/petroleum ether) to give 2.15 (59 mg, 88%) as a cream solid.  
mp 169-171˚C (Lit.6 172-174˚C). 
1H NMR (acetone-d6, 500 MHz) δ 7.02 (d, 2H, J = 9.3 Hz, ArH), 7.08 (d, 2H, J = 9.3 Hz, 
ArH), 7.31 (dd, 1H, J = 2.4, 7.8 Hz, ArH), 7.58 (t, 1H, J = 7.8 Hz, ArH), 7.64 (d, 1H, J = 
2.4 Hz, ArH), 7.83 (d, 1H, J = 7.8 Hz, ArH), 8.56 (s(br), 1H, OH). 
13C NMR (acetone-d6, 75 MHz) δ 114.61, 115.59, 119.54, 119.78, 121.5, 128.06, 130.31, 
146.55, 152.43, 157.4, 164.67. 
HRMS (M-H) Found 229.0502 (Calcd. For C13H9O4 229.0501). 
 
 
3-(4-Hydroxyphenoxy)benzyl alcohol (2.14) 
 
 
 
 
 
The acid 2.15 (82 mg, 0.36 mmol, 1 equiv) was dissolved in freshly distilled dry ether (5 
mL) under N2 atmosphere, and lithium aluminium hydride (33 mg, 0.90 mmol, 2.5 equiv) 
added at 0°C. The grey suspension was stirred at rt for 16 h at which time saturated 
aqueous ammonium chloride was added slowly until bubbling ceased. The mixture was 
extracted with ethyl acetate (3 x 20 mL). The organic phases were combined and washed 
with water, saturated aqueous sodium chloride, and dried over MgSO4. The solvent was 
removed by evaporation under reduced pressure to give a clear oil which was purified by 
column chromatography on silica (20% ethyl acetate/petroleum ether) to give 2.14 (25 mg, 
33%) as a cream solid.  
mp 106-109˚C (Lit.5 110-111˚C). 
1H NMR (acetone-d6, 500 MHz) δ 4.43 (s, 1H, OH), 4.71 (d, 2H, J = 6.4 Hz, CH2), 6.89 
(dd, 1H, J = 2.4, 7.8 Hz, ArH), 6.97 (d, 2H, J = 9.3 Hz, ArH), 7.02 (d, 2H, J = 9.3 Hz, 
ArH), 7.06 (d, 1H, J = 2.4 Hz, ArH), 7.14 (d, 1H, J = 7.8 Hz, ArH), 7.38 (t, 1H, J = 7.8 
Hz, ArH), 8.42 (s, 1H, OH). 
HO
O
OH
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13C NMR (acetone-d6, 75 MHz) δ 62.03, 113.68, 114.11, 114.77, 118.81, 119.58, 127.91, 
143.14, 147.64, 152.38, 157.5. 
HRMS Found 216.0789 (Calcd. for C13H12O3 216.0786). 
 
 
N-(3-Phenoxybenzoyl)glycine methyl ester (2.22) 
 
 
 
 
 
DIPEA (0.41 mL, 2.34 mmol, 1 equiv) was added to a stirring solution of glycine methyl 
ester hydrochloride (293 mg, 2.34 mmol, 1 equiv) in dry DCM (10 mL) under N2 
atmosphere. EDCI (448 mg, 2.34 mmol, 1 equiv), HOBt (316 mg, 2.34 mmol, 1 equiv) and 
3-phenoxybenzoic acid (500 mg, 2.34 mmol, 1 equiv) were added, and the resulting clear 
solution stirred at rt for 3 h. The solution was diluted with ethyl acetate (50 mL) and 
washed successively with 10% aqueous hydrochloric acid, 10% aqueous sodium 
bicarbonate, and water. The organic phase was dried over MgSO4 and the solvent removed 
by evaporation under reduced pressure to give 2.22 (596 mg, 85%) as viscous pale yellow 
oil. The product was not purified further. 
1H NMR (CDCl3, 500 MHz) δ 3.71 (s, 3H, OCH3), 4.14 (d, 2H, J = 4.8 Hz, CH2), 6.97 (d, 
2H, J = 7.8 Hz, ArH), 7.08 (m, 2H, ArH), 7.18 (s(br), 1H, NH), 7.30 (m, 3H, ArH), 7.48 
(m, 2H, ArH). 
13C NMR (CDCl3, 75 MHz) δ 41.53, 52.25, 117.28, 119.02, 121.45, 121.7, 123.65, 129.76, 
129.8, 135.29, 156.35, 157.5, 166.88, 170.31. 
HRMS Found 285.0998 (Calcd. for C16H15NO4 285.1001). 
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N-(3-Phenoxybenzoyl)glycine (2.16) 
 
 
 
 
 
The ester 2.22 (200 mg, 0.70 mmol, 1 equiv) was heated with potassium hydroxide (157 
mg, 2.80 mmol, 4 equiv) at reflux for 4 h in THF (3 mL) and water (3 mL). After cooling 
to rt, the solution was acidified with 10% aqueous hydrochloric acid until neutral pH 
(universal indicator paper), and extracted with ethyl acetate (3 x 50 mL). The organic 
phases were combined, dried over MgSO4, and the solvent removed by evaporation under 
reduced pressure. The resulting white solid was purified by column chromatography on 
silica (50% ethyl acetate/petroleum ether) to give 2.16 (124 mg, 65%) as a fluffy white 
solid.  
mp 144-146˚C (lit.7 148-150˚C). 
1H NMR (acetone-d6, 500 MHz) δ 4.23 (d, 2H, J = 5.9 Hz, CH2), 7.04 (d, 2H, J = 8.3 Hz, 
ArH), 7.18 (m, 2H, ArH), 7.41 (t, 1H, J = 7.3 Hz, ArH), 7.52 (m, 2H, ArH), 7.69 (d, 1H, J 
= 9.3 Hz, ArH), 7.92 (d, 1H, J = 9.7 Hz, ArH), 8.09 (s(br), 1H, NH), 8.69 (s, 1H, COOH). 
13C NMR (acetone-d6, 75 MHz) δ 39.41, 115.8, 117.46, 120.03, 120.4, 122.19, 128.47, 
134.66, 155.3, 156.03, 164.7, 168.97. 
HRMS Found 271.0853 (Calcd. for C15H13NO4 271.0845). 
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4.2.2 Yeast Estrogen Screen (YES) 
 
Preparation of yeast for assay 
 
The recombinant yeast required for the assay was obtained from the Sumpter group at 
Brunel University, London, UK. This group has frequently published results obtained with 
this assay, and one paper in particular was consulted for assay procedure.8 We obtained 
five vials of agar slopes containing recombinant Saccharomyces cerevisiae. Two yeast 
samples from each slope were transferred to cryovials with 15% sterile glycerol, and 
frozen at -80˚C. 
 
All work involving the yeast was carried out in a type II laminar flow cabinet at the 
Institute of Environmental Science and Research (ESR). All glassware, spatulas and 
stirring bars (which had no prior contact with steroids) were scrupulously cleaned and 
rinsed with ethanol to eliminate estrogenic contamination, and left to dry. The yeast 
required various solutions for storage and growth for assay use. These included: 
(i) Minimal medium 
(ii) 20% D-Glucose solution 
(iii) L-Aspartic acid solution 
(iv) Vitamin solution 
(v) L-Threonine solution 
(vi) Copper (II) sulfate solution 
 
 
Preparation and storage of yeast minimal medium and medium components 
 
Chemicals required for the yeast growth were obtained from Sigma Aldrich. Double 
distilled water was obtained from the chemistry department apparatus, and collected into 
large schott bottles with teflon lids. All solutions were stored in glass jars with teflon lids 
or aluminium foil lined lids. Autoclaving was done at 121˚C for 15 min.  
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Minimal media (pH 7.1) 
 
13.61 g KH2PO4, 1.98 g (NH4)2SO4, 4.2 g KOH, 200 mg MgSO4, 1 mL Fe2(SO4)3 solution 
(40 mg in 50 mL H2O), 50 mg, L-leucine, 50 mg L-histidine, 50 mg adenine, 20 mg L-
arginine-HCl, 20 mg L-methionine, 30 mg L-tyrosine, 30 mg L-isoleucine, 30 mg L-
lysine-HCl, 25 mg L-phenylalanine, 100 mg L-glutamic acid, 150 mg L-valine, and 375 
mg L-serine were added to 1 L of double distilled water. The solution was stirred with 
gentle heating until all solids had dissolved. Aliquots of 45 mL were dispensed into glass 
schott bottles, autoclaved to sterilise, and stored at rt. 
 
D-(+)-Glucose solution 
 
A 20% w/v solution in double distilled water was prepared, dispensed into 20 mL aliquots 
in glass vials, autoclaved and stored at rt. 
 
L-Aspartic acid 
 
A 4 mg/mL solution in double distilled water was prepared, which required sonication to 
dissolve the acid. Aliquots of 20 mL were dispensed into glass vials, autoclaved and stored 
at rt. 
 
Vitamin solution 
 
8 mg Thiamine, 8 mg pyridoxine, 8 mg pantothenic acid, 40 mg inositol, and 20 mL biotin 
solution (2 mg/100 mL H2O) were added to 180 mL double distilled water, and sterilised 
by filtering through a 0.2 µm pore size sterile disposable filter in a laminar flow cabinet. 
Aliquots of 10 mL were transferred to sterile glass vials and stored at 4˚C. 
 
L-Threonine 
 
A solution of 24 mg/mL in double distilled water was prepared, dispensed into 10 mL 
aliquots in glass vials, autoclaved and stored at 4˚C. 
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Copper (II) sulfate 
 
A 20 mM solution of copper (II) sulfate in double distilled water was prepared and 
sterilised as for the vitamin solution. Aliquots of 5 mL were stored in glass bottles at rt. 
 
Chlorophenol red-β-D-galactopyranoside (CPRG) 
 
A 10 mg/mL solution in double distilled water was prepared and sterilised by filtering (as 
for the vitamin solution) into sterile glass bottles in 5 mL aliquots and stored at 4˚C. 
 
 
Preparation and storage of yeast stock for assay use 
 
For short term storage of the yeast (maximum of four months), a 10 x concentrated yeast 
stock culture was prepared. This involved first preparing growth medium, which consisted 
of: 
(i) 45 mL Minimal medium 
(ii) 5 mL Glucose solution 
(iii) 1.25 mL L-Aspartic acid solution 
(iv) 0.5 mL Vitamin solution 
(v) 0.4 mL L-Threonine solution 
(vi) 125 µL Copper (II) sulfate solution 
 
The growth medium was added to a sterile conical flask and 125 µL yeast stock (initially 
from yeast stored at -80˚C and -20˚C thereafter) added. The solution was incubated for 24 
h at 28˚C on an orbital shaker, after which it was turbid. This 24 h culture was re-cultured 
by adding 1 mL to two sterile conical flasks containing growth medium. The two solutions 
were incubated at 28˚C on an orbital shaker for 24 h. Each culture was transferred to a 
sterile 50 mL centrifuge tube, and centrifuged at rt for 10 min at 2,000 g. The supernatant 
was decanted, and each culture resuspended in 5 mL minimal medium with 15% sterile 
glycerol (8 mL glycerol per 45 mL minimal medium). Aliquots of 0.5 mL were transferred 
to sterile glass tubes (those used for HPLC), and stored at -20˚C for a maximum of four 
months. 
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Assay procedure 
 
Test chemical solutions were prepared in AnalaR 96% ethanol, and weighed directly into 
volumetric flasks. The assay standard, 17β-estradiol, was prepared at a concentration of 2 x 
10-7 M (54.48 µg/L). The pyrethroid metabolites tested in this assay were prepared at a 
concentration of 2 x 10-2 M. All work involving the yeast was carried out in a type II 
laminar flow cabinet.  
 
To prepare the yeast for assay, growth medium was prepared and transferred to a sterile 
conical flask, and 125 µL yeast (from stock stored at -20˚C) was added. The solution was 
incubated for 24 h on an orbital shaker at 28˚C. 
 
Test chemical standard solutions of appropriate concentrations in ethanol were serially 
diluted by a factor of 2 in ethanol across selected rows in a 96 well plate. 100 µL of test 
chemical standard solution was added to the first well of the row and 50 µL of ethanol was 
added to each remaining well in the row. 50 µL of test chemical solution in the first well 
was transferred to the next well in the row which contained 50 µL of ethanol. This 
procedure was repeated for each remaining well in the row to give a range of 
concentrations of test chemical. 10 µL from each well in the row was transferred to the 
corresponding empty well in a new row, and allowed to evaporate. 17β-Estradiol (over the 
concentration range 0.049 to 10 nM) was used as a positive control, and ethanol used as a 
negative. For each assay, growth solution (50 mL) was seeded with 250 µL of 24 h yeast 
culture (optical density at 640 nm of 2.5, approx. 3 x 106 yeast cells), and CPRG (0.5 mL) 
was added. 200 µL of this assay medium was added to each well, and the plates were 
sealed with autoclave tape and shaken in a fixed wavelength plate reader (BIO-TEK 
EL312) for 2 min. The plates were incubated for 48 h at 30°C, until a colour degradation 
from red to yellow was observed across the estradiol standard. The production of 
chlorophenol red (indicating estrogenic activity) was monitored by measuring the 
absorbance at 540 nm. The absorbance at 610 nm was also measured to monitor the 
turbidity of the yeast culture. The negative control (ethanol blank) appeared a pale orange 
colour due to background β-galactosidase activity. The absorbance at 540 nm was 
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corrected for absorbance arising from the turbidity of the assay solution by applying; chem. 
abs. (540 nm) – [chem. abs. (610 nm) – blank abs. (610 nm)]. 
 
Absorbance values were entered into Excel to calculate the corrected absorbances (from 
the equation above). These values were presented graphically using SigmaPlot 8.0. An 
example is shown in the Appendix. For the metabolites that possessed estrogenic activity 
an EC50 was calculated (concentration of chemical required to induce 50% of the 
maximum estrogenic activity). This value was calculated in Excel using a mathematical 
equation obtained from the line fit generated in SigmaPlot. EC50 values of metabolites 
were compared to the 17β-estradiol EC50 in terms of a relative potency, where estradiol had 
a value of 1. Relative potency = estradiol EC50 / test chemical EC50. 
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4.3 EXPERIMENTAL WORK DESCRIBED IN CHAPTER 
THREE 
 
4.3.1 Synthesis of 5-aryl 1-methyl-pyridone/piperidone inhibitors 3.55-
3.57 
 
3-(4-Methoxyphenyl)pyridine (3.76) 
 
 
 
 
 
3-Bromopyridine (275 µL, 2.74 mmol, 1 equiv) was stirred in dry THF (10 mL) under N2 
atmosphere. Tetrakis(triphenylphosphine)palladium(0) (158 mg, 0.14 mmol, 0.05 equiv) 
was added, followed by p-methoxyphenyl boronic acid (500 mg, 3.29 mmol, 1.2 equiv), 
and anhydrous potassium hydroxide (460 mg, 8.22 mmol, 3 equiv). The resulting orange 
solution was heated at reflux for 16 h. The reaction mixture was cooled to rt, diluted with 
ethyl acetate, washed with brine (2 x 20 mL), and dried over MgSO4. Removal of the 
solvent by evaporation under reduced pressure gave a crude yellow oil which was purified 
by column chromatography on silica (50% ethyl acetate /petroleum ether) to give 3.76 
(367mg, 73%) as a yellow solid. 
mp 60-61˚C (Lit.9 63-64˚C). 
1H NMR (CDCl3, 500 MHz) δ 3.87 (s, 3H, OCH3), 7.02 (d, 2H, J = 8.3 Hz, ArH), 7.34 
(dd, 1H, J = 4.9, 7.8 Hz, ArH), 7.58 (d, 2H, J = 8.8 Hz, ArH), 7.83 (dt, 1H, J = 2, 7.8 Hz, 
ArH), 8.55 (dd, 1H, J = 1.5, 4.9 Hz, ArH), 8.82 (d, 1H, J = 2 Hz, ArH). 
13C NMR (CDCl3, 75 MHz) δ 55.17, 114.38, 123.33, 128.03, 130.03, 133.63, 136.03, 
147.70, 159.58. 
HRMS (M+H) Found 186.0928 (Calcd. For C12H12NO 186.0919). 
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5-(4-Methoxyphenyl)-1-methylpyridin-2(1H)-one (3.77) - Method 110 
 
 
 
 
 
 
3-Arylpyridine 3.76 (102 mg, 0.55 mmol, 1 equiv) was stirred at 80˚C for 30 min in 
dimethyl sulfate (0.05 mL, 0.55 mmol, 1 equiv). The dark brown mixture was cooled in ice 
and aqueous potassium ferricyanide (452 mg in 2 mL water, 1.38 mmol, 2.5 equiv) added, 
followed by the slow addition of potassium hydroxide (246 mg, 4.40 mmol, 8 equiv). 
DCM (2 mL) was then added and the mixture stirred at rt for 1.5 h. Further portions of 
aqueous potassium ferricyanide (226 mg in 2 mL water, 0.68 mmol, 1.25 equiv) and 
potassium hydroxide (123 mg, 2.20 mmol, 4 equiv) were added in a similar fashion as 
before. The mixture was stirred at rt for 16 h, then diluted with DCM and washed with 
water (3 x 20 mL). The organic phases were combined, dried over MgSO4 and the solvent 
removed by evaporation under reduced pressure. The resulting crude brown/red solid was 
purified by column chromatography on silica (several columns were required) (50% ethyl 
acetate/petroleum ether) to give 3.77 (9.5 mg, 8%) as a yellow solid. 
mp 99-103˚C. 
1H NMR (CD3OD, 500 MHz) δ 3.63 (s, 3H, NCH3), 3.81 (s, 3H, OCH3), 6.61 (d, 1H, J = 
9.3 Hz, COCH=CH), 6.97 (d, 2H, J = 8.8 Hz, ArH), 7.44 (d, 2H, J = 8.3 Hz, ArH), 7.83 
(dd, 1H, J = 2.4, 9.3 Hz, COCH=CH), 7.88 (d, 1H, J = 2.4 Hz, NHCH). 
13C NMR (CD3OD, 75 MHz) δ 38.60, 56.02, 115.70, 120.35, 122.62, 128.20, 129.88, 
137.31, 141.55, 160.89, 164.33. 
HRMS (M+H) Found 216.1014 (Calcd. For C13H14NO2 216.1025). 
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2-Fluoro-5-(4-methoxyphenyl)-pyridine (3.80)  
 
 
 
 
 
5-Bromo-2-fluoropyridine (1 mL, 9.72 mmol, 1 equiv) was stirred in THF (30 mL) under 
N2 atmosphere. Tetrakis(triphenylphosphine)palladium(0) (560 mg, 0.49 mmol, 0.05 
equiv) was added resulting in a clear yellow solution. p-Methoxyphenyl boronic acid (1.77 
g, 11.65 mmol, 1.2 equiv) was added to give an orange solution which turned yellow on 
further stirring. Powdered anhydrous potassium hydroxide (1.63 g, 29.16 mmol, 3 equiv) 
and n-tetrabutylammonium bromide (3.1 g, 9.72 mmol, 1 equiv) were added successively 
and the mixture heated at reflux for 19 h. The reaction mixture was cooled to rt, diluted 
with ethyl acetate, washed with water (2 x 50 mL), and dried over MgSO4. Removal of the 
solvent by evaporation under reduced pressure gave a dark brown oil which was purified 
by column chromatography on silica (10% ethyl acetate/petroleum ether) to give 3.80 (1.65 
g, 84%) as a fluffy white powder. 
mp 66-68°C (Lit.11 64°C). 
1H NMR (CDCl3, 500 MHz) δ 3.85 (s, 3H, OCH3), 6.98 (m, 3H, ArH), 7.46 (d, 2H, J = 8.3 
Hz, ArH), 7.91 (dt, 1H, J = 2.4, 8.7 Hz, ArH), 8.36 (d, 1H, J = 2.4 Hz, ArH). 
13C NMR (CDCl3, 75 MHz) δ 55.24, 109.2 (d, J = 37.4 Hz), 114.47, 128.01, 128.96, 
134.37, 139.14 (d, J = 7.8 Hz), 145.16 (d, J = 14.5 Hz), 156.65, 162.61 (d, J = 238.1 Hz). 
HRMS (M+H) Found 204.0828 (Calcd. For C12H11NOF 204.0825).  
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5-(4-Methoxyphenyl)pyridin-2(1H)-one (3.81)  
 
 
 
 
 
 
2-Fluoropyridine 3.80 (504 mg, 2.48 mmol) was heated at reflux for 24 h in 4 M aqueous 
hydrochloric acid in dioxane (5 mL) and water (1.67 mL). The solution was cooled to rt, 
and the solvent removed by evaporation under reduced pressure to give 3.81 (498 mg, 
quantitative) as a white solid. The product was not purified further. 
mp 186-188˚C. 
1H NMR (DMSO-d6, 500 MHz) δ 3.87 (s, 3H, OCH3), 6.81 (d, 1H, J = 9.3 Hz, 
COCH=CH), 7.09 (d, 2H, J = 8.8 Hz, ArH), 7.63 (d, 2H, J = 8.8 Hz, ArH), 7.94 (d, 1H, J 
= 2.9 Hz, NHCH), 8.11 (dd, 1H, J = 2.4, 9.3 Hz, COCH=CH). 
13C NMR (DMSO-d6, 75 MHz) δ 55.25, 114.45, 118.03, 120.00, 126.59, 128.68, 131.91. 
140.24, 158.44, 161.71. 
HRMS (M+H) Found 202.0859 (Calcd. For C12H12NO2 202.0868). 
 
 
5-(4-Methoxyphenyl)-1-methylpyridin-2(1H)-one (3.77) - Method 2 
 
 
 
 
 
 
To the pyridone 3.81 (145 mg, 0.72 mmol, 1 equiv) in DMF (2.5 mL) under N2 atmosphere 
was added lithium hydride (7 mg, 0.86 mmol, 1.2 equiv) and the grey suspension stirred at 
50°C for 1.5 h. Methyl iodide (67 µL, 1.08 mmol, 1.5 equiv) was added and the orange 
solution stirred at 50°C for 16 h. The mixture was cooled to rt, and saturated aqueous 
sodium bicarbonate was added to give a thick white suspension. The organic material was 
extracted with ethyl acetate (3 x 20 mL). The organic phases were combined and washed 
N
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with water (4 x 20 mL), dried over MgSO4 and the solvent removed by evaporation under 
reduced pressure. The resulting yellow oil was purified by column chromatography on 
silica (5% methanol/DCM) to give 3.77 (106 mg, 68%) as an orange solid. 
See 3.77 - Method 1 for characterisation. 
 
 
5-(4-Hydroxyphenyl)-1-methylpyridin-2(1H)-one (3.78) 
 
 
 
 
 
 
The methyl ether 3.77 (90 mg, 0.42 mmol) was heated at reflux for 16 h in 48% aqueous 
hydrobromic acid (1.5 mL) and acetic acid (1.5 mL). The solution was cooled to rt, and the 
solvent removed by evaporation under reduced pressure to give a brown residue that was 
dissolved in ethyl acetate. The solution was extracted with 1 M aqueous potassium 
hydroxide (3 x 20 mL). The aqueous phases were combined and acidified with 6 M 
aqueous hydrochloric acid until neutral pH (universal indicator paper). The aqueous 
solution was re-extracted with ethyl acetate (3 x 50 mL). The organic phases were 
combined and dried over MgSO4. Removal of the solvent by evaporation under reduced 
pressure gave an orange solid which was purified by column chromatography on silica (5% 
methanol/DCM) to give 3.78 (70 mg, 83%) as a cream powder. 
mp 246-248°C 
1H NMR (DMSO-d6, 500 MHz) δ 3.58 (s, 3H, NCH3), 6.56 (d, 1H, J = 9.3 Hz, 
COCH=CH), 6.90 (d, 2H, J = 8.8 Hz, ArH), 7.46 (d, 2H, J = 8.8 Hz, ArH), 7.84 (dd, 1H, J 
= 2.9, 9.8 Hz, COCH=CH), 8.08 (d, 1H, J = 2.9 Hz, NCH3CH). 
13C NMR (DMSO-d6, 75 MHz) δ 37.14, 115.74, 118.56, 118.93, 126.58, 126.78, 136.07, 
139.14, 156.61, 161.08. 
HRMS (M+H) Found 202.0858 (Calcd. For C12H12NO2 202.0868). 
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2-Bromo-N,N-diisopropylacetamide (3.83)12 
 
 
 
 
Benzyltriethylammonium chloride (80 mg, 0.35 mmol, 0.01 equiv) was dissolved in 1,2-
dichloroethane (26 mL). Diisopropylamine (6.01 mL, 34.50 mmol, 1 equiv) was added, 
followed by an aqueous solution of sodium hydroxide (1.38 g in 3 mL water, 34.50 mmol, 
1 equiv). The solution was cooled in ice and bromoacetyl bromide (3 mL, 34.50 mmol, 1 
equiv) was added dropwise to give a thick yellow precipitate. The solution was stirred at rt 
for 16 h. The reaction mixture was washed with 1 M aqueous sodium hydroxide (2 x 50 
mL), then 10% aqueous hydrochloric acid (2 x 50 mL), followed by brine. The organic 
phase was dried over MgSO4 and the solvent removed by evaporation under reduced 
pressure. The resulting orange oil was purified by column chromatography on silica (50% 
ethyl acetate/petroleum ether) to give 3.83 (5.71 g, 75%) as a white solid. 
mp 60-63˚C. 
1H NMR (CDCl3, 500 MHz) δ 1.24 (d, 6H, J = 6.4 Hz, (CH3)2), 1.38 (d, 6H, J = 6.8 Hz, 
(CH3)2), 3.42 (m, 1H, CH(CH3)2), 3.80 (s, 2H, CH2), 3.95 (m, 1H, CH(CH3)2). 
13C NMR (CDCl3, 75 MHz) δ 19.99, 20.58, 28.68, 46.14, 50.34, 165.22. 
HRMS (M+H) Found 222.0497 (Calcd. For C8H17NO79Br 222.0494). 
 
 
N-Allyl-2-bromoacetamide (3.84)  
 
 
 
 
 
Benzyltriethylammonium chloride (56 mg, 0.25 mmol, 0.01 equiv) was dissolved in 1,2-
dichloroethane (16 mL). Allylamine (1.88 mL, 25 mmol, 1 equiv) was added, followed by 
an aqueous solution of sodium hydroxide (1 g in 5 mL water, 25 mmol, 1 equiv). The 
solution was cooled in ice and bromoacetyl bromide (2.18 mL, 25 mmol, 1 equiv) was 
added dropwise. The solution was stirred at rt for 16 h. The reaction mixture was diluted 
Br
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with ethyl acetate, washed with 1 M aqueous sodium hydroxide (2 x 50 mL), 10% aqueous 
hydrochloric acid (2 x 50 mL), and brine. The organic phase was dried over MgSO4 and 
the solvent removed by evaporation under reduced pressure. The resulting clear oil was 
purified by column chromatography on silica (20% ethyl acetate/petroleum ether) to give 
3.84 (3.02 g, 67%) as a clear oil.  
1H NMR (CDCl3, 500 MHz) δ 3.92 (m, 4H, (CH2)2), 5.17 (m, 2H, CH=CH2), 5.85 (m, 1H, 
CH=CH2), 6.67 (s(br), 1H, NH). 
13C NMR (CDCl3, 75 MHz) δ 28.98, 42.32, 116.73, 133.14, 165.42. 
HRMS (M+H) Found 177.9859 (Calcd. For C5H9NO79Br 177.9868). 
 
 
N,N-Diisopropyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide 
(3.55)  
 
 
 
 
 
 
To the phenol 3.78 (100 mg, 0.49 mmol, 1 equiv) in DMSO (6 mL) under N2 atmosphere 
was added 2 M aqueous sodium hydroxide (0.37 mL, 0.75 mmol, 1.5 equiv) and the 
resulting brown solution stirred at 80°C for 30 min. 2-Bromo-N,N-diisopropylacetamide 
(3.83) (109 mg, 0.49 mmol, 1 equiv) was added and the solution stirred at 80°C for 16 h. 
The reaction mixture was cooled to rt, quenched with water (25 mL), and extracted with 
ethyl acetate (3 x 20 mL). The organic phases were combined and washed with water (4 x 
20 mL), 2 M aqueous sodium hydroxide (20 mL) and dried over MgSO4. Removal of the 
solvent by evaporation under reduced pressure gave a thick yellow oil which was purified 
by column chromatography on silica (5% methanol/DCM) to give 3.55 (78 mg, 46%) as a 
yellow oil. 
1H NMR (CD3OD, 500 MHz) δ 1.24 (d, 6H, J = 6.4 Hz, (CH3)2), 1.39 (d, 6H, J = 6.4 Hz, 
(CH3)2), 3.43 (m, 1H, CH(CH3)2), 3.61 (s, 3H, NCH3), 4.09 (m, 1H, CH(CH3)2), 4.72 (s, 
2H, CH2), 6.59 (d, 1H, J = 9.3 Hz, COCH=CH), 7.00 (d, 2H, J = 8.8 Hz, ArH), 7.43 (d, 
N
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2H, J = 8.8 Hz, ArH), 7.80 (dd, 1H, J = 2.4, 9.3 Hz, COCH=CH), 7.86 (d, 1H, J = 2.4 Hz, 
NCH3CH). 
13C NMR (CD3OD, 75 MHz) δ 21.01, 21.20, 38.64, 47.68, 69.22, 116.60, 120.44, 122.69, 
128.36, 130.83, 137.65, 141.75, 159.52, 164.63, 169.21. 
HRMS (M+H) Found 343.2032 (Calcd. For C20H27N2O3 343.2022). 
 
 
N,N-Diisopropyl-2-(4-(1-methyl-6-oxopiperidin-3-yl)phenoxy)acetamide (3.56)  
 
 
 
 
 
 
The 1-methyl pyridone 3.55 (21 mg, 0.06 mmol, 1 equiv) was dissolved in ethanol (10 mL) 
and 10% palladium on charcoal (20 mg) was added. The mixture was reacted with 
hydrogen (40 bar) in a PARR hydrogenator for 48 h. The catalyst was removed by 
filtration and the solvent removed by evaporation under reduced pressure. The resulting 
cream solid was purified by column chromatography on silica (5% methanol/DCM) to give 
3.56 (13 mg, 63%) as a white solid. 
1H NMR (CD3OD, 500 MHz) δ 1.24 (d, 6H, J = 6.4 Hz, (CH3)2), 1.38 (d, 6H, J = 6.8 Hz, 
(CH3)2), 2.02 (m, 2H, NCH3CH2), 2.46 (m, 2H, COCH2CH2), 2.94 (s, 3H, NCH3), 3.09 
(m, 1H, NCH3CH2CH), 3.41 (m, 2H, COCH2CH2), 3.54 (m, 1H, CH(CH3)2), 4.09 (m, 1H, 
CH(CH3)2), 4.67 (s, 2H, OCH2), 6.92 (d, 2H, J = 8.8 Hz, ArH), 7.23 (d, 2H, J = 8.3 Hz, 
ArH). 
13C NMR (DMSO-d6, 75 MHz) δ 20.43, 20.59, 28.00, 31.77, 34.00, 44.99, 47.80, 55.66, 
67.59, 114.57, 127.93, 128.06, 134.65, 157.05, 166.04, 168.30. 
HRMS (M+H) Found 347.2327 (Calcd. For C20H31N2O3 347.2335). 
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N-Allyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide (3.57)  
 
 
 
 
 
 
The phenol 3.78 (350 mg, 1.72 mmol, 1 equiv) was stirred in DMF (10 mL) under N2 
atmosphere to which 2 M aqueous potassium hydroxide (1.29 mL, 2.59 mmol, 1.5 equiv) 
was added and the mixture stirred at 80˚C for 1.5 h. N-Allyl-2-bromoacetamide (3.84) (333 
mg, 1.89 mmol, 1.1 equiv) was added and the solution stirred at 80˚C for 16 h. The 
reaction mixture was cooled to rt, quenched with water (25 mL), and extracted with ethyl 
acetate (3 x 20 mL). The organic phases were combined and washed with water (4 x 20 
mL), and dried over MgSO4. Removal of the solvent by evaporation under reduced 
pressure gave an orange oil which was purified by column chromatography on silica (5% 
methanol/DCM) to give 3.57 (239 mg, 79%) as a yellow solid. 
mp 160-162˚C. 
1H NMR (CD3OD, 500 MHz) δ 3.65 (s, 3H, NCH3), 3.89 (d(br), 2H, J = 5.4 Hz, NHCH2), 
4.55 (s, 2H, OCH2), 5.13 (m, 2H, CH=CH2), 5.85 (m, 1H, CH=CH2), 6.62 (d, 1H, J = 9.3 
Hz, COCH=CH), 7.06 (d, 2H, J = 8.8 Hz, ArH), 7.48 (d, 2H, J = 8.8 Hz, ArH), 7.83 (dd, 
1H, J = 2.4, 9.3 Hz, COCH=CH), 7.90 (d, 1H, J = 2.4 Hz, NCH3CH). 
13C NMR (CD3OD, 75 MHz) δ 38.66, 42.63, 68.54, 116.58, 116.70, 120.47, 122.55, 
128.47, 131.29, 135.54, 137.72, 141.70, 158.97, 164.63, 171.07. 
HRMS (M+H) Found 299.1390 (Calcd. For C17H19N2O3 299.1396). 
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4.3.2 Synthesis of 5-aryl 1-methyl-pyridone inhibitor 3.59 
 
6-Fluoropyridin-3-yl boronic acid (3.85)11 
 
 
 
 
 
n-Butyllithium (15% in hexane, 3.6 mL, 5.76 mmol, 1.2 equiv) was added to dry ether (5 
mL) in a flask under N2 atmosphere and cooled to -78°C. A solution of 5-bromo-2-
fluoropyridine (0.5 mL, 4.86 mmol, 1 equiv) in dry ether (3 mL) was added dropwise and 
the resulting yellow precipitate was stirred at -78°C for 45 min. Trimethylborate (0.66 mL, 
5.83 mmol, 1.2 equiv) was added and the reaction warmed to rt, then stirred for 1 h. The 
reaction mixture was treated with 5% aqueous sodium hydroxide (25 mL), cooled in ice 
and acidified with 3 M aqueous hydrochloric acid until neutral pH (universal indicator 
paper). The solution was extracted with ethyl acetate (3 x 50 mL) and the organic phases 
combined and dried over MgSO4. The solvent was removed by evaporation under reduced 
pressure to give a yellow solid which was washed with 10% ethyl acetate/petroleum ether 
to give 3.85 (456 mg, 73%) as a cream powder. 
mp 190-191˚C (Lit.13 190-191˚C). 
1H NMR (DMSO-d6, 500 MHz) δ 7.24 (dd, 1H, J = 2.5, 8.3 Hz, H5), 8.37 (dt, 1H, J = 2, 
8.3 Hz, H4), 8.52 (s(br), 2H, (OH)2), 8.64 (d, 1H, J = 2 Hz, H2). 
13C NMR (DMSO-d6, 75 MHz) δ 108.75 (d, J = 35.3 Hz), 147.66 (d, J = 7.8 Hz), 153.5 (d, 
J = 14.5 Hz), 164.54 (d, J = 237.6 Hz). 
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1-Bromo-4-(1,1-dimethoxy-2-phenylethyl)benzene (3.89)  
 
 
 
 
 
Benzyl-4-bromophenyl ketone (200 mg, 0.72 mmol, 1 equiv) and 4Å molecular sieves 
were added to a flask under N2 atmosphere. Methanol (2 mL), trimethylorthoformate (4 
mL), and a few drops of trifluoromethanesulfonic acid were added, and the solution heated 
at reflux for 19 h. The reaction mixture was cooled to rt, quenched with saturated aqueous 
sodium bicarbonate (15 mL), and extracted with ether (3 x 20 mL). The organic phases 
were combined, washed with water, and dried over MgSO4. The solvent was removed by 
evaporation under reduced pressure to give a clear pale yellow oil which was purified by 
column chromatography on silica (5% ethyl acetate/petroleum ether) to give 3.89 (169 mg, 
73%) as a colourless oil. 
1H NMR (CDCl3, 500 MHz) δ 3.16 (s, 2H, OCH2), 3.27 (s, 6H, (OCH3)2, 6.76 (d, 2H, J = 
9 Hz, ArH), 7.08 (m, 5H, ArH), 7.34 (d, 2H, J = 8.3 Hz, ArH). 
13C NMR (CDCl3, 75 MHz) δ 43.5, 49, 103.59, 121.69, 126.2, 127.65, 129.15, 130.24, 
130.7, 135.58, 139.21. 
No further analytical data was obtained due to product degradation. 
 
 
1-(4-Methoxyphenyl)-2-phenylethanone (3.93)14 
 
 
 
 
 
Aluminium chloride (1.2 g, 9.07 mmol, 1.2 equiv) was added to a flask under N2 
atmosphere containing 1, 2-dichloroethane (8 mL). Anisole (0.82 mL, 7.56 mmol, 1 equiv) 
was added and the mixture cooled in ice. Phenylacetyl chloride (1 mL, 7.56 mmol, 1 
equiv) was added dropwise, resulting in a bright fluorescent red mixture that was heated at 
reflux for 16 h. The reaction mixture was cooled to rt, poured into water (20 mL) and 
Br
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extracted with ethyl acetate (3 x 50 mL). The organic phases were combined and washed 
with water, brine, and dried over MgSO4. The solvent was removed by evaporation under 
reduced pressure to give an orange oil which was purified by column chromatography on 
silica (10% ethyl acetate/petroleum ether) to give 3.93 (1.07 g, 60%) as yellow crystals. 
mp 69-71˚C (Lit. 68-69˚C). 
1H NMR (CDCl3, 500 MHz) δ 3.86 (s, 3H, OCH3), 4.23 (s, 2H, CH2), 6.92 (d, 2H, J = 9.1 
Hz, ArH), 7.28 (m, 5H, ArH), 7.99 (d, 2H, J = 8.7 Hz, ArH). 
13C NMR (CDCl3, 75 MHz) δ 45.13, 55.33, 113.68, 126.66, 128.52, 129.28, 129.46, 
130.85, 133.35, 134.862, 163.42, 176.59, 196.21. 
 
 
 
1-(4-Hydroxyphenyl)-2-phenylethanone (3.94) 
 
 
 
 
 
The methyl ether 3.93 (300 mg, 1.33 mmol) was heated at reflux for 7 h in 48% aqueous 
hydrobromic acid (3 mL) and acetic acid (3 mL). The solution was cooled to rt, and the 
solvent removed by evaporation under reduced pressure to give a brown residue that was 
dissolved in ethyl acetate. The solution was extracted with 1 M aqueous potassium 
hydroxide (3 x 40 mL). The aqueous phases were combined and acidified with 6 M 
aqueous hydrochloric acid until neutral pH (universal indicator paper). The aqueous 
solution was re-extracted with ethyl acetate (3 x 80 mL). The organic phases were 
combined and dried over MgSO4. Removal of the solvent by evaporation under reduced 
pressure gave an orange solid which was purified by column chromatography on silica 
(50% ethyl acetate/petroleum ether) to give 3.94 (160 mg, 57%) as a white solid. 
mp 130-132 ˚C (Lit.15 134-136˚C). 
1H NMR (acetone-d6, 500 MHz) δ 4.38 (s, 2H, CH2), 7.04 (d, 2H, J = 10.7 Hz, ArH), 7.42 
(m, 5H, ArH), 8.11 (d, 2H, J = 11.2 Hz, ArH), 9.35 (s(br), 1H, OH). 
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4-(2-Phenylacetyl)phenyltrifluoromethanesulfonate (3.95) 
 
 
 
 
 
 
The phenol 3.94 (160 mg, 0.75 mmol, 1 equiv) was dissolved in dry ice cooled DCM (2 
mL) under N2 atmosphere and pyridine (0.5 mL) was added. Trifluoromethanesulfonic 
anhydride (0.19 mL, 1.13 mmol, 1.5 equiv) was added dropwise and the resulting red 
solution was stirred for 45 min in ice. The reaction was quenched by the addition of water 
(5 mL), and the organic layer was separated and diluted with DCM (20 mL). This solution 
was washed with 10% aqueous hydrochloric acid (3 x 20 mL), dried over Na2SO4, and the 
solvent removed by evaporation under reduced pressure. The resulting red/brown solid was 
purified by column chromatography on silica (50% ethyl acetate/petroleum ether) to give 
3.95 (152 mg, 59%) as a pale yellow solid. 
1H NMR (CDCl3, 500 MHz) δ 4.28 (s, 2H, CH2), 7.31 (m, 7H, ArH), 8.11 (d, 2H, J = 9.1 
Hz, ArH). 
13C NMR (CDCl3, 75 MHz) δ 45.63, 116.51, 120.76, 121.65, 127.17, 128.81, 129.34, 
130.85, 134.99 (d, J = 195 Hz), 152.38, 195.73. 
No further analytical data was obtained due to product degradation. 
 
 
1-(4-(6-Fluoropyridin-3-yl)phenyl)-2-phenylethanone (3.87) 
 
 
 
 
 
 
A flask was charged with benzyl-4-bromophenyl ketone (1.05 g, 3.82 mmol, 1 equiv) and 
tetrakis(triphenylphosphine)palladium(0) (440 mg, 0.38 mmol, 0.1 equiv) under N2 
atmosphere. A solution of 6-fluoropyridin-3-yl boronic acid (3.85) (1.07 g, 8.39 mmol, 2.2 
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equiv) in ethanol (15 mL) was added followed by toluene (30 mL), and 2 M aqueous 
sodium carbonate (4.18 mL, 8.39 mmol, 2.2 equiv). After 10 min the reaction mixture was 
slightly black in colour so a further small amount of catalyst was added. The solution was 
heated at reflux for 18 h, after which it was cooled to rt, diluted with ethyl acetate and 
washed with water. The organic phase was dried over MgSO4 and the solvent removed by 
evaporation under reduced pressure. The resulting yellow solid was purified by column 
chromatography on silica (15% ethyl acetate/petroleum ether) to give 3.87 (934 mg, 85%) 
as a fine white solid.  
mp 134-136°C. 
1H NMR (CDCl3, 500 MHz) δ 4.33 (s, 2H, CH2), 7.05 (dd, 1H, J = 2.8, 8.3 Hz, ArH), 7.31 
(m, 5H, ArH), 7.64 (d, 2H, J = 8.3 Hz, ArH), 8.0 (dt, 1H, J = 2.4, 8.3 Hz, ArH), 8.12 (d, 
2H, J = 8.3 Hz, ArH), 8.46 (d, 1H, J = 2 Hz, ArH). 
13C NMR (CDCl3, 75 MHz) δ 45.63, 109.73 (d, J = 37.9 Hz), 126.98, 127.19, 128.74, 
129.38, 129.49, 133.53, 134.30, 135.96, 139.78 (d, J = 7.8 Hz), 141.13, 146.06 (d, J = 15 
Hz), 163.52 (d, J = 240.7 Hz), 196.95. 
HRMS (M+H) Found 292.1132 (Calcd. For C19H15NOF 292.1138). 
 
 
5-(-4-(2-Phenylacetyl)phenyl)pyridin-2(1H)-one (3.88) 
 
 
 
 
 
 
2-Fluoropyridine 3.87 (187 mg, 0.64 mmol) was dissolved in 4 M aqueous hydrochloric 
acid in dioxane (3 mL) and H2O (1 mL). The solution was heated at reflux for 24 h, cooled 
to rt, and the solvent removed by evaporation under reduced pressure to give 3.88 (176 mg, 
95%) as a cream solid. The product was not purified further. 
mp 200-204°C. 
1H NMR (DMSO-d6, 500 MHz) δ 4.48 (s, 2H, CH2), 6.57 (d, 1H, J = 9.3 Hz, COCH=CH), 
7.25 (m, 5H, ArH), 7.84 (d, 2H, J = 8.3 Hz, ArH), 7.99 (d, 1H, J = 2.4 Hz, NHCH), 8.04 
(dd, 1H, J = 2.4, 9.3 Hz, COCH=CH), 8.16 (d, 2H, J = 8.8 Hz, ArH). 
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13C NMR (DMSO-d6, 75 MHz) δ 44.77, 108.17, 116.85, 120.13, 125.25, 126.58, 128.43, 
129.30, 129.75, 134.19, 135.32, 139.93, 140.75, 161.87, 197.10. 
HRMS (M+H) Found 290.1168 (Calcd. For C19H16NO2 290.1181). 
 
 
1-Methyl-5-(4-(2-phenylacetyl)phenyl)pyridin-2(1H)-one (3.59) 
 
 
 
 
 
 
To the pyridone 3.88 (140 mg, 0.48 mmol, 1 equiv) in DMF (4 mL) under N2 atmosphere 
was added lithium hydride (3.7 mg, 0.48 mmol, 1 equiv) and the grey suspension stirred at 
rt for 1 h. Methyl iodide (45 µL, 0.72 mmol, 1.5 equiv) was added and the yellow solution 
stirred at rt for 16 h. The reaction was quenched with water (10 mL), and the mixture was 
extracted with ethyl acetate (3 x 20 mL). The organic phases were combined and washed 
with water (4 x 20 mL), dried over MgSO4, and the solvent removed by evaporation under 
reduced pressure. The resulting yellow oil was purified by column chromatography on 
silica (5% methanol/DCM) to give 3.59 (90 mg, 52%) as a pale yellow solid. 
mp decomp.>140˚C. 
1H NMR (DMSO-d6, 500 MHz) δ 3.62 (s, 3H, NCH3), 4.49 (s, 2H, CH2), 6.61 (d, 1H, J = 
9.8 Hz, COCH=CH), 7.38 (m, 5H, ArH), 7.85 (d, 2H, J = 8.3 Hz, ArH), 8.02 (dd, 1H, J = 
2.7, 9.7 Hz, COCH=CH), 8.18 (d, 1H, J = 8.3 Hz, ArH), 8.41 (d, 1H, J = 2.9 Hz, 
NCH3CH). 
13C NMR (DMSO-d6, 75 MHz) δ 37.26, 44.77, 116.35, 119.34, 125.16, 126.59, 128.44, 
129.33, 129.76, 134.38, 135.33, 138.59, 139.74, 140.85, 161.91, 197.10. 
HRMS (M+H) Found 304.1340 (Calcd. for C20H18NO2 304.1338). 
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4.3.3 Synthesis of 1-aryl 2-methyl 2,3-dihydro-4-pyridone inhibitors 3.61 
 and 3.62 
 
1-(4-Methoxyphenyl)-2-methyl-2,3-dihydropyridin-4(1H)-one (3.98)  
 
 
 
 
 
Acetaldehyde (42 µL, 0.75 mmol, 1 equiv) was added to super-dry methanol (6 mL) under 
N2 atmosphere. p-Anisidine (93 mg, 0.75 mmol, 1 equiv) was added, followed by 
Danishefsky’s diene (291 µL, 1.50 mmol 2 equiv). The bright yellow solution was stirred 
at rt for 2 h, and quenched with 1 M aqueous hydrochloric acid (1.5 mL). The mixture was 
diluted with ether (50 mL), dried over MgSO4, and the solvent removed by evaporation 
under reduced pressure. The resulting yellow oil was purified by column chromatography 
on silica (5% methanol/DCM) to give 3.98 (145 mg, 89%) as a bright yellow oil.  
1H NMR (CDCl3, 500 MHz) δ 1.26 (d, 3H, J = 6.8 Hz, CHCH3), 2.30 (dd, 1H, J = 3.9, 
16.6 Hz, COCHaHb), 2.94 (dd, 1H, J = 6.8, 16.6 Hz, COCHaHb), 3.77 (s, 3H, OCH3), 4.19 
(m, 1H, CHCH3), 5.08 (d, 1H, J = 7.5 Hz, CH=CH), 6.86 (d, 2H, J = 9.1 Hz, ArH), 7.03 
(d, 2H, J = 9.1 Hz, ArH), 7.18 (d, 1H, J = 7.5 Hz, CH=CH). 
13C NMR (CDCl3, 75 MHz) δ 15.79, 42.60, 54.82, 55.52, 99.80, 114.73, 122.54, 137.66, 
148.76, 157.23, 191.28. 
HRMS (M+H) Found 218.1181 (Calcd. for C13H16NO2 218.1184). 
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1-(4-Hydroxyphenyl)-2-methyl-2,3-dihydropyridin-4(1H)-one (3.99)  
 
 
 
 
 
The methyl ether 3.98 (145 mg, 0.67 mmol, 1 equiv) was stirred at 80˚C for 8 h in 48% 
aqueous hydrobromic acid (1 mL) and acetic acid (1 mL). The solution was cooled to rt, 
and the solvent removed by evaporation under reduced pressure to give a brown residue 
that was dissolved in ethyl acetate. The solution was extracted with 1 M aqueous 
potassium hydroxide (3 x 40 mL). The aqueous phases were combined and acidified with 1 
M aqueous hydrochloric acid until neutral pH (universal indicator paper). The aqueous 
solution was re-extracted with ethyl acetate (3 x 50 mL). The organic phases were 
combined and dried over MgSO4. Removal of the solvent by evaporation under reduced 
pressure gave a brown oil which was purified by column chromatography on silica (5% 
methanol/DCM) to give 3.99 (89 mg, 66%) as a pale yellow solid. 
mp 171-173˚C. 
1H NMR (acetone-d6, 500 MHz) δ 1.22 (d, 3H, J = 6.8 Hz, CHCH3), 2.29 (dd, 1H, J = 3.9, 
16.6 Hz, COCHaHb), 2.97 (dd, 1H, J = 6.8, 16.6 Hz, COCHaHb), 4.30 (m, 1H, CHCH3), 
5.06 (d, 1H, J = 7.3 Hz, CH=CH), 6.82 (d, 2H, J = 8.8 Hz, ArH), 7.11 (d, 2H, J = 8.8 Hz, 
ArH), 7.46 (d, 1H, J = 7.8 Hz, CH=CH), 8.67 (s, 1H, OH). 
13C NMR (acetone-d6, 75 MHz) δ 13.65, 41.26, 53.31, 97.79, 114.76, 121.52, 135.84, 
147.07, 153.81, 188.49. 
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N,N-Diisopropyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy) 
acetamide (3.61) 
 
 
 
 
 
 
To the phenol 3.99 (30 mg, 0.15 mmol, 1 equiv) in DMF (2 mL) under N2 atmosphere was 
added 2 M aqueous potassium hydroxide (110 µL, 0.22 mmol, 1.5 equiv) and the 
yellow/green solution stirred at 80°C for 1 h. 2-Bromo-N,N-diisopropylacetamide (3.83) 
(32.5 mg, 0.15 mmol, 1 equiv) was added and the solution stirred at 80°C for 16 h. The 
reaction mixture was cooled to rt, quenched with 10% aqueous sodium bicarbonate (10 
mL), and extracted with ethyl acetate (3 x 10 mL). The organic phases were combined, 
washed with water (4 x 20 mL) and dried over MgSO4. Removal of the solvent by 
evaporation under reduced pressure gave a pale orange oil which was purified by column 
chromatography on silica (5% methanol/DCM) to give 3.61 (15 mg, 30%) as a yellow oil. 
1H NMR (CD3OD, 500 MHz) δ 1.25 (d, 3H, J = 6.3 Hz, NCHCH3), 1.25 (d, 6H, J = 6.3 
Hz, CH(CH3)2), 1.40 (d, 6H, J = 6.8 Hz, CH(CH3)2), 2.30 (dd, 1H, J = 3.2, 16.6 Hz, 
COCHaHb), 3.00 (dd, 1H, J = 6.8, 16.6 Hz, COCHaHb), 3.56 (m, 1H, CH(CH3)2), 4.08 (m, 
1H, CH(CH3)2), 4.37 (m, 1H, NCHCH3), 4.72 (s, 2H, OCH2), 5.09 (d, 1H, J = 7.8 Hz, 
COCH=CH), 7.01 (d, 2H, J = 9.3 Hz, ArH), 7.24 (d, 2H, J = 8.8 Hz, ArH), 7.53 (d, 1H, J 
= 7.8 Hz, COCH=CH). 
13C NMR (CD3OD, 75 MHz) δ 16.00, 21.00, 21.18, 43.10, 47.71, 48.45, 56.18, 69.33, 
99.60, 117.04, 124.33, 139.545, 152.56, 158.00, 169.11, 194.44. 
HRMS (M+H) Found 345.2188 (Calcd. for C20H29N2O3 345.2178). 
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N-Allyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide (3.62) 
 
 
 
 
 
 
To the phenol 3.99 (35 mg, 0.17 mmol, 1 equiv) in DMF (2 mL) under N2 atmosphere was 
added 2 M aqueous potassium hydroxide (129 µL, 0.26 mmol, 1.5 equiv) and the green 
solution stirred at 80°C for 1 h. N-Allyl-2-bromoacetamide (3.84) (30 mg, 0.17 mmol, 1 
equiv) was added and the solution stirred at 80°C for 16 h. The reaction mixture was 
cooled to rt, quenched with 10% aqueous sodium bicarbonate (10 mL), and extracted with 
ethyl acetate (3 x 10 mL). The organic phases were combined, washed with water (4 x 20 
mL) and dried over MgSO4. Removal of the solvent by evaporation under reduced pressure 
gave a yellow oil which was purified by column chromatography on silica (5% 
methanol/DCM) to give 3.62 (22 mg, 43%) as a yellow oil. 
1H NMR (CD3OD, 500 MHz) δ 1.25 (d, 3H, J = 6.4 Hz, CHCH3), 2.31 (dd, 1H, J = 2.9, 
16.6 Hz, COCHaHb), 3.01 (dd, 1H, J = 6.4, 16.6 Hz, COCH aHb), 3.88 (d(br), 2H, J = 4.9 
Hz, NHCH2), 4.39 (m, 1H, CHCH3), 4.55 (s, 2H, OCH2), 5.10 (d, 1H, J = 7.3 Hz, 
COCH=CH), 5.12 (m, 2H, CH2CH=CH2), 5.84 (m, 1H, CH2CH=CH2), 7.06 (d, 2H, J = 
8.8 Hz, ArH), 7.26 (d, 2H, J = 9.2 Hz, ArH), 7.54 (d, 1H, J =7.8 Hz, COCH=CH). 
13C NMR (CD3OD, 75 MHz) δ 15.70, 42.32, 42.80, 55.82, 68.45, 99.47, 116.28, 116.88, 
124.00, 135.23, 139.61, 152.05, 157.06, 170.66, 194.14. 
HRMS (M+H) Found 301.1546 (Calcd. For C17H21N2O3 301.1552). 
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1-(4-Methoxyphenyl)-2-phenyl-2,3-dihydropyridin-4(1H)-one (3.100)16 
 
 
 
 
 
Benzaldehyde (75 µL, 0.75 mmol, 1 equiv) was added to super-dry methanol (6 mL) under 
N2 atmosphere. p-Anisidine (93 mg, 0.75 mmol, 1 equiv) was added, followed by 
Danishefsky’s diene (291 µL, 1.50 mmol 2 equiv). The bright yellow solution was stirred 
at rt for 2 h, and quenched with 1 M aqueous hydrochloric acid (1.5 mL). The mixture was 
diluted with ether (50 mL), dried over MgSO4, and the solvent removed by evaporation 
under reduced pressure. The resulting orange oil was purified by column chromatography 
on silica (5% methanol/DCM) to give 3.100 (132 mg, 64%) as a bright yellow oil. 
1H NMR (CDCl3, 500 MHz) δ 2.77 (dd, 1H, J = 4.0, 16.7 Hz, COCHaHb), 3.26 (dd, 1H, J 
= 7.1, 16.3 Hz, COCHaHb), 3.76 (s, 3H, OCH3), 5.19 (m, 1H, CHPh), 5.23 (d, 1H, J = 7.9 
Hz, COCH=CH), 6.81 (d, 2H, J = 8.7 Hz, ArH), 6.96 (d, 2H, J = 9.1 Hz, ArH), 7.29 (m, 
5H, ArH), 7.55 (d, 1H, J = 7.5 Hz, COCH=CH). 
13C NMR (CDCl3, 75 MHz) δ 43.19, 55.41, 62.25, 101.25, 114.52, 121.07, 126.21, 127.80, 
128.84, 138.02, 138.10, 140.96, 156.86, 190.32. 
HRMS (M+H) Found 280.1324 (Calcd. For C18H18NO2 280.1338). 
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4.3.4 Synthesis of long carbon chain tethers 3.107 and 3.108 
 
16-(Acetylthio)hexadecanoic acid (3.103)1 
 
 
 
 
 
16-Mercaptohexadecanoic acid (1.5 g, 5.22 mmol, 1 equiv) was dissolved in DCM (24 
mL) and acetic acid (24 mL). Zinc powder (3 g) was added to the solution which was 
stirred for 15 min. The reaction mixture was cooled in ice and acetyl chloride (7.2 mL, 
10.44 mmol, 2 equiv) was added dropwise. The mixture was warmed to rt and stirring was 
continued for a further 10 min. The grey suspension was filtered to remove the zinc, and 
the filtrate washed with portions of iced 0.1 M aqueous hydrochloric acid (2 x 50 mL). The 
organic phase was dried over MgSO4 and the solvent removed by evaporation under 
reduced pressure to give 3.103 (1.43 g, 83%) as a white solid. The product was not purified 
further. 
mp 64-66°C. 
1H NMR (CDCl3, 500 MHz) δ 1.29 (m(br), 22H, (CH2)11), 1.55 (m, 2H, CH2), 1.62 (m, 
2H, CH2), 2.31 (s, 3H, OCH3), 2.34 (t, 2H, J = 7.5 Hz, CH2), 2.85 (t, 2H, J = 7.5 Hz, CH2). 
13C NMR (CDCl3, 75 MHz) δ 196.17, 180.06, 34.03, 30.62, 29.59, 29.55, 29.46, 29.40, 
29.21, 29.14, 29.09, 29.03, 28.79, 24.65. 
HRMS (M+H) Found 331.2304 (Calcd. For C18H35O3S 331.2307). 
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N-2-(2-Hydroxyethyl)-16-(acetylthio)hexadecanamide (3.104) 
 
 
 
 
 
A mixture of the acid 3.103 (300 mg, 0.91 mmol, 1 equiv), EDCI (261 mg, 1.37 mmol, 1.5 
equiv), HOBt (184 mg, 1.37 mmol, 1.5 equiv), and ethanolamine (82 µL, 1.37 mmol, 1.5 
equiv) was stirred in DCM (20 mL) under N2 atmosphere at rt for 16 h. The clear solution 
was diluted with ethyl acetate (25 mL), washed with 0.1 M aqueous hydrochloric acid (2 x 
10 mL), and water (10 mL). The organic phase was dried over MgSO4 and the solvent 
removed by evaporation under reduced pressure to give 3.104 (316 mg, 93%) as a white 
solid. The product was not purified further. 
mp 65-67˚C. 
1H NMR (CDCl3, 500 MHz) δ 1.28 (m(br), 22H, (CH2)11), 1.58 (m, 4H, (CH2)2), 2.19 (t, 
2H, J = 7.7 Hz, CH2), 2.31 (s, 3H, OCH3), 2.85 (t, 2H, J = 7.3 Hz, CH2), 3.42 (m, 2H, 
NHCH2CH2), 3.72 (t, 2H, J = 5.0 Hz, NHCH2CH2), 6.16 (s(br), 1H, NH). 
13C NMR (CDCl3, 75 MHz) δ 25.71, 28.79, 29.09, 29.15, 29.23, 29.30, 29.44, 29.59, 
30.64, 36.63, 42.45, 62.32, 174.94, 196.23. 
HRMS (M+H) Found 374.2748 (Calcd. For C20H40NO3S 374.2729). 
 
 
Allyl ethyl carbonate (3.106)17 
 
 
 
 
Allyl alcohol (1 mL, 0.02 mmol, 1 equiv) was stirred in freshly distilled THF (15 mL) 
under N2 atmosphere. DMAP (3.6 g, 0.03 mmol, 2 equiv) was added and the solution 
stirred for 10 min. Ethyl chloroformate (1.4 mL, 0.02 mmol, 1 equiv) was added with ice 
cooling, and the cream suspension stirred at rt for 3 h. The reaction mixture was acidified 
with 10% aqueous hydrochloric acid until neutral pH (universal indicator paper), and 
extracted with ether (3 x 50 mL). The organic phases were combined, washed with brine, 
S
O
O
N
H15
OH
O
O
O
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and dried over MgSO4. The solvent was removed by evaporation under reduced pressure to 
give a pale yellow oil which was purified by column chromatography on silica (10% ethyl 
acetate/petroleum ether to give 3.106 (900 mg, 47%) as a colourless oil. 
1H NMR (CDCl3, 500 MHz) δ 1.95 (t, 3H, J = 7.1 Hz, CH2CH3), 4.19 (q, 2H, J = 7.1, Hz, 
CH2CH3), 4.60 (d(br), 2H, J = 5.9 Hz, CH2OCO), 5.3 (m, 2H, H2C=CH), 5.92 (m, 1H, 
CH2=CH). 
 
 
2-(16-(Acetylthio)hexadecanamido)ethylpent-4-enoate (3.107) 
 
 
 
 
The alcohol 3.104 (100 mg, 0.27 mmol, 1 equiv) was stirred with 4-pentenoic acid (27 µL, 
0.27 mmol, 1 equiv) and DMAP (16 mg, 0.14 mmol, 0.5 equiv) in ice cooled DCM (5 mL) 
under N2 atmosphere. EDCI (52 mg, 0.29 mmol, 1.1 equiv) was added and the solution 
stirred at rt for 3 h. The reaction mixture was diluted with ethyl acetate (20 mL), washed 
with saturated aqueous sodium bicarbonate (10 mL) and water (10 mL). The organic phase 
was dried over MgSO4 and the solvent removed by evaporation under reduced pressure to 
give 3.107 (60 mg, 49%) as a white solid. The product was not purified further. 
mp 70-71°C. 
1H NMR (CDCl3, 500 MHz) δ 1.23 (m(br), 22H, (CH2)11), 1.51 (m, 4H, (CH2)2), 2.15 (t, 
2H, J = 7.7 Hz, CH2), 2.31 (s, 3H, OCH3), 2.40 (m, 4H, COCH2CH2), 2.84 (t, 3H, J = 7.3 
Hz, CH2), 3.50 (m, 2H, NHCH2CH2), 4.16 (t, 2H, J = 5.1 Hz, NHCH2CH2), 5.03 (m, 2H, 
CH=CH2), 5.71 (s(br), 1H, NH), 5.81 (m, 1H, CH=CH2). 
13C NMR (CDCl3, 75 MHz) δ 173.25, 172.96, 136.45, 115.49, 63.11, 38.54, 36.57, 33.23, 
30.52, 29.50, 29.49, 29.44, 29.37, 29.35, 29.25, 29.17, 29.02, 28.99, 28.69, 28.67, 25.58. 
HRMS (M+H) Found 456.3132 (Calcd. for C25H46NO4S 456.3148). 
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N-(5-Hydroxy-3-oxapentyl)-16-(acetylthio)hexadecanamide (3.105) 
 
 
 
 
 
A mixture of the acid 3.103 (100 mg, 0.30 mmol, 1 equiv), EDCI (87 mg, 0.45 mmol, 1 
equiv), HOBt (61 mg, 0.45 mmol, 1.5 equiv), and 2-(2-aminoethoxy)ethanol (46 µL, 0.45 
mmol, 1.5 equiv) was stirred in DCM (5 mL) under N2 atmosphere at rt for 16 h. The clear 
solution was diluted with ethyl acetate (10 mL), washed with 0.1 M aqueous hydrochloric 
acid (2 x 10 mL), and water (10 mL). The organic phase was dried over MgSO4, and the 
solvent removed by evaporation under reduced pressure to give 3.105 (316 mg, 93%) as a 
white solid. The product was not purified further. 
mp 78-81˚C. 
1H NMR (CDCl3, 500 MHz) δ 1.29 (m(br), 22H, (CH2)11), 1.58 (m, 4H, (CH2)2), 2.17 (t, 
2H, J = 7.5 Hz, CH2), 2.31 (s, 3H, OCH3), 2.85 (t, 2H, J = 7.3 Hz, CH2), 3.47 (m, 2H, 
NHCH2CH2), 3.57 (m, 4H,OCH2CH2), 3.75 (t, 2H, J = 5.2 Hz, NHCH2CH2), 5.87 (s(br), 
1H, NH). 
13C NMR (CDCl3, 75 MHz) δ 25.68, 28.71, 29.01, 29.06, 29.24, 29.30, 29.37, 29.42, 
29.46, 29.53, 30.55, 36.61, 39.09, 61.52, 69.89, 72.20, 173.62, 196.13. 
HRMS (M+H) Found 418.2996 (Calcd. For C22H44NO4S 418.2991). 
 
 
2-(2-(16-(Acetylthio)hexadecanamido)ethoxy)ethylpent-4-enoate (3.108) 
 
 
 
 
 
The alcohol 3.105 (120 mg, 0.29 mmol, 1 equiv) was stirred with 4-pentenoic acid (30 µL, 
0.29 mmol, 1 equiv) and DMAP (18 mg, 0.15 mmol, 0.5 equiv) in ice cooled DCM (5 mL) 
under N2 atmosphere. EDCI (61 mg, 0.32 mmol, 1.1 equiv) was added and the solution 
stirred at rt for 3 h. The reaction mixture was diluted with ethyl acetate (20 mL) and 
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washed with saturated aqueous sodium bicarbonate (10 mL), and water (10 mL). The 
organic phase was dried over MgSO4 and the solvent removed by evaporation under 
reduced pressure to give 3.108 (89 mg, 62%) as a white solid. The product was not purified 
further. 
mp 57-60˚C. 
1H NMR (CDCl3, 500 MHz) δ 1.29 (m(br), 22H, (CH2)11), 1.59 (m, 4H, (CH2)2), 2.16 (t, 
2H, J = 7.7 Hz, CH2), 2.31 (s, 3H, OCH3), 2.42 (m, 4H, COCH2CH2), 2.44 (m, 2H, CH2), 
2.85 (t, 2H, J = 7.5 Hz, CH2), 3.44 (m, 2H, NHCH2CH2), 3.54 (t, 2H, J = 5.2 Hz, 
NHCH2CH2), 3.65 (t, 2H, J = 4.8 Hz, OCH2), 4.23 (t, 2H, J = 4.8 Hz, OCH2), 5.03 (m, 2H, 
CH=CH2), 5.81 (m, 1H, CH=CH2), 5.85 (s(br), 1H, NH). 
13C NMR (CDCl3, 75 MHz) δ 25.66, 28.72, 29.02, 29.06, 29.24, 29.29, 29.41, 29.47, 
29.53, 29.54, 30.55, 33.33, 36.68, 38.97, 63.15, 68.90, 69.78, 115.53, 136.41, 172.93. 
173.15, 195.99. 
HRMS (M+H) Found 500.3414 (Calcd. For C27H50NO5S 500.3410). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four – Experimental 
 
 
 
190
NO
O N
H
O O
O
N
H
S
O
15
O
4.3.5 Synthesis of inhibitor-tether conjugates 3.110 and 3.111 
 
2-(16-(Acetylthio)hexadecanamido)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-
3-yl)phenoxy)acetamido)hex-4-enoate (3.110) 
 
 
 
 
 
 
 
 
A solution of 3.57 (50 mg, 0.23mmol, 1 equiv) and 3.107 (73 mg, 0.23 mmol, 1 equiv) in 
1,1,2-trichloroethane (4 mL) was stirred under a steady flow of N2. Grubb’s second 
generation catalyst (26 mg, 0.05 mmol, 0.20 equiv) was added, resulting in a reddish-
brown solution which was stirred at rt for 16 h. The solvent was removed by evaporation 
under reduced pressure to give a brown oil which was purified by column chromatography 
on silica (5% methanol/DCM) to give 3.110 (35 mg, 30%) as a fine white solid.  
mp 69-71˚C. 
1H NMR (CDCl3, 500 MHz) δ 1.29 (m(br), 22H, (CH2)11), 1.56 (m, 4H, (CH2)2), 2.16 (t, 
2H, J = 7.5 Hz, CH2), 2.30 (s, 3H, CH3CO), 2.40 (m, 4H, COCH2CH2), 2.83 (t, 2H, J = 
7.1 Hz, CH2), 3.48 (m, 2H, NHCH2CH2), 3.60 (s, 3H, NCH3), 3.90 (t, 2H, J = 5.9 Hz, 
NHCH2CH=CH), 4.14 (t, 2H, J = 5.2 Hz, NHCH2CH2), 4.50 (s, 2H, OCH2CO), 5.56 (m, 
2H, CH2CH=CH), 5.96 (s(br), 1H, NHCH2CH2), 6.64 (d, 1H, J = 9.5 Hz, COCH=CH), 
6.71 (s(br), 1H, NHCH2CH=CH), 6.95 (d, 2H, J = 8.7 Hz, ArH), 7.34 (d, 2H, J = 8.7 Hz, 
ArH), 7.44 (d, 1H, J = 2.4 Hz, NCH3CH), 7.57 (dd, 1H, J = 2.4, 9.5 Hz, COCH=CH). 
13C NMR (CDCl3, 75 MHz) δ 25.59, 27.185, 28.66, 28.96, 29.01, 29.17, 29.24, 29.34, 
29.37, 29.41, 29.49, 30.51, 33.38, 36.50, 37.87, 38.53, 40.58, 63.16, 67.29, 115.17, 119.51, 
120.45, 126.32, 126.49, 127.09, 130.29, 131.02, 135.16, 139.23, 156.50, 162.20, 167.72, 
172.81, 173.49, 196.06. 
HRMS (M+H) Found 726.4182 (Calcd. For C40H60N3O7S 726.4152). 
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2-(2-(16-(Acetylthio)hexadecanamido)ethoxy)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-
dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate (3.111) 
 
 
 
 
 
 
 
 
A solution of 3.57 (70 mg, 0.23 mmol, 1 equiv) and 3.108 (116 mg, 0.23 mmol, 1 equiv) in 
1,1,2-trichloroethane (4 mL) was stirred under a steady flow of N2. Grubb’s second 
generation catalyst (38 mg, 0.05 mmol, 0.2 equiv) was added, resulting in a reddish-brown 
solution which was stirred at rt for 16 h. The solvent was removed by evaporation under 
reduced pressure to give a brown oil which was purified by column chromatography on 
silica (5% methanol/DCM) to give 3.111 (94 mg, 52%) as a fine white solid.  
mp 60-62˚C. 
1H NMR (CDCl3, 500 MHz) δ 1.28 (m(br), 20H, (CH2)10), 1.58 (m, 6H, (CH2)3), 2.16 (t, 
2H, J = 7.5 Hz, CH2), 2.31 (s, 3H, CH3CO), 2.40 (m, 4H, COCH2CH2), 2.84 (t, 2H, J = 
7.5 Hz, CH2), 3.43 (m, 2H, NHCH2CH2), 3.53 (t, 2H, J = 5.2 Hz, NHCH2 CH2), 3.61 (s, 
3H, NCH3), 3.63 (t, 2H, J = 4.8 Hz, OCH2), 3.92 (t, 2H, J = 5.9 Hz, NHCH2CH=CH), 4.21 
(t, 2H, J = 4.8 Hz, OCH2), 4.51 (s, 2H, OCH2CO), 5.57 (m, 2H, CH2CH=CH), 5.95 (s(br), 
1H, NHCH2CH2), 6.64 (d, 1H, J = 9.5 Hz, COCH=CH), 6.67 (s,(br), 1H, 
NHCH2CH=CH), 6.96 (d, 2H J = 8.7 Hz, ArH), 7.35 (d, 2H, J = 8.7 Hz, ArH), 7.44 (d, 
1H, J = 2.8 Hz, NCH3CH), 7.57 (dd, 1H, J = 2.8, 9.5 Hz, COCH=CH). 
13C NMR (CDCl3, 75 MHz) δ 25.69, 27.297, 28.74, 29.04, 29.08, 29.27, 29.32, 29.41, 
29.44, 29.49, 29.57, 30.58, 33.51, 36.66, 37.96, 39.03, 40.63, 63.24, 67.37, 68.86, 69.79, 
108.48, 114.53, 115.23, 119.61, 120.58, 126.60, 127.18, 130.39, 131. 27, 135.21, 139.31, 
156.55, 162.28, 167.70, 172.79, 173.36, 196.10. 
HRMS (M+H) Found 770.4426 (Calcd. For C42H64N3O8S 770.4414). 
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4.3.6 Steroid 5α-reductase inhibition assay 
 
The proposed steroid 5α-reductase inhibitors synthesised in this thesis were assayed in the 
laboratory of Professor Rolf Hartmann at Saarland University, Germany. The human 
embryonic cell line HEK293 used was stably transfected with cDNA for either of the 
steroid 5α-reductase isozymes (type 1 or 2).18 HEK-I cells express the type 1 isozyme, and 
HEK-II express type 2. The separate cell lines allow assay of potential inhibitors separately 
against both isozymes. A cell free assay was used to avoid cell permeation issues. 
 
 
Homogenate preparation 
 
HEK-I and HEK-II cells were grown according to Reichert et al.18 The subconfluent cells 
(approximately 80% of the monolayer surface covered) were washed twice with PBS 
buffer (pH 7.3), and harvested in cold homogenate buffer (pH 7.3) containing Tris-HCl (50 
mM), EDTA (1 mM), and sucrose (300 mM). The cells were homogenised on ice using an 
ultrasonic rod (5 x 30 seconds at intervals of 60 seconds). 
 
 
Inhibition assay 
 
Incubation of cell homogenate and test compound was carried out for 30min at 37˚C, with 
a total volume of 500 µL using Tris-HCl buffer (50 mM, pH 7.3) and ETDA (1 mM). The 
incubation mixture contained NADP+ (0.55 mM), glucose-6-phosphate (5 mM), glucose-6-
phosphate-dehydrogenase (1.2 U/mL), androstenedione (505 nM) including [1β-3H]-
androstenedione (3.2 µCi), and 2% MeOH with or without test compound. A standard 
concentration of 10 µM was used for test compounds. 
 
The reaction was started by adding the enzyme preparation to the incubation mixture, and 
stopped by extracting the steroids with cold diethyl ether (750 µL). The mixture was 
shaken for 10 min and centrifuged for 10 min at 4000 g. The water layer was frozen and 
the ether layer decanted into fresh tubes and evaporated to dryness. The steroids were 
dissolved in methanol (50 µL) prior to HPLC analysis. 
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For inhibition of type 1 5α-reductase, 0.3 x 106 HEK-I cells, and for type 2, 0.14 x 106 
HEK-II cells, were used per test vial. As a control for conversion, a triplicate of wells 
without inhibitors was used. 
 
The steroids were analysed by HPLC (Agilent 1100 Series, Agilent Chemstation for LC 
3D). 12.5 µL of the steroids (androstenedione and androstanedione) were injected into the 
computer controlled HPLC system that was checked before use by running labelled 
reference controls. Radioactivity was measured with a radioflow monitor (Berthold 
LB509). A mobile phase of MeOH/H2O (65:35 v/v) was used with a flow of 0.35 mL min-
1, as well as an additive flow of 1 mL (quickszint flow 302) with a RP18 Nucleodur 
column. Baseline separation of the steroid substrate and product was achieved within 15 
min. Results were expressed as the amount of androstanedione formed as a percent of the 
control values. 
 
In this assay finasteride was used as a positive control, which had an IC50 of 453 nM for 
type 1, and an IC50 of 25 nM for type 2. 
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SAMPLE OF YEAST ASSAY ANALYSIS AND EC50 CALCULATION  
 
Example for 17β-estradiol (Assay 15) 
 
Well # Absorbance 540 nm Absorbance 610 nm Absorbance blank 
610 nm 
Corrected 
Absorbance 
Estradiol conc. 
nM 
1 2.401 1.288 0.982 2.073 9.984 
2 2.569 1.314 0.981 2.215 4.992 
3 2.509 1.286 1.007 2.183 2.496 
4 2.326 1.255 0.949 2.031 1.248 
5 2.274 1.253 0.94 1.981 0.624 
6 1.735 1.128 0.98 1.567 0.312 
7 1.396 1.017 0.924 1.339 0.156 
8 1.223 0.997 0.95 1.186 0.078 
9 1.132 1.001 0.968 1.091 0.039 
10 1.075 0.942 0.98 1.093 0.02 
11 1.059 0.95 0.948 1.069 0.01 
12 0.915 0.843 0.906 1.032 0.005 
 Avg. = 0.960 
Corrected Absorbance = Abs 540 - (Abs 610 - Abs blank 610) 
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 Equation of line determined by SigmaPlot® = f=y0+a/(1+exp(-(x-x0)/b)) 
 Sigmoidal 4 Parameter 
 Coefficient Std. 
Error 
t P 
a 1.785 0.6761 2.6402 0.0297
b 0.2412 0.0729 3.3085 0.0107
x0 0.1112 0.1918 0.5798 0.578
y0 0.3499 0.6679 0.5239 0.6146
 
x(EC50) f 
0.331 1.623072
  
y50 1.6235
 
 
 
 
 
 
Assay #15 Estradiol
Concentration of estradiol per well (nM)
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